

CITATION REPORT

List of articles citing

Mechanisms of cancer drug resistance

DOI: 10.1146/annurev.med.53.082901.103929
Annual Review of Medicine, 2002, 53, 615-27.

Source: <https://exaly.com/paper-pdf/34061874/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2114	Dynamic alteration of gene expression induced by anticancer-agent exposure in gastric cancer cell lines. 1994 , 21, 451		
2113	Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. 2002 , 62, 1-6		147
2112	MDR1 inhibition: less resistance or less relevance?. 2002 , 38, 2337-40		31
2111	Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs. 2002 , 2, 431-41		63
2110	Etoposide-mediated sensitization of squamous cell carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced loss in mitochondrial membrane potential. 2003 , 39, 269-76		7
2109	Modulation von Protein-Protein-Wechselwirkungen mit niedermolekularen organischen Molekülen. 2003 , 115, 2566-2586		38
2108	Modulation of protein-protein interactions with small organic molecules. 2003 , 42, 2462-81		260
2107	Kinetic study of azole-bridged dinuclear platinum(II) complexes reacting with a hairpin-stabilized double-stranded oligonucleotide. 2003 , 96, 357-66		37
2106	Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. 2003 , 28, 203-28		153
2105	Mechanisms of Taxol resistance related to microtubules. 2003 , 22, 7280-95		559
2104	P-glycoprotein: from genomics to mechanism. 2003 , 22, 7468-85		847
2103	ATP binding cassette transporters and drug resistance in breast cancer. 2003 , 10, 43-73		187
2102	Multidrug resistance reversal agents. 2003 , 46, 4805-17		262
2101	Relationship between activation of microsomal glutathione S-transferase and metabolism behavior of chlorambucil. 2003 , 48, 623-30		4
2100	Analysis of catalytic carboxylate mutants E552Q and E1197Q suggests asymmetric ATP hydrolysis by the two nucleotide-binding domains of P-glycoprotein. 2003 , 42, 12875-85		31
2099	Structural basis of multiple drug-binding capacity of the AcrB multidrug efflux pump. 2003 , 300, 976-80		337
2098	Colorectal cancer cell adhesion attenuates Ad-E2F-1 mediated apoptosis. 2003 , 113, 81-7		3

2097	Mechanisms of anticancer drug resistance. 2003 , 33, 651-67	29
2096	Drug resistance and the microenvironment: nature and nurture. 2003 , 6, 169-72	138
2095	Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications. 2003 , 170, 1383-7	61
2094	Transition state P-glycoprotein binds drugs and modulators with unchanged affinity, suggesting a concerted transport mechanism. 2003 , 42, 1345-53	51
2093	Induction of apoptosis in the human mast cell leukemia cell line HMC-1 by various antineoplastic drugs. 2003 , 44, 509-15	15
2092	Anticancer Agents from Unique Natural Products Sources. 2003 , 41, 15-38	18
2091	High cloning capacity of in vitro packaged SV40 vectors with no SV40 virus sequences. 2003 , 14, 167-77	39
2090	Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. 2003 , 170, 4905-13	350
2089	Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in <i>Lactococcus lactis</i> . 2003 , 278, 20645-51	130
2088	Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. 2004 , 22, 2092-100	111
2087	Down-regulation and altered localization of gamma-catenin in cisplatin-resistant adenocarcinoma cells. 2004 , 65, 1217-24	14
2086	Hypoxia-inducible factor 1alpha- mediated resistance to phenolic anticancer. 2004 , 50, 119-26	14
2085	Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts. 2004 , 10, 4538-49	61
2084	Using microarrays to predict resistance to chemotherapy in cancer patients. 2004 , 5, 611-25	13
2083	Reversible transport by the ATP-binding cassette multidrug export pump LmrA: ATP synthesis at the expense of downhill ethidium uptake. 2004 , 279, 11273-80	53
2082	Activation of the MDR1 upstream promoter in breast carcinoma as a surrogate for metastatic invasion. 2004 , 10, 2776-83	40
2081	Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. 2004 , 10, 272-84	156
2080	Pharmacoproteomic approach to the study of drug mode of action, toxicity, and resistance: applications in diabetes and cancer. 2004 , 18, 413-22	25

2079	Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway. 2004 , 23, 1754-65	83
2078	Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. 2004 , 23, 2934-49	475
2077	Role of the p53/p21 system in the response of human colon carcinoma cells to Doxorubicin. 2004 , 4, 92	50
2076	Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. 2004 , 58, 914-26	84
2075	The ABC transporter structure and mechanism: perspectives on recent research. 2004 , 61, 682-99	406
2074	Proton motive force mediates a reorientation of the cytosolic domains of the multidrug transporter LmrP. 2004 , 61, 2646-57	13
2073	Anomalies of deconvolution via discrete Fourier transform: a case study on assessing transport at live cell preparations. 2004 , 23, 459-567	8
2072	Tubulin inhibitors. Synthesis and biological activity of HTI-286 analogs with B-segment heterosubstituents. 2004 , 14, 4329-32	7
2071	Synthesis and biological activity of analogues of the antimicrotubule agent N,beta,beta-trimethyl-L-phenylalanyl-N(1)-[(1S,2E)-3-carboxy-1-isopropylbut-2-enyl]-N(1),3-dimethyl-L-valinamide (HTI-286). 2004 , 47, 4774-86	40
2070	The molecular basis of the action of disulfiram as a modulator of the multidrug resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRP1 (ABCC1). 2004 , 65, 675-84	73
2069	Biochemical basis of polyvalency as a strategy for enhancing the efficacy of P-glycoprotein (ABCB1) modulators: stipiamide homodimers separated with defined-length spacers reverse drug efflux with greater efficacy. 2004 , 43, 2262-71	56
2068	Rifampicin and verapamil induce the expression of P-glycoprotein in vivo in Ehrlich ascites tumor cells. 2004 , 205, 107-15	13
2067	The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography. 2004 , 305, 866-9	396
2066	Herbal modulation of P-glycoprotein. 2004 , 36, 57-104	316
2065	Mechanism targeted discovery of antitumor marine natural products. 2004 , 11, 1725-56	60
2064	Sphingolipid metabolism enzymes as targets for anticancer therapy. 2004 , 5, 375-82	40
2063	Suppression of ovarian cancer cell tumorigenicity and evasion of Cisplatin resistance using a truncated epidermal growth factor receptor in a rat model. 2005 , 65, 3243-8	26
2062	Transcription factor Nrf2 regulates promoter activity of mouse aldose reductase (AKR1B3) gene. 2005 , 97, 43-51	59

2061	Establishment and gene analysis of a cisplatin-resistant cell line, Sa-3R, derived from oral squamous cell carcinoma. 2005 , 13, 709	2
2060	Differentiation and drug resistance relationships in leukemia cells. 2005 , 94, 98-108	9
2059	Acquisition of multidrug resistance by L1210 leukemia cells decreases their tumorigenicity and enhances their susceptibility to the host immune response. 2005 , 54, 328-36	5
2058	EM012, a microtubule-interfering agent, inhibits the progression of multidrug-resistant human ovarian cancer both in cultured cells and in athymic nude mice. 2005 , 55, 461-5	32
2057	Expression of lung resistance-related protein, LRP, and multidrug resistance-related protein, MRP1, in normal human lung cells in long-term cultures. 2005 , 79, 600-9	8
2056	Mécanismes de résistance Données générales. 2005 , 7, 403-405	0
2055	The steady-state Michaelis-Menten analysis of P-glycoprotein mediated transport through a confluent cell monolayer cannot predict the correct Michaelis constant Km. 2005 , 22, 1667-77	48
2054	Changes in P-glycoprotein activity are mediated by the growth of a tumour cell line as multicellular spheroids. 2005 , 5, 20	21
2053	An ETP model (exclusion-tolerance-progression) for multi drug resistance. 2005 , 2, 17	2
2052	Regulation of hepatic transporters by xenobiotic receptors. 2005 , 6, 309-28	149
2051	Principles of Chemotherapy for Genitourinary Cancer. 2005 , 51-87	
2050	Extracellular matrix in bone marrow can mediate drug resistance in myeloma. 2005 , 46, 803-11	43
2049	Metabolism of ATP-binding cassette drug transporter inhibitors: complicating factor for multidrug resistance. 2005 , 1, 219-32	13
2048	Tumor necrosis factor alpha-dependent drug resistance to purine and pyrimidine analogues in human colon tumor cells mediated through IKK. 2005 , 280, 7634-44	10
2047	P-Glycoprotein is localized in intermediate-density membrane microdomains distinct from classical lipid rafts and caveolar domains. 2005 , 272, 4924-37	53
2046	Knocking down transport: applications of RNA interference in the study of drug transport proteins. 2005 , 37, 705-23	11
2045	New horizon of MDR1 (P-glycoprotein) study. 2005 , 37, 489-510	17
2044	Interaction of LDS-751 with P-glycoprotein and mapping of the location of the R drug binding site. 2005 , 44, 643-55	94

2043	Peptide motifs for cell-surface intervention: application to anti-infective and biopharmaceutical development. 2005 , 19, 261-78	11
2042	Disulfiram, an old drug with new potential therapeutic uses for human cancers and fungal infections. 2005 , 1, 127-34	78
2041	Proteomic evidence for roles for nucleolin and poly[ADP-ribosyl] transferase in drug resistance. 2005 , 4, 1583-91	27
2040	Anti-sense trefoil factor family-3 (intestinal trefoil factor) inhibits cell growth and induces chemosensitivity to adriamycin in human gastric cancer cells. 2005 , 76, 2581-92	22
2039	Modulation of MRP1 protein transport by plant, and synthetically modified flavonoids. 2005 , 77, 1879-91	36
2038	Neoplastic growth: the consequence of evolutionary malignant resistance to chronic damage for survival of cells (review of a new theory of the origin of cancer). 2005 , 65, 595-604	11
2037	Regulation of volume-sensitive Cl ⁻ channels in multi-drug resistant MCF7 cells. 2005 , 334, 1266-78	12
2036	Polyphyllin D is a potent apoptosis inducer in drug-resistant HepG2 cells. 2005 , 217, 203-11	124
2035	Potentiation by alpha-tocopheryl succinate of the etoposide response in multidrug resistance protein 1-expressing glioblastoma cells. 2005 , 217, 181-90	15
2034	The elementary mass action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells. 2005 , 88, 715-38	57
2033	A chemical strategy to manipulate the intracellular localization of drugs in resistant cancer cells. 2005 , 44, 15743-9	39
2032	Hybrids of the hemiasterlin analogue taltobulin and the dolastatins are potent antimicrotubule agents. 2005 , 127, 17667-71	22
2031	Deciphering cellular states of innate tumor drug responses. 2006 , 7, R19	97
2030	Reversal of ABC Transporter-Dependent Multidrug Resistance in Cancer. 2006 , 5, 285-297	9
2029	Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules. 2006 , 5, 270-8	125
2028	Cancer Drug Resistance. 2006 ,	17
2027	Stimulatory effect of insecticides on partially purified P-glycoprotein ATPase from the resistant pest <i>Helicoverpa armigera</i> . 2006 , 84, 1045-50	20
2026	Complete reversal of ABCG2-depending atypical multidrug resistance by RNA interference in human carcinoma cells. 2006 , 16, 263-74	28

2025	A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. 2006 , 317, 1372-81	297
2024	Shedding light on drug transport: structure and function of the P-glycoprotein multidrug transporter (ABCB1). 2006 , 84, 979-92	83
2023	P-glycoprotein effect on the properties of its natural lipid environment probed by Raman spectroscopy and Langmuir-Blodgett technique. 2006 , 580, 4953-8	10
2022	P-glycoprotein (ABCB1) interacts directly with lipid-based anti-cancer drugs and platelet-activating factors. 2006 , 84, 1022-33	32
2021	Anticancer efficacies of cisplatin-releasing pH-responsive nanoparticles. 2006 , 7, 829-35	149
2020	Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. 2006 , 15, 933-46	297
2019	P-Glycoprotein (P-gp) expressed in a confluent monolayer of hMDR1-MDCKII cells has more than one efflux pathway with cooperative binding sites. 2006 , 45, 15505-19	24
2018	Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma. 2006 , 69, 1801-9	70
2017	Alterations in the mitochondrial proteome of adriamycin resistant MCF-7 breast cancer cells. 2006 , 5, 2389-95	28
2016	Glycosphingolipids and drug resistance. 2006 , 1758, 2096-103	85
2015	Silencing of astrin induces the p53-dependent apoptosis by suppression of HPV18 E6 expression and sensitizes cells to paclitaxel treatment in HeLa cells. 2006 , 343, 428-34	21
2014	Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells. 2006 , 231, 87-93	63
2013	Chemotherapy resistance in osteosarcoma: current challenges and future directions. 2006 , 6, 1075-85	276
2012	Multidrug resistance mediated by ABC transporters in osteosarcoma cell lines: mRNA analysis and functional radiotracer studies. 2006 , 33, 831-40	33
2011	Studies of Drug Resistance Using Organelle Proteomics. 2006 , 241-257	
2010	. 2006 ,	4
2009	Drug-resistant T-lymphoid tumors undergo apoptosis selectively in response to an antimicrotubule agent, EM011. 2006 , 107, 2486-92	59
2008	OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. 2006 , 108, 697-704	370

2007	Conformational and functional characterization of trapped complexes of the P-glycoprotein multidrug transporter. 2006 , 399, 315-23	29
2006	MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance. 2006 , 7, 813-21	67
2005	Cytotoxicity of Marchantia convoluta leaf extracts to human liver and lung cancer cells. 2006 , 39, 731-8	27
2004	The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. 2006 , 25, 1743-52	95
2003	A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. 2006 , 23, 1574-85	244
2002	The role of the VPS4A-exosome pathway in the intrinsic egress route of a DNA-binding anticancer drug. 2006 , 23, 1687-95	29
2001	The anti-hepatitis drug DDB chemosensitizes multidrug resistant cancer cells in vitro and in vivo by inhibiting P-gp and enhancing apoptosis. 2007 , 25, 95-105	27
2000	Non-destructive micromethod for MRP1 functional assay in human lung tumor cells. 2006 , 80, 125-33	10
1999	4-Alkoxy substitution enhancing the anti-mitotic effect of 5-(3,4,5-trisubstituted)anilino-4-hydroxy-8-nitroquinazolines as a novel class of anti-microtubule agents. 2006 , 16, 5864-9	17
1998	Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas. 2006 , 100, 152-9	56
1997	The nitroxide Tempol modulates anthracycline resistance in breast cancer cells. 2006 , 40, 1409-18	18
1996	Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. 2006 , 71, 416-25	158
1995	Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells. 2006 , 71, 1162-74	63
1994	Alternating current electrical stimulation enhanced chemotherapy: a novel strategy to bypass multidrug resistance in tumor cells. 2006 , 6, 72	33
1993	Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective. 2006 , 207, 571-81	77
1992	The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). 2006 , 7, 893-909	198
1991	Evolution of resistance to cancer therapy. 2006 , 12, 261-71	68
1990	Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. 2006 , 3, e420	745

1989	Rational design of the microtubule-targeting anti-breast cancer drug EM015. 2006 , 66, 3782-91	53
1988	Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. 2006 , 66, 4263-72	78
1987	Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death. 2006 , 281, 1107-18	36
1986	Implications of tissue transglutaminase expression in malignant melanoma. 2006 , 5, 1493-503	79
1985	The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. 2006 , 66, 1033-9	165
1984	mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. 2006 , 12, 854-9	138
1983	Post-transcriptional regulation of P-glycoprotein expression in cancer cell lines. 2007 , 5, 641-53	34
1982	Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. 2007 , 8, 29-39	78
1981	The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model. 2007 , 97, 562-73	43
1980	Chemogenomics of Sensitivity and Resistance to Anticancer Drugs. 2007 , 5, 11-19	
1979	Pheophorbide a, an active component in Scutellaria barbata, reverses P-glycoprotein-mediated multidrug resistance on a human hepatoma cell line R-HepG2. 2007 , 6, 504-9	31
1978	Mechanismen der Chemotherapieresistenz beim Ovarialkarzinom. 2007 , 67, 831-836	
1977	Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. 2007 , 104, 12117-22	241
1976	Ability to acquire drug resistance arises early during the tumorigenesis process. 2007 , 67, 1130-7	48
1975	Increased levels of thiols protect antimony unresponsive Leishmania donovani field isolates against reactive oxygen species generated by trivalent antimony. 2007 , 134, 1679-87	86
1974	Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer. 2007 , 13, 3875-82	66
1973	The evolution of two mutations during clonal expansion. 2007 , 177, 2209-21	47
1972	Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. 2007 , 14, 1029-38	34

1971	Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets. 2007 , 6, 1089-98	98
1970	Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes. 2007 , 31, 419	3
1969	Overexpression of Survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein. 2007 ,	4
1968	Targeted inhibition of COX-2 expression by RNA interference suppresses tumor growth and potentiates chemosensitivity to cisplatin in human gastric cancer cells. 2007 ,	4
1967	Role of the highly structured 5Kend region of MDR1 mRNA in P-glycoprotein expression. 2007 , 406, 445-55	25
1966	Toxicokinetics. 2007 , 179-230	
1965	Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. 2007 ,	2
1964	Multidrug Resistance Protein: P-Glycoprotein. 223-262	13
1963	ATP-binding cassette multidrug transporters in Indian-rock oyster <i>Saccostrea forskali</i> and their role in the export of an environmental organic pollutant tributyltin. 2007 , 85, 124-32	36
1962	Inhibition of Fas expression by RNAi modulates 5-fluorouracil-induced apoptosis in HCT116 cells expressing wild-type p53. 2007 , 1772, 40-7	37
1961	Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells. 2007 , 1771, 1407-17	69
1960	Interaction of insecticides with mammalian P-glycoprotein and their effect on its transport function. 2007 , 1768, 1750-7	45
1959	Protein kinase C-alpha antagonizes apoptosis induction by histone deacetylase inhibitors in multidrug resistant leukaemia cells. 2007 , 39, 1877-85	10
1958	Regulation of MDK expression in human cancer cells modulates sensitivities to various anticancer drugs: MDK overexpression confers to a multi-drug resistance. 2007 , 247, 40-7	37
1957	Immunization with liposome-anchored pegylated peptides modulates doxorubicin sensitivity in P-glycoprotein-expressing P388 cells. 2007 , 257, 165-71	17
1956	Chemoinformatics analysis identifies cytotoxic compounds susceptible to chemoresistance mediated by glutathione and cystine/glutamate transport system xc-. 2007 , 50, 1896-906	36
1955	Apoptosis, Senescence, and Cancer. 2007 ,	6
1954	Ceramide and Multidrug Resistance. 2007 , 299-312	

1953	Curcumin activates human glutathione S-transferase P1 expression through antioxidant response element. 2007 , 170, 238-47	113
1952	Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. 2007 , 7, 447-59	253
1951	Biological Background. 2007 , 3-18	
1950	Production of P-glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first-line chemotherapy in advanced breast cancer. 2008 , 122, 1058-67	16
1949	Synthesis and biological activity of vicinal diaryl-substituted 1H-imidazoles. 2007 , 63, 4571-4624	201
1948	Synthesis, biological evaluations, and tubulin binding poses of C-2alpha sulfur linked taxol analogues. 2007 , 17, 3191-4	4
1947	Contrasting features of MDR phenotype in leukemias by using two fluorochromes: implications for clinical practice. 2007 , 31, 445-54	32
1946	Inhibition of the epidermal growth factor receptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly increases apoptosis. 2007 , 99, 196-201	5
1945	Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. 2008 , 99, 121-8	156
1944	Pretreatment with insulin enhances anticancer functions of 5-fluorouracil in human esophageal and colonic cancer cells. 2007 , 28, 721-30	13
1943	Synergistic effect of combining paeonol and cisplatin on apoptotic induction of human hepatoma cell lines. 2007 , 28, 869-78	36
1942	Human renal UOK130 tumor cells: a drug resistant cell line with highly selective over-expression of glutathione S-transferase-pi isozyme. 2007 , 568, 61-7	9
1941	Anticancer drugs from nature--natural products as a unique source of new microtubule-stabilizing agents. 2007 , 24, 327-57	205
1940	Functional imaging of multidrug resistance in an orthotopic model of osteosarcoma using ^{99m} Tc-sestamibi. 2007 , 34, 1793-803	20
1939	Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors. 2007 , 60, 203-9	23
1938	ABCG transporters: structure, substrate specificities and physiological roles : a brief overview. 2007 , 39, 465-71	65
1937	Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro. 2008 , 24, 165-74	36
1936	Reversal of P-glycoprotein-mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus Schizandrae. 2008 , 62, 1015-26	71

1935	Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin. 2008 , 122, 2368-76	26
1934	Identification of genomic changes associated with cisplatin resistance in testicular germ cell tumor cell lines. 2008 , 47, 604-13	19
1933	Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type. 2008 , 83, 795-9	74
1932	Cell death signal by glycine- and proline-rich plant glycoprotein is transferred from cytochrome c and nuclear factor kappa B to caspase 3 in Hep3B cells. 2008 , 19, 166-74	6
1931	A structural analysis of the differential cytotoxicity of chemicals in the NCI-60 cancer cell lines. 2008 , 16, 4052-63	6
1930	A New Soy-Based Hydrogels: Development, Viscoelastic Properties, and Application for Controlled Drug Release. 2008 , 17-38	
1929	Investigating the role of the invariant carboxylate residues E552 and E1197 in the catalytic activity of Abcb1a (mouse Mdr3). 2008 , 275, 3312-24	9
1928	Nanoparticle therapeutics: an emerging treatment modality for cancer. 2008 , 7, 771-82	3332
1927	Antiproliferation and apoptosis induction of paeonol in human esophageal cancer cell lines. 2008 , 21, 723-9	34
1926	A novel indole ethyl isothiocyanate (7Me-IEITC) with anti-proliferative and pro-apoptotic effects on platinum-resistant human ovarian cancer cells. 2008 , 109, 240-9	18
1925	Progesterone facilitates cisplatin toxicity in epithelial ovarian cancer cells and xenografts. 2008 , 110, 251-5	20
1924	Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes. 2008 , 8, 487-92	10
1923	Taxanes, microtubules and chemoresistant breast cancer. 2008 , 1785, 96-132	230
1922	Potential mechanisms of resistance to microtubule inhibitors. 2008 , 35, S22-7	31
1921	Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells. 2008 , 12, 928-41	27
1920	Lobeline, a piperidine alkaloid from Lobelia can reverse P-gp dependent multidrug resistance in tumor cells. 2008 , 15, 754-8	50
1919	pH-responsive nanoparticles for cancer drug delivery. 2008 , 437, 183-216	47
1918	Effects of sampling rate on the interpretation of cellular transport measurements. 2008 , 80, 7684-9	2

1917	Effects of photoactivated 5-aminolevulinic acid hexyl ester on MDR1 over-expressing human uterine sarcoma cells. 2008 , 181, 7-12	19
1916	Synergistic effect of paeonol and cisplatin on oesophageal cancer cell lines. 2008 , 40, 531-9	24
1915	Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. 2008 , 10, R105	83
1914	Effective topical treatment of subcutaneous murine B16F10-Nex2 melanoma by the antimicrobial peptide gomesin. 2008 , 10, 61-8	70
1913	Reversal effect of resveratrol on multidrug resistance in KBv200 cell line. 2008 , 62, 622-9	38
1912	Reversal effect of tyroservatide (YSV) tripeptide on multi-drug resistance in resistant human hepatocellular carcinoma cell line BEL-7402/5-FU. 2008 , 269, 101-10	39
1911	Modeling therapy resistance in genetically engineered mouse cancer models. 2008 , 11, 51-60	27
1910	Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?. 2008 , 100, 521-3	24
1909	Angiogenesis. 2008 ,	25
1908	Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. 2008 , 13, 1207-23	65
1907	Multidrug resistance-associated protein-overexpressing teniposide-resistant human lymphomas undergo apoptosis by a tubulin-binding agent. 2008 , 68, 1495-503	26
1906	RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. 2008 , 68, 7975-84	286
1905	ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. 2008 , 14, 5594-601	83
1904	Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. 2008 , 7, 3081-91	130
1903	Induction of paclitaxel resistance by the Kaposi's sarcoma-associated herpesvirus latent protein LANA2. 2008 , 82, 1518-25	18
1902	A role for ceramide in driving cancer cell resistance to doxorubicin. 2008 , 22, 2541-51	125
1901	Innovative Leukemia and Lymphoma Therapy. 2008 ,	
1900	Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin. 2008 , 14, 1510-8	31

1899	Ellipticine derivative NSC 338258 represents a potential new antineoplastic agent for the treatment of multiple myeloma. 2008 , 7, 500-9	15
1898	Salmonella enterica serovar Typhimurium modulates P-glycoprotein in the intestinal epithelium. 2008 , 294, G1392-400	22
1897	Toxicity Resistance. 2008 , 597-641	19
1896	Places of Microemulsion and Emulsion in Cancer Therapy. 2008 ,	
1895	A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. 2008 , 112, 2935-45	100
1894	Chromatin remodeling agents for cancer therapy. 2008 , 3, 192-203	16
1893	Multiple pathways are involved in drug resistance to doxorubicin in an osteosarcoma cell line. 2008 , 19, 257-65	40
1892	Proteomic approaches in understanding action mechanisms of metal-based anticancer drugs. 2008 , 2008, 716329	23
1891	Management of advanced breast cancer with the epothilone B analog, ixabepilone. 2009 , 3, 163-71	7
1890	The Role of PPARs in MDR - a lesson from embryonic development. 2009 , 56, 279-83	8
1889	Reversal of multidrug resistance by magnetic Fe ₃ O ₄ nanoparticle copolymerizing daunorubicin and 5-bromotetrandrine in xenograft nude-mice. 2009 , 4, 73-8	29
1888	Overexpression of kinesins mediates docetaxel resistance in breast cancer cells. 2009 , 69, 8035-42	94
1887	Long-term survival following a single treatment of kidney tumors with multiwalled carbon nanotubes and near-infrared radiation. 2009 , 106, 12897-902	265
1886	Antitumor effect of extracts from moutan cortex on DLD-1 human colon cancer cells in vitro. 2010 , 3, 57-61	15
1885	Towards understanding the role of cancer-associated inflammation in chemoresistance. 2009 , 15, 1844-53	36
1884	An unusual case of self-defense. 2009 , 8, 3452	
1883	Induction of apoptosis by viruses: what role does the nucleolus play?. 2009 , 8, 3452-3	3
1882	Spindle function in yeast: A human motor to the rescue. 2009 , 8, 3452-3454	2

1881	High heterogeneity of plasma membrane microfluidity in multidrug-resistant cancer cells. 2009 , 14, 034030	19
1880	Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. 2009 , 15, 3423-32	319
1879	The reversal of drug-resistance in tumors using a drug-carrying nanoparticulate system. 2009 , 10, 3776-92	38
1878	Small interfering RNA-mediated silencing of heat shock protein 27 (HSP27) increases chemosensitivity to paclitaxel by increasing production of reactive oxygen species in human ovarian cancer cells (HO8910). 2009 , 37, 1375-88	33
1877	Combination effects of SC144 and cytotoxic anticancer agents. 2009 , 20, 312-20	10
1876	Nilotinib (AMN107, Tassigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. 2009 , 78, 153-61	179
1875	Transport of lipids by ABC proteins: interactions and implications for cellular toxicity, viability and function. 2009 , 180, 327-39	86
1874	Why doesn't high-dose chemotherapy improve survival, as was expected, in advanced or relapsed germ cell tumours?. 2009 , 56, 46-7	1
1873	Chitosan-phospholipid blend for sustained and localized delivery of docetaxel to the peritoneal cavity. 2009 , 377, 76-84	29
1872	The enhancement of Raf-1 kinase activity by knockdown of Spry2 is associated with high sensitivity to paclitaxel in v-Ha-ras-transformed NIH 3T3 fibroblasts. 2009 , 332, 189-97	10
1871	Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. 2009 , 114, 195-201	72
1870	Impact of novel MDR modulators on human cancer cells: reversal activities and induction studies. 2009 , 26, 182-8	16
1869	Mechanism of drug resistance identified in human lung adenocarcinoma cell line SPC-A1 selected for resistance to docetaxel. 2009 , 21, 207-216	2
1868	mRNA expression profile of multidrug resistance genes in childhood acute lymphoblastic leukemia. Low expression levels associated with a higher risk of toxic death. 2009 , 53, 996-1004	29
1867	Expression of multidrug resistance-associated protein 1 in invasive ovarian carcinoma: implication for prognosis. 2009 , 54, 657-66	26
1866	Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. 2009 , 86, 368-77	146
1865	Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. 2009 , 8, 806-23	667
1864	Polymeric Carriers for Anticancer Drugs. 2009 , 207-243	

1863	Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. 2009 , 8, 2086-95	368
1862	Pharmaceutical Perspectives of Cancer Therapeutics. 2009 ,	11
1861	Effect of Ganoderma on drug-sensitive and multidrug-resistant small-cell lung carcinoma cells. 2009 , 277, 182-9	37
1860	USP15 plays an essential role for caspase-3 activation during Paclitaxel-induced apoptosis. 2009 , 388, 366-71	47
1859	Is resistance useless? Multidrug resistance and collateral sensitivity. 2009 , 30, 546-56	195
1858	ABC efflux pump-based resistance to chemotherapy drugs. 2009 , 109, 2989-3011	457
1857	siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells. 2009 , 8, 28	38
1856	A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin. 2009 , 11, 1064-73	59
1855	Promise and challenges in drug discovery and development of hybrid anticancer drugs. 2009 , 4, 1099-111	127
1854	Antitumor properties of <i>Gymnosperma glutinosum</i> leaf extracts. 2009 , 27, 149-55	10
1853	Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro. 2009 , 50, 437-46	5
1852	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells. 2009 , 52, 3191-204	125
1851	Nanoparticle therapeutics: an emerging treatment modality for cancer. 2009 , 239-250	34
1850	Therapeutic nanoparticles to combat cancer drug resistance. 2009 , 10, 836-41	161
1849	Targeting DNA double-strand break repair: is it the right way for sensitizing cells to 5-fluorouracil?. 2010 , 21, 277-87	20
1848	Drug Transport and Membrane Transport Proteins. 2010 , 447-498	
1847	A review of selected anti-tumour therapeutic agents and reasons for multidrug resistance occurrence. 2004 , 56, 1067-81	26
1846	The ability of selected pyridinium salts to increase the cytotoxic activity of vincristine but not doxorubicin towards sensitive and multidrug resistant promyelocytic leukaemia HL60 cells. 2008 , 60, 647-53	3

1845	Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. 2010 , 13, 109-18	273
1844	Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. 2010 , 5, 597-615	234
1843	Increased expression of p27 is associated with the cisplatin resistance in gastric cancer cell line YCC-3. 2010 , 33, 1127-32	12
1842	The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapy. 2010 , 10, 204	14
1841	Drug penetration model of vinblastine-treated Caco-2 cultures. 2010 , 41, 96-106	31
1840	Codrug: an efficient approach for drug optimization. 2010 , 41, 571-88	63
1839	Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. 2010 , 1806, 258-67	120
1838	Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells. 2010 , 80, 1497-506	49
1837	Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro. 2010 , 119, 140-5	13
1836	Cationic polymer-mediated small interfering RNA delivery for P-glycoprotein down-regulation in tumor cells. 2010 , 116, 5544-54	31
1835	Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma. 2010 , 126, 437-49	72
1834	Multifunctional nanoscale platforms for targeting of the cancer cell immortality spectrum. 2010 , 31, 202-16	4
1833	Lysosomal destabilization and cathepsin B contributes for cytochrome c release and caspase activation in embelin-induced apoptosis. 2010 , 49, 324-36	38
1832	Fabrication of micellar nanoparticles for drug delivery through the self-assembly of block copolymers. 2010 , 35, 1128-1143	392
1831	BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. 2010 , 34, 1255-68	208
1830	CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients. 2010 , 43, 373-9	52
1829	Livin gene plays a role in drug resistance of colon cancer cells. 2010 , 43, 655-60	40
1828	A self-organized 3-diethylaminopropyl-bearing glycol chitosan nanogel for tumor acidic pH targeting: in vitro evaluation. 2010 , 78, 120-6	69

1827	Bisbibenzyl derivatives sensitize vincristine-resistant KB/VCR cells to chemotherapeutic agents by retarding P-gp activity. 2010 , 18, 6725-33	41
1826	Synthesis and evaluation of indole, pyrazole, chromone and pyrimidine based conjugates for tumor growth inhibitory activities--development of highly efficacious cytotoxic agents. 2010 , 45, 4968-82	59
1825	Circumvention of multi-drug resistance of cancer cells by Chinese herbal medicines. 2010 , 5, 26	53
1824	Drug binding and resistance mechanism of KIT tyrosine kinase revealed by hydrogen/deuterium exchange FTICR mass spectrometry. 2010 , 19, 703-15	24
1823	Combinatorial drug conjugation enables nanoparticle dual-drug delivery. 2010 , 6, 1442-8	147
1822	IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer. 2010 , 29, 1681-90	98
1821	Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB. 2010 , 5, e12038	94
1820	Nanoparticle-assisted combination therapies for effective cancer treatment. 2010 , 1, 323-34	381
1819	N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier. 2010 , 38, 917-22	35
1818	Vectorial transport of nucleoside analogs from the apical to the basolateral membrane in double-transfected cells expressing the human concentrative nucleoside transporter hCNT3 and the export pump ABCC4. 2010 , 38, 1054-63	20
1817	Error-prone translesion synthesis mediates acquired chemoresistance. 2010 , 107, 20792-7	158
1816	Verotoxin-1 treatment or manipulation of its receptor globotriaosylceramide (gb3) for reversal of multidrug resistance to cancer chemotherapy. 2010 , 2, 2467-77	11
1815	Interaction of tyrosine kinase inhibitors with the MDR- related ABC transporter proteins. 2010 , 11, 618-28	38
1814	P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer ¹¹ C-N-desmethyl-loperamide. 2010 , 51, 559-66	116
1813	Cancer stem cells: a novel paradigm for cancer prevention and treatment. 2010 , 10, 359-71	72
1812	Circumventing tumor resistance to chemotherapy by nanotechnology. 2010 , 596, 467-88	222
1811	Molecular mechanisms of drug resistance in single-step and multi-step drug-selected cancer cells. 2010 , 596, 77-93	32
1810	Drug resistance is affected by colocalization of P-glycoproteins in raft-like structures unexpected in eggshells of the nematode <i>Haemonchus contortus</i> . 2010 , 88, 459-67	9

1809	Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling. 2010 , 9, 145	114
1808	Drug resistance in breast cancer cells: biophysical characterization of and doxorubicin interactions with membrane lipids. 2010 , 7, 2334-48	87
1807	Polymer--cisplatin conjugate nanoparticles for acid-responsive drug delivery. 2010 , 4, 251-8	337
1806	Properties, engineering and applications of lipid-based nanoparticle drug-delivery systems: current research and advances. 2010 , 5, 1237-60	71
1805	Purinergic mechanisms in breast cancer support intravasation, extravasation and angiogenesis. 2010 , 291, 131-41	21
1804	P-glycoprotein ATPase from the resistant pest, <i>Helicoverpa armigera</i> : purification, characterization and effect of various insecticides on its transport function. 2010 , 1798, 1135-43	46
1803	Cytotoxicity, intracellular distribution and uptake of doxorubicin and doxorubicin coupled to cell-penetrating peptides in different cell lines: a comparative study. 2010 , 391, 419-25	87
1802	Modulation of DNA methylation levels sensitizes doxorubicin-resistant breast adenocarcinoma cells to radiation-induced apoptosis. 2010 , 392, 113-7	16
1801	Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. 2010 , 4, 4539-50	748
1800	Dormancy of metastatic melanoma. 2010 , 23, 41-56	94
1799	LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. 2010 , 29, 5785-95	95
1798	Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. 2010 , 9, 3126-36	122
1797	Phenylsulfonylfuroxans as modulators of multidrug-resistance-associated protein-1 and P-glycoprotein. 2010 , 53, 5467-75	49
1796	Metalloprobes for functional monitoring of tumour multidrug resistance by nuclear imaging. 2011 , 40, 5377-93	22
1795	Synthetic lethal hubs associated with vincristine resistant neuroblastoma. 2011 , 7, 200-14	9
1794	Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin. 2011 , 54, 4987-97	32
1793	Combination drug delivery strategy for the treatment of multidrug resistant ovarian cancer. 2011 , 8, 260-9	38
1792	A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. 2011 , 7, 787-93	132

1791	Reversal effects of traditional Chinese herbs on multidrug resistance in cancer cells. 2011 , 25, 1885-9	15
1790	Nitric oxide donor doxorubicins accumulate into Doxorubicin-resistant human colon cancer cells inducing cytotoxicity. 2011 , 2, 494-7	58
1789	Single-cell-kinetics approach to compare multidrug resistance-associated membrane transport in subpopulations of cells. 2011 , 83, 6132-4	8
1788	Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy. 2011 , 8, 1401-7	154
1787	pH-Triggered Micelles for Tumor Delivery. 2011 , 1099-1131	
1786	Dodging drug-resistant cancer with diamonds. 2011 , 3, 73ps8	34
1785	The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. 2011 , 18, 488-95	107
1784	Oncoproteomics. 2011 , 412, 217-26	16
1783	Indomethacin and SC236 enhance the cytotoxicity of doxorubicin in human hepatocellular carcinoma cells via inhibiting P-glycoprotein and MRP1 expression. 2011 , 304, 90-6	36
1782	Suppression of autophagy sensitizes multidrug resistant cells towards Src tyrosine kinase specific inhibitor PP2. 2011 , 310, 188-97	27
1781	Tualang honey induces apoptosis and disrupts the mitochondrial membrane potential of human breast and cervical cancer cell lines. 2011 , 49, 871-8	148
1780	Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. 2011 , 14, 191-201	426
1779	Estrogen receptor of breast cancer stem cells depending on the original breast cancers. 2011 , 77, 71-3	4
1778	Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. 2011 , 54, 3606-23	162
1777	Mechanism of cell death resulting from DNA interstrand cross-linking in mammalian cells. 2011 , 2, e187	33
1776	Drug resistance and cellular adaptation to tumor acidic pH microenvironment. 2011 , 8, 2032-8	326
1775	Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer. 2011 , 185, 2376-81	40
1774	MCF-7 Breast Cancer Cell Line, a Model for the Study of the Association Between Inflammation and ABCG2-Mediated Multi Drug Resistance. 2011 ,	

1773	Correlation of Early Systemic Recurrence with In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay in Stage II and III Breast Cancer Patients Treated with Doxorubicin-Based Chemotherapy. 2011 , 14, S50	1
1772	The efficacy of mitochondrial targeting antiresistant epirubicin liposomes in treating resistant leukemia in animals. 2011 , 6, 3125-37	17
1771	Multidrug Resistance Transporters [Roles in maintaining Cancer Stem-Like Cells. 2011 ,	1
1770	Population Pharmacoeconomics. 2011 , 511-517	1
1769	Novel Oncology Drug Development Strategies in the Era of Personalised Medicine. 2011 ,	
1768	Phase I/II study of biweekly vinorelbine and oxaliplatin as first-line treatment in patients with metastatic breast cancer. 2011 , 22, 283-9	3
1767	An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies. 2011 , 22, 531-42	17
1766	Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer. 2011 , 34, 488-93	25
1765	Plasma membrane microorganization of LR73 multidrug-resistant cells revealed by FCS. 2011 ,	1
1764	Synthesis and Comparison of the Antitumor Activities of Steroids on ABCB1-transfected Mouse Lymphoma and Human Ovary Carcinoma. 2011 , 8, 138-147	
1763	Biotransformation of a taxadiene by ginkgo cell cultures and the tumor multi-drug resistant reversal activities of the metabolites. 2011 , 59, 1038-41	3
1762	ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. 2011 , 30, 4874-86	135
1761	Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. 2011 , 89, 491-502	202
1760	Prognostic value of ABCG2 in moderately and poorly differentiated intrahepatic cholangiocarcinoma. 2011 , 59, 235-46	13
1759	AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group. 2011 , 255, 40-7	57
1758	Nuclear translocation of MRP1 contributes to multidrug resistance of mucoepidermoid carcinoma. 2011 , 47, 1134-40	12
1757	Reversal effect of 2-(4-hydroxy-6-methoxy-3,5-dimethylchalcone) on multi-drug resistance in resistant human hepatocellular carcinoma cell line BEL-7402/5-FU. 2011 , 18, 1086-92	30
1756	Piperine, a piperidine alkaloid from Piper nigrum re-sensitizes P-gp, MRP1 and BCRP dependent multidrug resistant cancer cells. 2011 , 19, 83-7	96

1755	P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells. 2011 , 317, 1736-45	11
1754	Yin-yang balance therapy on regulating cancer stem cells. 2011 , 31, 158-60	10
1753	Membrane-active host defense peptides--challenges and perspectives for the development of novel anticancer drugs. 2011 , 164, 766-81	305
1752	Non-coding RNAs as theranostics in human cancers. 2012 , 113, 1451-9	44
1751	Targeting therapy with mitosomal daunorubicin plus amlodipine has the potential to circumvent intrinsic resistant breast cancer. 2011 , 8, 162-75	32
1750	Sensitizing effect of silencing Ape1/Ref-1 on doxorubicin-induced apoptosis in human carcinoma cells. 2011 , 7, 389-397	2
1749	Discovery of (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a kinesin spindle protein inhibitor and potential anticancer agent. 2011 , 54, 6734-50	54
1748	Sea Urchin Embryotoxicity Test for Environmental Contaminants Potential Role of the MRP Proteins. 2011 , 217, 627-636	11
1747	Targeting the autophagy pathway using ectopic expression of Beclin 1 in combination with rapamycin in drug-resistant v-Ha-ras-transformed NIH 3T3 cells. 2011 , 31, 231-8	33
1746	Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer cell lines with different drug resistance mechanisms. 2011 , 7, 324-32	58
1745	Involvement of the epidermal growth factor receptor in the modulation of multidrug resistance in human hepatocellular carcinoma cells in vitro. 2011 , 11, 40	17
1744	Compound Kushen Injection suppresses human breast cancer stem-like cells by down-regulating the canonical Wnt/ β -catenin pathway. 2011 , 30, 103	47
1743	Overexpression of Lewis(y) antigen protects ovarian cancer RMG-1 cells from carboplatin-induced apoptosis by the upregulation of Topo-I and Topo-II β . 2011 , 294, 961-9	12
1742	Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. 2011 , 32, 259-69	46
1741	Sphingolipid metabolism and drug resistance in hematological malignancies. 2011 , 11, 891-903	14
1740	Strategies on the development of small molecule anticancer drugs for targeted therapy. 2011 , 11, 611-24	13
1739	Pancreatic cancer: understanding and overcoming chemoresistance. 2011 , 8, 27-33	257
1738	miRNAs in lung cancer: large roles for small players. 2011 , 7, 1045-55	31

1737	Chemotherapeutic resistance: surviving stressful situations. 2011 , 71, 5062-6	44
1736	Mechanisms and therapeutic implications of cell death induction by indole compounds. 2011 , 3, 2955-74	27
1735	Developing central nervous system and vulnerability to platinum compounds. 2011 , 2011, 315418	20
1734	Apoptotic sphingolipid ceramide in cancer therapy. 2011 , 2011, 565316	63
1733	Establishment of cisplatin-resistant ovarian yolk sac tumor cells and investigation of the mechanism of cisplatin resistance using this cell line. 2011 , 71, 104-11	5
1732	FER tyrosine kinase (FER) overexpression mediates resistance to quinacrine through EGF-dependent activation of NF-kappaB. 2011 , 108, 7968-73	36
1731	Conformational analysis of human ATP-binding cassette transporter ABCB1 in lipid nanodiscs and inhibition by the antibodies MRK16 and UIC2. 2011 , 286, 39489-96	59
1730	Dietary isothiocyanate-induced apoptosis via thiol modification of DNA topoisomerase II β . 2011 , 286, 33591-600	37
1729	Autophagy protects breast cancer cells from epirubicin-induced apoptosis and facilitates epirubicin-resistance development. 2011 , 7, 1035-44	126
1728	Revisiting the ABCs of multidrug resistance in cancer chemotherapy. 2011 , 12, 570-94	155
1727	Radical decisions in cancer: redox control of cell growth and death. 2012 , 4, 442-74	52
1726	Expression and function of heme oxygenase-1 in human gastric cancer. 2012 , 237, 362-71	43
1725	Xenobiotic metabolism and disposition in human lung cell models: comparison with in vivo expression profiles. 2012 , 40, 1953-65	61
1724	Promises and challenges of exhausting pediatric neural cancer stem cells. 2012 , 71, 523-8	4
1723	Anticancer drug discovery from the marine environment. 2012 , 7, 218-32	38
1722	Preclinical models for pediatric solid tumor drug discovery: current trends, challenges and the scopes for improvement. 2012 , 7, 1093-106	4
1721	The mesenchymal tumor microenvironment: a drug-resistant niche. 2012 , 6, 285-96	36
1720	Association of ABCB1 polymorphisms with survival and in vitro cytotoxicity in de novo acute myeloid leukemia with normal karyotype. 2012 , 12, 111-8	31

1719	Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling. 2012 , 13, 793-803	24
1718	Multifaceted recognition of vertebrate Rev1 by translesion polymerases β and γ 2012 , 287, 26400-8	63
1717	Oral delivery of chemotherapeutic agents: background and potential of drug delivery systems for colon delivery. 2012 , 22, 459-468	11
1716	Extracellular matrix proteins modulate antimigratory and apoptotic effects of Doxorubicin. 2012 , 2012, 268681	17
1715	Focal adhesion-chromatin linkage controls tumor cell resistance to radio- and chemotherapy. 2012 , 2012, 319287	18
1714	Proteomic footprinting of drug-treated cancer cells as a measure of cellular vaccine efficacy for the prevention of cancer recurrence. 2012 , 11, M111.014480	12
1713	miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2. 2012 , 44, 269-77	45
1712	Fullerenes for cancer diagnosis and therapy: preparation, biological and clinical perspectives. 2012 , 13, 1035-45	84
1711	Targeting cancer stem cells with natural products. 2012 , 13, 1054-64	24
1710	Secretase inhibition combined with cisplatin enhances apoptosis of nasopharyngeal carcinoma cells. 2012 , 3, 357-361	18
1709	A mediator lost in the war on cancer. 2012 , 151, 927-9	12
1708	Realizing the clinical potential of cancer nanotechnology by minimizing toxicologic and targeted delivery concerns. 2012 , 72, 5663-8	71
1707	Structural insight into the mechanism of epothilone A bound to beta-tubulin and its mutants at Arg282Gln and Thr274Ile. 2012 , 30, 559-73	11
1706	Proteomic analysis of ovarian cancer cell responses to cytotoxic gold compounds. 2012 , 4, 307-14	33
1705	Transporting Systems. 2012 , 199-222	
1704	DNA origami as a carrier for circumvention of drug resistance. 2012 , 134, 13396-403	561
1703	The use of a tumor metastasis targeting peptide to deliver doxorubicin-containing liposomes to highly metastatic cancer. 2012 , 33, 8451-60	94
1702	Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production. 2012 , 135, 737-47	73

1701	Silencing expression of ribosomal protein L26 and L29 by RNA interfering inhibits proliferation of human pancreatic cancer PANC-1 cells. 2012 , 370, 127-39	34
1700	DNA methylation of circulating DNA: a marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients. 2012 , 33, 1837-43	38
1699	Self-Assembly of Polymers into Soft Nanoparticles and Nanocapsules. 2012 ,	1
1698	Nicotine induces inhibitor of differentiation-1 in a Src-dependent pathway promoting metastasis and chemoresistance in pancreatic adenocarcinoma. 2012 , 14, 1102-14	47
1697	A novel sulfonamide agent, MPSP-001, exhibits potent activity against human cancer cells in vitro through disruption of microtubule. 2012 , 33, 261-70	25
1696	Interferon- β -armed oncolytic adenovirus induces both apoptosis and necroptosis in cancer cells. 2012 , 44, 737-45	22
1695	Reversal of multidrug resistance by morning glory resin glycosides in human breast cancer cells. 2012 , 75, 93-7	59
1694	Stem Cell Characters in Primary and Metastatic Tumour Establishment. 2012 , 533-580	1
1693	Enhancement of cellular uptake and cytotoxicity of curcumin-loaded PLGA nanoparticles by conjugation with anti-P-glycoprotein in drug resistance cancer cells. 2012 , 33, 823-31	86
1692	Cancer Stem Cells: Novel Target Using Dietary Components for Prevention and Treatment. 2012 , 11-38	
1691	Cancer invasion and resistance: interconnected processes of disease progression and therapy failure. 2012 , 18, 13-26	118
1690	The role of autophagy in cytotoxicity induced by new oncogenic B-Raf inhibitor UI-152 in v-Ha-ras transformed fibroblasts. 2012 , 417, 857-63	9
1689	Epigenetic loss of CDH1 correlates with multidrug resistance in human hepatocellular carcinoma cells. 2012 , 422, 739-44	10
1688	YHHU0895, a novel synthetic small-molecule microtubule-destabilizing agent, effectively overcomes P-glycoprotein-mediated tumor multidrug resistance. 2012 , 314, 54-62	12
1687	Ginsenoside F2 induces apoptosis accompanied by protective autophagy in breast cancer stem cells. 2012 , 321, 144-53	116
1686	Microparticles and their emerging role in cancer multidrug resistance. 2012 , 38, 226-34	121
1685	Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. 2012 , 15, 70-80	128
1684	Epigenetic modulation of the biophysical properties of drug-resistant cell lipids to restore drug transport and endocytic functions. 2012 , 9, 2730-42	45

1683	Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies. 2012 , 21, 205-16	59
1682	Dual regulation of P-glycoprotein expression by trichostatin A in cancer cell lines. 2012 , 13, 25	12
1681	Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line. 2012 , 12, 139	78
1680	The stem cell factor antibody enhances the chemotherapeutic effect of adriamycin on chemoresistant breast cancer cells. 2012 , 12, 21	6
1679	Versatile inhibitory effects of the flavonoid-derived PI3K/Akt inhibitor, LY294002, on ATP-binding cassette transporters that characterize stem cells. 2012 , 1, 24	33
1678	Secondary Metabolites from Plants Inhibiting ABC Transporters and Reversing Resistance of Cancer Cells and Microbes to Cytotoxic and Antimicrobial Agents. 2012 , 3, 130	101
1677	7,3,4-Trihydroxyisoflavone modulates multidrug resistance transporters and induces apoptosis via production of reactive oxygen species. 2012 , 302, 221-32	37
1676	Long-circulating PEG-PE micelles co-loaded with paclitaxel and elacridar (GG918) overcome multidrug resistance. 2012 , 19, 363-70	43
1675	Challenges in design of translational nanocarriers. 2012 , 164, 156-69	191
1674	OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance. 2012 , 84, 766-74	20
1673	Pseudozyma spp. and Barnettozyma spp. effectively kill cancer cells in vitro. 2012 , 4, 61-64	2
1672	Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. 2012 , 7, 367-379	252
1671	Normal and Neoplastic Stem Cells. 2012 ,	
1670	Marine compounds selectively induce apoptosis in female reproductive cancer cells but not in primary-derived human reproductive granulosa cells. 2012 , 10, 64-83	38
1669	Analytical strategy to reveal the in vivo process of multi-component herbal medicine: a pharmacokinetic study of licorice using liquid chromatography coupled with triple quadrupole mass spectrometry. 2012 , 1258, 84-93	73
1668	Significant activity of ecdysteroids on the resistance to doxorubicin in mammalian cancer cells expressing the human ABCB1 transporter. 2012 , 55, 5034-43	39
1667	Taxol, Camptothecin and Beyond for Cancer Therapy. 2012 , 133-178	3
1666	Cancer treatment as a game: integrating evolutionary game theory into the optimal control of chemotherapy. 2012 , 9, 065007	56

1665	Lipid nanoparticles for chemotherapeutic applications: strategies to improve anticancer efficacy. 2012 , 9, 767-81	20
1664	Reversing ABCB1-mediated multi-drug resistance from within cells using translocating immune conjugates. 2012 , 20, 445-52	5
1663	Mechanisms of resistance to histone deacetylase inhibitors. 2012 , 116, 39-86	68
1662	Antimitotic inhibitors. 2012 , 26, 607-28, viii-ix	13
1661	Inhibitors of fatty acid synthesis in prokaryotes and eukaryotes as anti-infective, anticancer and anti-obesity drugs. 2012 , 4, 1113-51	14
1660	A marine anthraquinone SZ-685C overrides adriamycin-resistance in breast cancer cells through suppressing Akt signaling. 2012 , 10, 694-711	28
1659	Multidrug resistance associated proteins in multidrug resistance. 2012 , 31, 58-72	165
1658	Failure of Pancreatic Cancer Chemotherapy: Consequences of Drug Resistance Mechanisms. 2012 ,	1
1657	Cisplatin Resistance in Malignant Pleural Mesothelioma. 2012 ,	
1656	Molecular targeting of liposomal nanoparticles to tumor microenvironment. 2013 , 8, 61-71	50
1655	Reversal effects of components from the fruits of <i>Illicium simonsii</i> on human Adriamycin-resistant MCF-7 and 5-fluorouracil-resistant Bel7402 cells. 2012 , 26, 562-7	11
1654	MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy. 2012 , 287, 4148-56	153
1653	Long-term cisplatin exposure impairs autophagy and causes cisplatin resistance in human lung cancer cells. 2012 , 364, 11-8	56
1652	Combinatorial drug therapy for cancer in the post-genomic era. 2012 , 30, 679-92	670
1651	Comparison of NMR lipid profiles in mitotic arrest and apoptosis as indicators of paclitaxel resistance in cervical cell lines. 2012 , 68, 369-77	13
1650	A new anticancer compound, oblongifolin C, inhibits tumor growth and promotes apoptosis in HeLa cells through Bax activation. 2012 , 131, 1445-54	42
1649	Managing drug resistance in cancer: lessons from HIV therapy. 2012 , 12, 494-501	135
1648	Chromosomal instability and aneuploidy in cancer: from yeast to man. 2012 , 13, 515-27	155

1647	Study of the anticancer properties of tin(IV) carboxylate complexes on a panel of human tumor cell lines. 2012 , 7, 301-10	42
1646	Discovery of novel 2-N-aryl-substituted benzenesulfonamidoacetamides: orally bioavailable tubulin polymerization inhibitors with marked antitumor activities. 2012 , 7, 680-93	15
1645	Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. 2012 , 64, 706-21	565
1644	Resistance to chemotherapy in non-small cell lung cancer with Keap1 gene mutation. 2012 , 1, 63-66	
1643	Drug resistance in glioblastoma: a mini review. 2012 , 37, 1192-200	184
1642	Doxorubicin and MBO-asGCS oligonucleotide loaded lipid nanoparticles overcome multidrug resistance in adriamycin resistant ovarian cancer cells (NCI/ADR-RES). 2012 , 431, 222-9	27
1641	Nuclear export of proteins and drug resistance in cancer. 2012 , 83, 1021-32	261
1640	Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. 2012 , 83, 1104-11	505
1639	Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma. 2012 , 33, 1808-20	74
1638	Indeno[1,2-b]indole derivatives as a novel class of potent human protein kinase CK2 inhibitors. 2012 , 20, 2282-9	59
1637	Nanotechnology applied to overcome tumor drug resistance. 2012 , 162, 45-55	243
1636	PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter. 2012 , 103, 1531-7	34
1635	A benzopyrane derivative as a P-glycoprotein stimulator: a potential agent to decrease β -amyloid accumulation in Alzheimer's disease. 2012 , 7, 391-5	10
1634	Multidrug resistance reversal effect of DMC derived from buds of <i>Cleistocalyx operculatus</i> in human hepatocellular tumor xenograft model. 2012 , 92, 135-40	25
1633	A novel nanoparticle formulation overcomes multiple types of membrane efflux pumps in human breast cancer cells. 2012 , 2, 95-105	32
1632	Ion channels in pediatric CNS Atypical Teratoid/Rhabdoid Tumor (AT/RT) cells: potential targets for novel therapeutic agents. 2012 , 107, 111-9	4
1631	Deconstructing the mechanisms and consequences of TGF- β -induced EMT during cancer progression. 2012 , 347, 85-101	171
1630	Tumor-initiating stem-like cells and drug resistance: carcinogenesis through Toll-like receptors, environmental factors, and virus. 2013 , 3, 152-64	5

1629	Carbon nanotubes in hyperthermia therapy. 2013 , 65, 2045-60	164
1628	Extensive characterization of sphere models established from colorectal cancer cell lines. 2013 , 70, 729-42	16
1627	Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer. 2013 , 62, 405-10	65
1626	Next-generation metal anticancer complexes: multitargeting via redox modulation. 2013 , 52, 12276-91	303
1625	Carboplatin resistant human laryngeal carcinoma cells are cross resistant to curcumin due to reduced curcumin accumulation. 2013 , 27, 523-32	11
1624	The anticancer agent prodigiosin is not a multidrug resistance protein substrate. 2013 , 32, 90-7	38
1623	Cancer cell bioenergetics and pH regulation influence breast cancer cell resistance to paclitaxel and doxorubicin. 2013 , 45, 467-75	48
1622	DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology. 2013 , 20, 648-59	354
1621	Nanopreparations to overcome multidrug resistance in cancer. 2013 , 65, 1748-62	244
1620	Imaging P-glycoprotein function in rats using [(11)C]-N-desmethyl-loperamide. 2013 , 27, 618-24	9
1619	Identification and characterization of a 66-68-kDa protein as a methotrexate-binding protein in murine leukemia L1210 cells. 2013 , 18, 223-34	5
1618	Carbon nanotubes for delivery of small molecule drugs. 2013 , 65, 1964-2015	427
1617	Rationally designed nanovehicles to overcome cancer chemoresistance. 2013 , 65, 1716-30	166
1616	Lung cancer-initiating cells: a novel target for cancer therapy. 2013 , 8, 159-172	21
1615	Bioengineering strategies for designing targeted cancer therapies. 2013 , 118, 1-59	49
1614	Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein. 2013 , 36, 583-7	18
1613	The quest to overcome resistance to EGFR-targeted therapies in cancer. 2013 , 19, 1389-400	684
1612	Enhancing cell nucleus accumulation and DNA cleavage activity of anti-cancer drug via graphene quantum dots. 2013 , 3, 2852	133

1611	Design, synthesis and evaluation of inhibitor of apoptosis protein (IAP) antagonists that are highly selective for the BIR2 domain of XIAP. 2013 , 23, 4253-7	12
1610	A novel SERCA inhibitor demonstrates synergy with classic SERCA inhibitors and targets multidrug-resistant AML. 2013 , 10, 4358-66	23
1609	Post-transcriptional controls by ribonucleoprotein complexes in the acquisition of drug resistance. 2013 , 14, 17204-20	19
1608	Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles. 2013 , 65, 1686-98	148
1607	Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities. 2013 , 65, 1731-47	189
1606	The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines. 2013 , 31, 461-8	44
1605	Activity of fungicides and modulators of membrane drug transporters in field strains of <i>Botrytis cinerea</i> displaying multidrug resistance. 2013 , 135, 683-693	49
1604	Investigating the effects of ABC transporter-based acquired drug resistance mechanisms at the cellular and tissue scale. 2013 , 5, 555-68	8
1603	Amurensin G enhances the susceptibility to tumor necrosis factor-related apoptosis-inducing ligand-mediated cytotoxicity of cancer stem-like cells of HCT-15 cells. 2013 , 104, 1632-9	9
1602	The role of microvesicles in cancer progression and drug resistance. 2013 , 41, 293-8	27
1601	Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance. 2013 , 117, 59-89	101
1600	Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. 2013 , 7, 994-1005	456
1599	Gambogic acid as a non-competitive inhibitor of ATP-binding cassette transporter B1 reverses the multidrug resistance of human epithelial cancers by promoting ATP-binding cassette transporter B1 protein degradation. 2013 , 112, 25-33	39
1598	Mitochondrial localization of P-glycoprotein and peptide transporters in corneal epithelial cells--novel strategies for intracellular drug targeting. 2013 , 106, 47-54	13
1597	An isoquinoline alkaloid from the Chinese herbal plant <i>Corydalis yanhusuo</i> W.T. Wang inhibits P-glycoprotein and multidrug resistance-associate protein 1. 2013 , 136, 1117-21	41
1596	Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells. 2013 , 372, 65-74	14
1595	Importance of detecting multidrug resistance proteins in acute leukemia prognosis and therapy. 2013 , 27, 62-71	21
1594	Expedient synthesis of highly potent antagonists of inhibitor of apoptosis proteins (IAPs) with unique selectivity for ML-IAP. 2013 , 8, 725-32	24

1593	Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis. 2013 , 130, 369-76	31
1592	Hepatic embolotherapy in interventional oncology: technology, techniques, and applications. 2013 , 68, 1-15	30
1591	Elevated serum IL-22 levels correlate with chemoresistant condition of colorectal cancer. 2013 , 147, 38-39	41
1590	PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors. 2013 , 48, 644-9	35
1589	Multifunctional albumin nanoparticles as combination drug carriers for intra-tumoral chemotherapy. 2013 , 2, 1236-45	45
1588	Design and biological evaluation of cell-penetrating peptide-doxorubicin conjugates as prodrugs. 2013 , 10, 488-99	76
1587	Characterizing binding of small molecules. II. Evaluating the potency of small molecules to combat resistance based on docking structures. 2013 , 53, 1213-22	18
1586	Gene expression alterations in doxorubicin resistant MCF7 breast cancer cell line. 2013 , 101, 213-20	107
1585	Gold nanorod-cored biodegradable micelles as a robust and remotely controllable doxorubicin release system for potent inhibition of drug-sensitive and -resistant cancer cells. 2013 , 14, 2411-9	106
1584	PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells. 2013 , 72, 189-99	42
1583	pH-responsive hydrogels containing PMMA nanoparticles: an analysis of controlled release of a chemotherapeutic conjugate and transport properties. 2013 , 24, 1027-40	13
1582	Chapter 1: Targeted Drug Delivery in Oncology: Current Paradigm and Challenges. 2013 , 1-19	1
1581	Doxorubicin loading, release, and stability of polyamidoamine dendrimer-coated magnetic nanoparticles. 2013 , 102, 1825-1835	39
1580	Phosphanegold(I) dithiocarbamates, R ₃ PAu[SC(=S)N((i)Pr)CH ₂ CH ₂ OH] for R = Ph, Cy and Et: role of phosphane-bound R substituents upon in vitro cytotoxicity against MCF-7R breast cancer cells and cell death pathways. 2013 , 67, 127-41	41
1579	Alkaloids Derived from Lysine: Piperidine Alkaloids. 2013 , 303-341	12
1578	Reversal effects of Radosia rubescens extract on multidrug resistance of MCF-7/Adr cells in vitro. 2013 , 51, 1196-203	10
1577	The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. 2013 , 67, 669-80	127
1576	Current progress for the use of miRNAs in glioblastoma treatment. 2013 , 48, 757-68	32

1575	Tumor suppressor genes associated with drug resistance in ovarian cancer (review). 2013 , 30, 3-10	43
1574	Lysosomal membrane permeabilization by targeted magnetic nanoparticles in alternating magnetic fields. 2013 , 7, 5091-101	186
1573	Drug delivery systems based on nucleic acid nanostructures. 2013 , 172, 467-83	70
1572	Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. 2013 , 328, 307-17	92
1571	Testing the substrate-envelope hypothesis with designed pairs of compounds. 2013 , 8, 2433-41	27
1570	Structures of ABCB10, a human ATP-binding cassette transporter in apo- and nucleotide-bound states. 2013 , 110, 9710-5	193
1569	Magnetic nanoparticle hyperthermia enhancement of cisplatin chemotherapy cancer treatment. 2013 , 29, 845-51	49
1568	Novel bourgeonal fragrance conjugates for the detection of prostate cancer. 2013 , 31, 1151-7	5
1567	Near-infrared imaging loaded polymeric nanoparticles:in vitroandin vivostudies. 2013 ,	2
1566	Biology of ocular transporters: efflux and influx transporters in the eye. 2013 , 37-84	5
1565	Tualang honey promotes apoptotic cell death induced by tamoxifen in breast cancer cell lines. 2013 , 2013, 989841	44
1564	MDR gene expression analysis of six drug-resistant ovarian cancer cell lines. 2013 , 2013, 241763	72
1563	Changes in Gene Methylation Following Chemotherapy in Breast Cancer Cell Lines. 2013 , 38, 154-162	
1562	Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR-CML cell lines?. 2013 , 33,	51
1561	The role of the dysfunctional akt-related pathway in cancer: establishment and maintenance of a malignant cell phenotype, resistance to therapy, and future strategies for drug development. 2013 , 2013, 317186	34
1560	Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy. 2013 , 3, 261	57
1559	Multidrug resistance and cancer stem cells in neuroblastoma and hepatoblastoma. 2013 , 14, 24706-25	69
1558	Bipiperidinyl derivatives of 23-hydroxybetulinic acid reverse resistance of HepG2/ADM and MCF-7/ADR cells. 2013 , 24, 441-54	6

1557	Upregulation of drug transporter expression by osteopontin in prostate cancer cells. 2013 , 83, 968-77	30
1556	Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors. 2013 , 19, 5972-83	42
1555	Nanomaterials in medicine and pharmaceuticals: nanoscale materials developed with less toxicity and more efficacy. 2013 , 5,	24
1554	Genome-wide analysis of miRNA signature differentially expressed in doxorubicin-resistant and parental human hepatocellular carcinoma cell lines. 2013 , 8, e54111	26
1553	Nanomaterials for reversion of multidrug resistance in cancer: a new hope for an old idea?. 2013 , 4, 134	26
1552	Vascular permeability and drug delivery in cancers. 2013 , 3, 211	187
1551	Antiproliferative activity of methanolic extracts from two green algae, <i>Enteromorpha intestinalis</i> and <i>Rizoclonium riparium</i> on HeLa cells. 2013 , 21, 72	18
1550	Sphingolipid metabolic pathway: an overview of major roles played in human diseases. 2013 , 2013, 178910	85
1549	Evaluation of hydro-alcoholic extract of <i>Eclipta alba</i> for its multidrug resistance reversal potential: an in vitro study. 2013 , 65, 775-80	10
1548	Functionalized DNA Nanostructures for Nanomedicine. 2013 , 53, 555-566	6
1547	MicroRNAs: key players of taxane resistance and their therapeutic potential in human cancers. 2013 , 17, 1207-17	20
1546	References. 2013 , 217-288	
1545	An inulin and doxorubicin conjugate for improving cancer therapy. 2013 , 23, 111-118	16
1544	Mechanisms and insights into drug resistance in cancer. 2013 , 4, 28	380
1543	Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy. 2013 , 4,	38
1542	Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition. 2013 , 42, 1139-50	24
1541	Brahma-related gene 1-associated expression of 9-27 and IFI-27 is involved in acquired cisplatin resistance of gastric cancer cells. 2013 , 8, 747-50	5
1540	Deltonin induces apoptosis in MDA-MB-231 human breast cancer cells via reactive oxygen species-mediated mitochondrial dysfunction and ERK/AKT signaling pathways. 2013 , 7, 1038-44	17

1539	Molecular mechanisms of radiation resistance in doxorubicin-resistant breast adenocarcinoma cells. 2013 , 42, 1692-708	12
1538	Double inhibition of NF- κ B and XIAP via RNAi enhances the sensitivity of pancreatic cancer cells to gemcitabine. 2013 , 29, 1659-65	14
1537	Nano-hole induction by nanodiamond and nanoplatinum liquid, DPV576, reverses multidrug resistance in human myeloid leukemia (HL60/AR). 2013 , 8, 2567-73	13
1536	Sequestration of AS-DACA into acidic compartments of the membrane trafficking system as a mechanism of drug resistance in rhabdomyosarcoma. 2013 , 14, 13042-62	3
1535	Screening compounds with a novel high-throughput ABCB1-mediated efflux assay identifies drugs with known therapeutic targets at risk for multidrug resistance interference. 2013 , 8, e60334	37
1534	bba, a synthetic derivative of 23-hydroxybutulinic acid, reverses multidrug resistance by inhibiting the efflux activity of MRP7 (ABCC10). 2013 , 8, e74573	11
1533	Anticancer agent shikonin is an incompetent inducer of cancer drug resistance. 2013 , 8, e52706	41
1532	Microbubble-mediated ultrasound therapy: a review of its potential in cancer treatment. 2013 , 7, 375-88	124
1531	Biodegradable Polymersomes for the Delivery of Gemcitabine to Panc-1 Cells. 2013 , 2013,	2
1530	MRP1 but Not MDR1 Is Associated with Response to Neoadjuvant Chemotherapy in Breast Cancer Patients. 2013 , 34, 387-393	21
1529	Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics. 2013 , 8, 2677-88	70
1528	Imaging the urokinase plasminogen activator receptor in preclinical breast cancer models of acquired drug resistance. 2014 , 4, 267-79	29
1527	Antiproliferative activity of the isofuranonaphthoquinone isolated from <i>Bulbine frutescens</i> against Jurkat T cells. 2014 , 2014, 752941	8
1526	Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs. 2014 , 9, e95240	270
1525	A new diterpene from <i>Litsea cubeba</i> fruits: structure elucidation and capability to induce apoptosis in HeLa cells. 2014 , 19, 6838-50	8
1524	Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops. 2013 , 8, 193-202	46
1523	Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma. 2014 , 7, 1971-7	9
1522	The ability of hyaluronan fragments to reverse the resistance of C6 rat glioma cell line to temozolomide and carmustine. 2014 , 18, 323-8	5

1521	Antiproliferative and antibacterial activity evaluation of red microalgae <i>Rhodospirillum rubrum</i> . 2014 , 13, 4169-4175	1
1520	. 2014 ,	4
1519	Failure Modes in Anticancer Drug Discovery and Development. 2014 , 567-581	
1518	Calcium-channel blocking and nanoparticles-based drug delivery for treatment of drug-resistant human cancers. 2014 , 5, 763-80	8
1517	Membrane transporters and transporter substrates as biomarkers for drug pharmacokinetics, pharmacodynamics, and toxicity/adverse events. 2014 , 947-963	2
1516	ABC transporter-dependent brain uptake of the 5-HT _{1B} receptor radioligand [(11)C]AZ10419369: a comparative PET study in mouse, rat, and guinea pig. 2014 , 4, 64	3
1515	Cancer stem-like sphere cells induced from de-differentiated hepatocellular carcinoma-derived cell lines possess the resistance to anti-cancer drugs. 2014 , 14, 722	56
1514	Establishment and characterization of a cisplatin-resistant human osteosarcoma cell line. 2014 , 32, 1133-9	9
1513	Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib. 2014 , 5, e1162	15
1512	Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP). 2014 , 10, 1827-41	24
1511	Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance. 2014 , 6, 1925-52	46
1510	A long non-coding RNA snR contributes to 5-fluorouracil resistance in human colon cancer cells. 2014 , 37, 540-6	64
1509	Cellular levels of oxidative stress affect the response of cervical cancer cells to chemotherapeutic agents. 2014 , 2014, 574659	38
1508	Cancer stem cells: biological functions and therapeutically targeting. 2014 , 15, 8169-85	56
1507	Reduced Intracellular Drug Accumulation in Drug-Resistant Leukemia Cells is Not Only Solely Due to MDR-Mediated Efflux but also to Decreased Uptake. 2014 , 4, 306	18
1506	Role of receptor tyrosine kinases and their ligands in glioblastoma. 2014 , 3, 199-235	54
1505	Regulation of microRNAs by natural agents: new strategies in cancer therapies. 2014 , 2014, 804510	88
1504	Comparative Study of 17-AAG and NVP-AUY922 in Pancreatic and Colorectal Cancer Cells: Are There Common Determinants of Sensitivity?. 2014 , 7, 590-604	29

1503	Spatial-temporal FUCI imaging of each cell in a tumor demonstrates locational dependence of cell cycle dynamics and chemoresponsiveness. 2014 , 13, 2110-9	52
1502	A light-activated metal complex targets both DNA and RNA in a fluorescent in vitro transcription and translation assay. 2014 , 15, 507-11	14
1501	Anticancer profile of a series of gold(III) (2-phenyl)pyridine complexes. 2014 , 9, 2781-90	20
1500	Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells. 2014 , 105, 545-52	30
1499	Novel Insights into Combating Cancer Chemotherapy Resistance Using a Plasmonic Nanocarrier: Enhancing Drug Sensitiveness and Accumulation Simultaneously with Localized Mild Photothermal Stimulus of Femtosecond Pulsed Laser. 2014 , 24, 4229-4239	110
1498	Dual drug release from core-shell nanoparticles with distinct release profiles. 2014 , 103, 3205-16	33
1497	The role of the SHH gene in prostate cancer cell resistance to paclitaxel. 2014 , 74, 1142-52	18
1496	Trends of Gold Nanoparticle-based Drug Delivery System in Cancer Therapy. 2014 , 6, 172-178	101
1495	Inhibition of glutathione peroxidase mediates the collateral sensitivity of multidrug-resistant cells to tiopronin. 2014 , 289, 21473-89	31
1494	A Systems Biology Approach to Blood. 2014 ,	2
1493	The Q loops of the human multidrug resistance transporter ABCB1 are necessary to couple drug binding to the ATP catalytic cycle. 2014 , 28, 4335-46	33
1492	Drug resistance. 2014 , 844, 303-16	5
1491	Combinatorial nanotherapeutics: rewiring, then killing, cancer cells. 2014 , 7, pe13	10
1490	Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMab. 2014 , 6, 740-8	13
1489	A short update on cancer chemoresistance. 2014 , 164, 456-60	26
1488	Synergistic effects of isomorellin and forbesione with doxorubicin on apoptosis induction in human cholangiocarcinoma cell lines. 2014 , 14, 68	14
1487	An improved D- α -tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance. 2014 , 196, 272-86	49
1486	Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells. 2014 , 25, 255-69	21

1485	Evolutionary Dynamics of Cancer Cell Populations under Immune Selection Pressure and Optimal Control of Chemotherapy. 2014 , 9, 88-104	4
1484	An Introspective Update on the Influence of miRNAs in Breast Carcinoma and Neuroblastoma Chemoresistance. 2014 , 2014, 743050	7
1483	Resistance mechanisms of cancer cells to the novel vacuolar H(+)-ATPase inhibitor archazolid B. 2014 , 32, 893-903	8
1482	Effect of three fatty acids from the leaf extract of <i>Tiliacora triandra</i> on P-glycoprotein function in multidrug-resistant A549RT-eto cell line. 2014 , 10, S549-56	9
1481	Herbal nanoparticles: A patent review. 2014 , 8, 58	12
1480	Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy. 2014 , 35, 5965-76	79
1479	Group-based QSAR and molecular dynamics mechanistic analysis revealing the mode of action of novel piperidinone derived protein-protein inhibitors of p53-MDM2. 2014 , 51, 64-72	15
1478	Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers. 2014 , 8, 1231-9	61
1477	Role of the interleukin 6 receptor family in epithelial ovarian cancer and its clinical implications. 2014 , 1845, 117-25	21
1476	Sulindac and Celecoxib regulate cell cycle progression by p53/p21 up regulation to induce apoptosis during initial stages of experimental colorectal cancer. 2014 , 68, 301-19	17
1475	MicroRNAs delivered by extracellular vesicles: an emerging resistance mechanism for breast cancer. 2014 , 35, 2883-92	43
1474	Cytotoxicity and modes of action of five Cameroonian medicinal plants against multi-factorial drug resistance of tumor cells. 2014 , 153, 207-19	66
1473	Evolution of acquired resistance to anti-cancer therapy. 2014 , 355, 10-20	167
1472	Invading cancer cells are predominantly in G0/G1 resulting in chemoresistance demonstrated by real-time FUCCI imaging. 2014 , 13, 953-60	49
1471	Reaction dynamics of ATP hydrolysis catalyzed by P-glycoprotein. 2014 , 53, 991-1000	12
1470	MicroRNAs: master regulators of drug resistance, stemness, and metastasis. 2014 , 92, 321-36	52
1469	Self-Reporting Liposomes for Intracellular Drug Release. 2014 , 10, 1261-1265	33
1468	Cytokine regulation of mammary gland development and epithelial cell functions through discrete activities of Stat proteins. 2014 , 382, 552-559	3

1467	Bridging cancer biology and the patientskneeds with nanotechnology-based approaches. 2014 , 40, 626-35	40
1466	Using SV119-gold nanocage conjugates to eradicate cancer stem cells through a combination of photothermal and chemo therapies. 2014 , 3, 1283-91	61
1465	The scope of nanoparticle therapies for future metastatic melanoma treatment. 2014 , 15, e22-32	66
1464	Total synthesis and structural revision of sekothrixide. 2014 , 16, 2794-7	19
1463	Capillary-wall collagen as a biophysical marker of nanotherapeutic permeability into the tumor microenvironment. 2014 , 74, 4239-46	56
1462	MicroRNA Targeted Cancer Therapy. 2014 ,	1
1461	Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy. 2014 , 15, 1955-69	379
1460	The clinical relevance and prognostic significance of adenosine triphosphate ATP-binding cassette (ABCB5) and multidrug resistance (MDR1) genes expression in acute leukemia: an Egyptian study. 2014 , 140, 1323-30	11
1459	Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones. 2014 , 57, 2930-41	36
1458	Merging the best of both worlds: hybrid lipid-enveloped matrix nanocomposites in drug delivery. 2014 , 43, 444-72	133
1457	Nanotherapeutic approaches for brain cancer management. 2014 , 10, 905-19	70
1456	Inorganic nanoparticle-based drug codelivery nanosystems to overcome the multidrug resistance of cancer cells. 2014 , 11, 2495-510	120
1455	Evolving concepts in cancer therapy through targeting sphingolipid metabolism. 2014 , 1841, 1174-88	87
1454	The Multiple Therapeutic Targets of A20. 2014 ,	
1453	Single-cell analyses of transcriptional heterogeneity during drug tolerance transition in cancer cells by RNA sequencing. 2014 , 111, E4726-35	123
1452	Role of AMP-activated protein kinase in cross-talk between apoptosis and autophagy in human colon cancer. 2014 , 5, e1504	39
1451	Antioxidant and Antiproliferative Activities of Extracts of Selected Red and Brown Seaweeds from the Mandapam Coast of Tamil Nadu. 2014 , 38, 92-101	21
1450	Colon cancer: cancer stem cells markers, drug resistance and treatment. 2014 , 68, 911-6	148

1449	Mathematical modeling for novel cancer drug discovery and development. 2014 , 9, 1133-50	17
1448	A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression. 2014 , 24, 1241-50	17
1447	Combinatorial approach in the design of multifunctional polymeric nano-delivery systems for cancer therapy. 2014 , 2, 8069-8084	47
1446	Characterization of Peucedani Radix extract-derived angular-type pyranocoumarins in rats using ultra-high performance liquid chromatography coupled with hybrid triple quadrupole-linear ion trap mass spectrometry. 2014 , 6, 5198-5206	2
1445	Flavonostilbenes from Sophora alopecuroides L. as multidrug resistance associated protein 1 (MRP1) inhibitors. 2014 , 28, 2195-8	15
1444	Engineered nanoparticles: thrombotic events in cancer. 2014 , 6, 14141-52	8
1443	Paclitaxel-loaded N-octyl-O-sulfate chitosan micelles for superior cancer therapeutic efficacy and overcoming drug resistance. 2014 , 11, 145-57	57
1442	Impact of pediatric exclusivity on drug labeling and demonstrations of efficacy. 2014 , 134, e512-8	61
1441	Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1. 2014 , 90, 367-78	46
1440	Multifunctional tumor pH-sensitive self-assembled nanoparticles for bimodal imaging and treatment of resistant heterogeneous tumors. 2014 , 136, 5647-55	378
1439	3-Methyladenine can depress drug efflux transporters via blocking the PI3K-AKT-mTOR pathway thus sensitizing MDR cancer to chemotherapy. 2014 , 22, 839-48	14
1438	Proteasome inhibitor patents (2010 - present). 2014 , 24, 369-82	2
1437	Stromal microRNA-21 levels predict response to 5-fluorouracil in patients with pancreatic cancer. 2014 , 110, 952-9	37
1436	Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrier. 2014 , 11, 4164-78	71
1435	Polymer-controlled core-shell nanoparticles: a novel strategy for sequential drug release. 2014 , 4, 30430-30439	39
1434	Epigallocatechin-3-gallate potentiates the effect of curcumin in inducing growth inhibition and apoptosis of resistant breast cancer cells. 2014 , 42, 1279-300	44
1433	Organo-tin antitumor compounds: Their present status in drug development and future perspectives. 2014 , 423, 26-37	80
1432	Exosomes from docetaxel-resistant breast cancer cells alter chemosensitivity by delivering microRNAs. 2014 , 35, 9649-59	112

1431	Synergistic anti-carcinogenic effect of interferon- β with cisplatin on human breast adenocarcinoma MDA MB231 cells. 2014 , 23, 222-8	9
1430	Cytotoxic effects of escin on human castration-resistant prostate cancer cells through the induction of apoptosis and G2/M cell cycle arrest. 2014 , 84, 982.e1-7	23
1429	Functional differentiation of cytotoxic cancer drugs and targeted cancer therapeutics. 2014 , 70, 46-53	33
1428	Osthol and curcumin as inhibitors of human Pgp and multidrug efflux pumps of <i>Staphylococcus aureus</i> : reversing the resistance against frontline antibacterial drugs. 2014 , 5, 1540-1547	34
1427	Exosomes mediate drug resistance transfer in MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein. 2014 , 35, 10773-9	161
1426	Genkwadaphnin induces reactive oxygen species (ROS)-mediated apoptosis of squamous cell carcinoma (SCC) cells. 2014 , 450, 1115-9	11
1425	Delivery of siRNA by MRI-visible nanovehicles to overcome drug resistance in MCF-7/ADR human breast cancer cells. 2014 , 35, 9495-507	59
1424	Water-soluble and cleavable quercetin-amino acid conjugates as safe modulators for P-glycoprotein-based multidrug resistance. 2014 , 57, 7216-33	41
1423	Interleukin 22 protects colorectal cancer cells from chemotherapy by activating the STAT3 pathway and inducing autocrine expression of interleukin 8. 2014 , 154, 116-26	32
1422	Synthesis, in vitro cytotoxicity and apoptosis inducing study of 2-aryl-3-nitro-2H-chromene derivatives as potent anti-breast cancer agents. 2014 , 86, 562-9	75
1421	Site-directed delivery of nitric oxide to cancers. 2014 , 43, 8-16	35
1420	Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. 2014 , 194, 238-56	257
1419	Multixenobiotic Resistance Mechanism in Gills of Reared vs. Wild Mediterranean Mussel <i>Mytilus galloprovincialis</i> (Lamarck, 1819). 2014 , 225, 1	3
1418	Inhibition of survivin restores the sensitivity of breast cancer cells to docetaxel and vinblastine. 2014 , 174, 667-81	37
1417	RPN2-mediated glycosylation of tetraspanin CD63 regulates breast cancer cell malignancy. 2014 , 13, 134	58
1416	Cyanogramide with a new spiro[indolinone-pyrroloimidazole] skeleton from <i>Actinoalloteichus cyanogriseus</i> . 2014 , 16, 3708-11	40
1415	Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics. 2014 , 88, 1205-48	54
1414	Rapid assessment of drug response in cancer cells using microwell array and molecular imaging. 2014 , 406, 4195-206	8

1413	A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53(mut) exhibits ATP-binding cassette transporter upregulation and high glutathione levels. 2014 , 140, 1689-704	24
1412	Expression of HIF-1 β and MDR1/P-glycoprotein in refractory mesial temporal lobe epilepsy patients and pharmaco-resistant temporal lobe epilepsy rat model kindled by coriaria lactone. 2014 , 35, 1203-8	12
1411	The siRNA-mediated downregulation of N-Ras sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors. 2014 , 392, 239-47	6
1410	MicroRNAs: short non-coding players in cancer chemoresistance. 2014 , 2, 16	29
1409	Co-delivery of doxorubicin and RNA using pH-sensitive poly (amino ester) nanoparticles for reversal of multidrug resistance of breast cancer. 2014 , 35, 6047-59	104
1408	11a-N-Tosyl-5-deoxy-pterocarpan (LQB-223), a promising prototype for targeting MDR leukemia cell lines. 2014 , 78, 190-7	10
1407	Changes in gene expression profile in two multidrug resistant cell lines derived from a same drug sensitive cell line. 2014 , 38, 983-7	24
1406	Genetic markers for prediction of treatment outcomes in ovarian cancer. 2014 , 14, 401-10	13
1405	Mitochondrial P-glycoprotein ATPase contributes to insecticide resistance in the cotton bollworm, <i>Helicoverpa armigera</i> (Noctuidae: Lepidoptera). 2014 , 70, 651-60	4
1404	miR-22 targets the 3KUTR of HMGB1 and inhibits the HMGB1-associated autophagy in osteosarcoma cells during chemotherapy. 2014 , 35, 6021-8	58
1403	Association of ABCB1, β -tubulin I, and III with multidrug resistance of MCF7/DOC subline from breast cancer cell line MCF7. 2014 , 35, 8883-91	17
1402	Ratiometric delivery of cisplatin and doxorubicin using tumour-targeting carbon-nanotubes entrapping platinum(IV) prodrugs. 2014 , 5, 2265-2270	61
1401	Multi-drug resistance in a canine lymphoid cell line due to increased P-glycoprotein expression, a potential model for drug-resistant canine lymphoma. 2014 , 28, 1498-506	28
1400	RSF1 is a positive regulator of NF- κ B-induced gene expression required for ovarian cancer chemoresistance. 2014 , 74, 2258-69	27
1399	Redox potential ultrasensitive nanoparticle for the targeted delivery of camptothecin to HER2-positive cancer cells. 2014 , 11, 1897-905	49
1398	Design and synthesis of human ABCB1 (P-glycoprotein) inhibitors by peptide coupling of diverse chemical scaffolds on carboxyl and amino termini of (S)-valine-derived thiazole amino acid. 2014 , 57, 4058-72	39
1397	Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. 2014 , 350, 43-51	20
1396	ER β directly activated the MDR1 transcription to increase paclitaxel-resistance of ER β -positive breast cancer cells in vitro and in vivo. 2014 , 53, 35-45	23

1395	NFB mediates cisplatin resistance through histone modifications in head and neck squamous cell carcinoma (HNSCC). 2014 , 4, 96-104	72
1394	BH3-mimetic gossypol-induced autophagic cell death in mutant BRAF melanoma cells with high expression of p21Cip1. 2014 , 102, 41-8	14
1393	Peptide-based cancer therapy: opportunity and challenge. 2014 , 351, 13-22	191
1392	AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. 2014 , 350, 61-8	29
1391	DNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivity. 2014 , 8, 458-68	37
1390	Qualitative analysis and enantiospecific determination of angular-type pyranocoumarins in Peucedani Radix using achiral and chiral liquid chromatography coupled with tandem mass spectrometry. 2014 , 1338, 24-37	38
1389	Management of T-cell lymphomas: overcoming challenges and choosing the best treatment. 2014 , 51, 1-4	5
1388	Cellular communication via microparticles: role in transfer of multidrug resistance in cancer. 2014 , 10, 655-69	26
1387	Silica Nanoparticle Bioconjugates. 2014 , 327-343	1
1386	miR-22 inhibits osteosarcoma cell proliferation and migration by targeting HMGB1 and inhibiting HMGB1-mediated autophagy. 2014 , 35, 7025-34	62
1385	ARRY-334543 reverses multidrug resistance by antagonizing the activity of ATP-binding cassette subfamily G member 2. 2014 , 115, 1381-91	16
1384	Controlled release of free doxorubicin from peptide-drug conjugates by drug loading. 2014 , 191, 123-30	79
1383	Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. 2014 , 89, 52-61	43
1382	Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells. 2014 , 10, 2609-12	
1381	Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance. 2014 , 19, 13848-77	83
1380	Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections. 2014 , 4, 872-92	166
1379	p62/SQSTM1 is involved in cisplatin resistance in human ovarian cancer cells via the Keap1-Nrf2-ARE system. 2014 , 45, 2341-8	51
1378	The novel bis-benzylisoquinoline PY35 reverses P-glycoprotein-mediated multidrug resistance. 2014 , 32, 1211-7	6

1377	Upregulation of NEK2 is associated with drug resistance in ovarian cancer. 2014 , 31, 745-54	56
1376	Tumor-Initiating Stem-Like Cells. 2014 , 361-372	
1375	PHARMACOGENETICS AND PHARMACOGENOMICS IN PERSONALIZED MEDICINE: ROLE OF GENE POLYMORPHISM IN DRUG RESPONSE. 2014 , 35-71	
1374	Differential protein expression and novel biomarkers related to 5-FU resistance in a 3D colorectal adenocarcinoma model. 2014 , 32, 1427-34	8
1373	Downregulation of tumor suppressor gene ribonuclease T2 and gametogenetin binding protein 2 is associated with drug resistance in ovarian cancer. 2014 , 32, 362-72	15
1372	Downregulation of HNF1 homeobox B is associated with drug resistance in ovarian cancer. 2014 , 32, 979-88	20
1371	Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. 2014 , 44, 1634-42	26
1370	A Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of Doxorubicin. 2015 , 104, 4409-4416	10
1369	Ectokinases as novel cancer markers and drug targets in cancer therapy. 2015 , 4, 404-14	13
1368	Signaling pathways in HPV-associated cancers and therapeutic implications. 2015 , 25 Suppl 1, 24-53	55
1367	Modeling cancer metabolism on a genome scale. 2015 , 11, 817	122
1366	Antibody-drug conjugates as novel anti-cancer chemotherapeutics. 2015 , 35,	237
1365	Towards inverse modeling of intratumor heterogeneity. 2015 , 13,	1
1364	Emergence of cytotoxic resistance in cancer cell populations*. 2015 , 5, 00009	
1363	Inhibition of microvesiculation sensitizes prostate cancer cells to chemotherapy and reduces docetaxel dose required to limit tumor growth in vivo. 2015 , 5, 13006	56
1362	Microparticles as Biomarkers of Blood Coagulation in Cancer. 2015 , 7, 51-6	23
1361	Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro. 2015 , 15, 927	13
1360	Overcoming multiple drug resistance by spatial-temporal synchronization of epirubicin and pooled siRNAs. 2015 , 11, 1775-81	12

1359	Modeling drug resistance in a conjoint normal-tumor setting. 2015 , 12, 3	5
1358	Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. 2015 , 15, 71	275
1357	Human amniotic mesenchymal stromal cells (hAMSCs) as potential vehicles for drug delivery in cancer therapy: an in vitro study. 2015 , 6, 155	44
1356	Dissortativity and duplications in oral cancer. 2015 , 88, 1	9
1355	Akt regulation of Aven contributes to the sensitivity of cancer cells to chemotherapeutic agents. 2015 , 11, 3866-71	2
1354	Combined Delivery of Temozolomide and Anti-miR221 PNA Using Mesoporous Silica Nanoparticles Induces Apoptosis in Resistant Glioma Cells. 2015 , 11, 5687-95	89
1353	IL-12 augments antitumor responses to cycled chemotherapy. 2015 , 38, 137-44	8
1352	Rapid Identification of Chemoresistance Mechanisms Using Yeast DNA Mismatch Repair Mutants. 2015 , 5, 1925-35	5
1351	Bio-guided Isolation of a New Sesterterpene from <i>Serjania goniocarpa</i> . 2015 , 10, 1934578X1501000	
1350	BMS-536924, an ATP-competitive IGF-1R/IR inhibitor, decreases viability and migration of temozolomide-resistant glioma cells in vitro and suppresses tumor growth in vivo. 2015 , 8, 689-97	10
1349	Down-regulation of ARNT promotes cancer metastasis by activating the fibronectin/integrin β /FAK axis. 2015 , 6, 11530-46	27
1348	Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy. 2015 , 7, 2360-71	143
1347	Two hits are better than one: synergistic anticancer activity of β -helical peptides and doxorubicin/epirubicin. 2015 , 6, 1769-78	28
1346	BCc1, the novel antineoplastic nanocomplex, showed potent anticancer effects in vitro and in vivo. 2016 , 10, 59-70	6
1345	Combined therapy for gastrointestinal carcinomas: exploiting synergies between gene therapy and classical chemo-radiotherapy. 2015 , 15, 151-60	6
1344	Perspective of Targeting Cancer-Associated Fibroblasts in Melanoma. 2015 , 6, 717-26	68
1343	Phthalocyanine-loaded graphene nanoplatform for imaging-guided combinatorial phototherapy. 2015 , 10, 2347-62	50
1342	Neurotoxic Effects of Platinum Compounds: Studies on Intracellular Calcium Homeostasis in the Immature Central Nervous System. 2015 , 3, 224-248	5

1341	Neolignans from <i>Nectandra megapotamica</i> (Lauraceae) Display in vitro Cytotoxic Activity and Induce Apoptosis in Leukemia Cells. 2015 , 20, 12757-68	8
1340	STAT3-Mediated Metabolic Reprogramming in Cellular Transformation and Implications for Drug Resistance. 2015 , 5, 121	76
1339	Membrane Transition Temperature Determines Cisplatin Response. 2015 , 10, e0140925	12
1338	Cytotoxicity of the Sesquiterpene Lactones Neoambrosin and Damsin from <i>Ambrosia maritima</i> Against Multidrug-Resistant Cancer Cells. 2015 , 6, 267	26
1337	Inorganic nanolayers: structure, preparation, and biomedical applications. 2015 , 10, 5609-33	43
1336	Autophagy facilitates multidrug resistance development through inhibition of apoptosis in breast cancer cells. 2015 , 62, 199-208	31
1335	Alpha-helical cationic anticancer peptides: a promising candidate for novel anticancer drugs. 2015 , 15, 73-81	64
1334	Phenolic indeno[1,2-b]indoles as ABCG2-selective potent and non-toxic inhibitors stimulating basal ATPase activity. 2015 , 9, 3481-95	17
1333	The Emerging Genetic Basis and Its Clinical Implication in Pancreatic Cancer. 2015 , 2, 131-143	
1332	DNA damage and inhibition of akt pathway in mcf-7 cells and ehrlich tumor in mice treated with 1,4-naphthoquinones in combination with ascorbate. 2015 , 2015, 495305	22
1331	Overcoming Multidrug Resistance in Cancer Stem Cells. 2015 , 2015, 635745	104
1330	The Emerging Role of Extracellular Vesicle-Mediated Drug Resistance in Cancers: Implications in Advanced Prostate Cancer. 2015 , 2015, 454837	34
1329	Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance. 2015 , 6, 1143-56	136
1328	MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer. 2015 , 290, 6215-25	79
1327	Redox- and pH-Sensitive Polymeric Micelles Based on Poly(β-amino ester)-Grafted Disulfide Methylene Oxide Poly(ethylene glycol) for Anticancer Drug Delivery. 2015 , 48, 4046-4054	71
1326	Mechanism study of peptide GMBP1 and its receptor GRP78 in modulating gastric cancer MDR by iTRAQ-based proteomic analysis. 2015 , 15, 358	21
1325	ATP-Binding Cassette Transporter Structure Changes Detected by Intramolecular Fluorescence Energy Transfer for High-Throughput Screening. 2015 , 88, 84-94	15
1324	ABC Transporter Modulatory Drugs from Marine Sources: A New Approach to Overcome Drug Resistance in Cancer. 2015 , 183-208	2

1323	Low inducible expression of p21Cip1 confers resistance to paclitaxel in BRAF mutant melanoma cells with acquired resistance to BRAF inhibitor. 2015 , 406, 53-62	3
1322	Increased sensitivity of human lung adenocarcinoma cells to cisplatin associated with downregulated contactin-1. 2015 , 71, 172-84	11
1321	Revealing the fate of cell surface human P-glycoprotein (ABCB1): The lysosomal degradation pathway. 2015 , 1853, 2361-70	19
1320	Potency of non-steroidal anti-inflammatory drugs in chemotherapy. 2015 , 3, 3-12	37
1319	Cytotoxic activity of ten algae from the Persian Gulf and Oman Sea on human breast cancer cell lines; MDA-MB-231, MCF-7, and T-47D. 2015 , 7, 133-7	9
1318	Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells. 2015 , 19, 1795-804	11
1317	Properties of Stem Cells of Breast Cancer. 2015 , 57-74	
1316	Redox-Responsive Polyphosphoester-Based Micellar Nanomedicines for Overriding Chemoresistance in Breast Cancer Cells. 2015 , 7, 26315-25	40
1315	Breast Cancer Stem Cells & Therapy Resistance. 2015 ,	3
1314	Glutathione S-transferase pi (GST-pi) inhibition and anti-inflammation activity of the ethyl acetate extract of Streptomyces sp. strain MJM 8637. 2015 , 22, 744-51	2
1313	Molecular aspects of breast cancer resistance to drugs (Review). 2015 , 47, 437-45	18
1312	AURKA upregulation plays a role in fibroblast-reduced gefitinib sensitivity in the NSCLC cell line HCC827. 2015 , 33, 1860-6	15
1311	Upregulated Annexin A1 promotes cellular invasion in triple-negative breast cancer. 2015 , 33, 1064-70	28
1310	Cross-platform meta-analysis of multiple gene expression profiles identifies novel expression signatures in acquired anthracycline-resistant breast cancer. 2015 , 33, 1985-93	5
1309	Transcriptional regulation, stabilization, and subcellular redistribution of multidrug resistance-associated protein 1 (MRP1) by glycogen synthase kinase 3β: novel insights on modes of cadmium-induced cell death stimulated by MRP1. 2015 , 89, 1271-84	13
1308	Concentrations of Erlotinib in Tumor Tissue and Plasma in Non-Small-Cell Lung Cancer Patients After Neoadjuvant Therapy. 2015 , 16, 320-4	15
1307	Activating adaptive cellular mechanisms of resistance following sublethal cytotoxic chemotherapy: implications for diagnostic microdosing. 2015 , 136, 1485-93	8
1306	The emerging role of microRNAs in resistance to lung cancer treatments. 2015 , 41, 160-9	77

1305	Rational design of cancer-targeted selenium nanoparticles to antagonize multidrug resistance in cancer cells. 2015 , 11, 947-58	116
1304	Resistance to Targeted ABC Transporters in Cancer. 2015 ,	3
1303	Mechanism-independent optimization of combinatorial nanodiamond and unmodified drug delivery using a phenotypically driven platform technology. 2015 , 9, 3332-44	77
1302	Using hollow carbon nanospheres as a light-induced free radical generator to overcome chemotherapy resistance. 2015 , 137, 1947-55	164
1301	25 years of small molecular weight kinase inhibitors: potentials and limitations. 2015 , 87, 766-75	102
1300	<i>Pseudomonas aeruginosa</i> exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines. 2015 , 64, 164-173	22
1299	Ten things you should know about protein kinases: IUPHAR Review 14. 2015 , 172, 2675-700	180
1298	Effects of <i>Withania somnifera</i> and <i>Tinospora cordifolia</i> extracts on the side population phenotype of human epithelial cancer cells: toward targeting multidrug resistance in cancer. 2015 , 14, 156-71	14
1297	Understanding cancer and the anticancer activities of naphthoquinones [a review]. 2015 , 5, 20309-20338	189
1296	Ginsenoside F2 Initiates an Autophagic Progression in Breast Cancer Stem Cells. 2015 , 81-90	
1295	Emergence of drug tolerance in cancer cell populations: an evolutionary outcome of selection, nongenetic instability, and stress-induced adaptation. 2015 , 75, 930-9	78
1294	Cytotoxic acyl amides from the soil fungus <i>Gymnascella dankaliensis</i> . 2015 , 23, 712-9	18
1293	Xanthone analogues as potent modulators of intestinal P-glycoprotein. 2015 , 93, 237-45	20
1292	Nanotherapy for Cancer: Targeting and Multifunctionality in the Future of Cancer Therapies. 2015 , 1, 64-78	118
1291	Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer. 2015 , 32, 2097-109	61
1290	Novel non-substrate modulators of the transmembrane efflux pump P-glycoprotein (ABCB1). 2015 , 6, 860-866	1
1289	Protamine-carboxymethyl cellulose magnetic nanocapsules for enhanced delivery of anticancer drugs against drug resistant cancers. 2015 , 11, 969-81	50
1288	Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters. 2015 , 75, 281-91	17

1287	Differential activation of NF- κ B signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells. 2015 , 61, 90-102	27
1286	An in-vivo evaluation of a MEMS drug delivery device using Kunming mice model. 2015 , 17, 6	9
1285	The role of matrix compliance on cell responses to drugs and toxins: towards predictive drug screening platforms. 2015 , 15, 589-99	9
1284	Modeling the effects of space structure and combination therapies on phenotypic heterogeneity and drug resistance in solid tumors. 2015 , 77, 1-22	70
1283	Antibody Drug Conjugates: Preclinical Considerations. 2015 , 17, 525-34	31
1282	Lycorine induces programmed necrosis in the multiple myeloma cell line ARH-77. 2015 , 36, 2937-45	14
1281	Simultaneous quantification of 25 active constituents in the total flavonoids extract from Herba Desmodii Styracifolii by high-performance liquid chromatography with electrospray ionization tandem mass spectrometry. 2015 , 38, 1156-63	13
1280	Cellular mechanism of oral absorption of solidified polymer micelles. 2015 , 11, 1993-2002	16
1279	Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells. 2015 , 336, 23-32	26
1278	Translational Nano-Medicines: Targeted Therapeutic Delivery for Cancer and Inflammatory Diseases. 2015 , 17, 813-27	30
1277	Lower antioxidative capacity of multidrug-resistant cancer cells confers collateral sensitivity to protoflavone derivatives. 2015 , 76, 555-65	11
1276	Biotin-Containing Reduced Graphene Oxide-Based Nanosystem as a Multieffect Anticancer Agent: Combining Hyperthermia with Targeted Chemotherapy. 2015 , 16, 2766-75	46
1275	Design, synthesis, in vitro cytotoxic activity evaluation, and apoptosis-induction study of new 9(10H)-acridinone-1,2,3-triazoles. 2015 , 19, 787-95	36
1274	Potential of hyphenated ultra-high performance liquid chromatography-scheduled multiple reaction monitoring algorithm for large-scale quantitative analysis of traditional Chinese medicines. 2015 , 5, 57372-57382	22
1273	Lanthanum strontium manganese oxide (LSMO) nanoparticles: a versatile platform for anticancer therapy. 2015 , 5, 60254-60263	23
1272	Preparation and antitumor effect evaluation of composite microparticles co-loaded with siRNA and paclitaxel by a supercritical process. 2015 , 3, 6439-6447	10
1271	Multiple drug resistance due to resistance to stem cells and stem cell treatment progress in cancer (Review). 2015 , 9, 289-293	53
1270	Factors that Determine Sensitivity and Resistances of Tumor Cells Towards Antibody-Targeted Protein Toxins. 2015 , 57-73	1

1269	A set of NF- κ B-regulated microRNAs induces acquired TRAIL resistance in lung cancer. 2015 , 112, E3355-64	60
1268	Nanomedicine for Combination Therapy of Cancer. 2015 , 2, 366-7	13
1267	The emerging role of hypoxia-inducible factor-2 involved in chemo/radioresistance in solid tumors. 2015 , 41, 623-33	36
1266	Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar. 2015 , 56, 82-7	36
1265	Spatial heterogeneity in drug concentrations can facilitate the emergence of resistance to cancer therapy. 2015 , 11, e1004142	69
1264	Cytotoxic Effect of Turkish Propolis on Liver, Colon, Breast, Cervix and Prostate Cancer Cell Lines. 2015 , 14, 777	34
1263	miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment. 2015 , 28, 431-41	35
1262	NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo. 2015 , 137, 134-42	9
1261	Lapatinib enhances the cytotoxic effects of doxorubicin in MCF-7 tumorspheres by inhibiting the drug efflux function of ABC transporters. 2015 , 72, 37-43	39
1260	Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates. 2015 , 32, 3458-69	23
1259	YY1 suppresses FEN1 over-expression and drug resistance in breast cancer. 2015 , 15, 50	44
1258	Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?. 2015 , 8, 16	67
1257	Enzyme-instructed self-assembly: a multistep process for potential cancer therapy. 2015 , 26, 987-99	102
1256	Mechanisms of Tumor Cell Resistance to ALA-PDT. 2015 , 213-228	
1255	Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo. 2015 , 21, 2558-68	36
1254	Cancer nanotherapeutics in clinical trials. 2015 , 166, 293-322	30
1253	Nanotechnology-Based Precision Tools for the Detection and Treatment of Cancer. 2015 ,	22
1252	Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor β signaling in HCT116 colon cancer cells. 2015 , 12, 192-8	56

1251	In vitro and in vivo Anticancer Effects of a Novel 9-Phenyldibenzo[a,c]phenazin-9-ium Cation and Its Ligands. 2014 , 60, 261-6	
1250	Multifunctional effects of honokiol as an anti-inflammatory and anti-cancer drug in human oral squamous cancer cells and xenograft. 2015 , 53, 274-84	27
1249	Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression. 2015 , 235, 76-84	57
1248	Spectroscopic and electrochemical studies on molecular recognition of tetrathiafulvalene derivative with P-glycoprotein and drug-resistant leukemia cells. 2015 , 58, 1193-1199	3
1247	Intrinsic and induced drug resistance mechanisms: in silico investigations at the cellular and tissue scales. 2015 , 7, 1044-60	4
1246	Biocompatible nanoparticles sensing the matrix metallo-proteinase 2 for the on-demand release of anticancer drugs in 3D tumor spheroids. 2015 , 135, 707-716	15
1245	Hybrid nanoparticles for combination therapy of cancer. 2015 , 219, 224-236	86
1244	Bioactive compounds from brown seaweeds: Phloroglucinol, fucoxanthin and fucoidan as promising therapeutic agents against breast cancer. 2015 , 14, 91-98	108
1243	Downregulation of STAT3 phosphorylation enhances tumoricidal effect of IL-15-activated dendritic cell against doxorubicin-resistant lymphoma and leukemia via TNF- α . 2015 , 67, 1-13	14
1242	Phenotypic drug profiling in droplet microfluidics for better targeting of drug-resistant tumors. 2015 , 15, 4441-50	32
1241	1-[(2E)-3-Phenylprop-2-enoyl]-1H-benzimidazoles as anticancer agents: synthesis, crystal structure analysis and binding studies of the most potent anticancer molecule with serum albumin. 2015 , 6, 1942-1953	10
1240	Synthesis of aqueous AgInS/ZnS@PEI as a self-indicating nonviral vector for plasmid DNA self-tracking delivery. 2015 , 3, 8518-8527	10
1239	Identification of the specific epigenetic alterations associated with chemo-resistance via reprogramming of cancer cells. 2015 , 85, 710-4	1
1238	Gambogic acid-loaded pH-sensitive mixed micelles for overcoming breast cancer resistance. 2015 , 495, 840-8	39
1237	Active Drug Targeting of a Folate-Based Cyclodextrin-Doxorubicin Conjugate and the Cytotoxic Effect on Drug-Resistant Mammary Tumor Cells In Vitro. 2015 , 104, 2934-40	14
1236	Architecture of Chimeric Spheroids Controls Drug Transport. 2015 , 8, 101-9	10
1235	Recent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and Imaging. 2015 , 11, 1859-98	83
1234	Self-delivery nanoparticles from an amphiphilic covalent drug couple of irinotecan and bendamustine for cancer combination chemotherapy. 2015 , 5, 86254-86264	31

1233	MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer. 2015 , 6, e1845	59
1232	Multiscale Framework for Imaging Radiolabeled Therapeutics. 2015 , 12, 4554-60	13
1231	Nanoparticle therapeutics: Technologies and methods for overcoming cancer. 2015 , 97, 140-51	58
1230	MiRNA-149 modulates chemosensitivity of ovarian cancer A2780 cells to paclitaxel by targeting MyD88. 2015 , 8, 48	18
1229	CancerHSP: anticancer herbs database of systems pharmacology. 2015 , 5, 11481	33
1228	Integrated proteo-genomic approach for early diagnosis and prognosis of cancer. 2015 , 369, 28-36	24
1227	Albumin stabilized silver nanoparticles-clotrimazole β -cyclodextrin hybrid nanocomposite for enriched anti-fungal activity in normal and drug resistant Candida cells. 2015 , 5, 71190-71202	17
1226	APC selectively mediates response to chemotherapeutic agents in breast cancer. 2015 , 15, 457	28
1225	Chimaphilin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines through insulin-like growth factor-I receptor (IGF-IR) signaling. 2015 , 237, 25-30	12
1224	Novel delivery approaches for cancer therapeutics. 2015 , 219, 248-268	99
1223	Synergistic antitumor effect of β -pinene and α -pinene with paclitaxel against non-small-cell lung carcinoma (NSCLC). 2015 , 65, 214-8	29
1222	Sustained Epigenetic Drug Delivery Depletes Cholesterol-Sphingomyelin Rafts from Resistant Breast Cancer Cells, Influencing Biophysical Characteristics of Membrane Lipids. 2015 , 31, 11564-73	15
1221	Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma. 2015 , 80, 66-73	19
1220	Effects of a novel porphyrin-based photosensitizer on sensitive and multidrug-resistant human gastric cancer cell lines. 2015 , 151, 186-93	5
1219	Naphthalocyanine-Based Biodegradable Polymeric Nanoparticles for Image-Guided Combinatorial Phototherapy. 2015 , 27, 6155-6165	56
1218	Casein Kinase 2 (CK2)-mediated Phosphorylation of Hsp90 α as a Novel Mechanism of Rifampin-induced MDR1 Expression. 2015 , 290, 17029-40	20
1217	Quantifying and Reducing Uncertainties in Cancer Therapy. 2015 , 9412,	2
1216	A 3D spheroid system to evaluate inhibitors of the ABCG2 transporter in drug uptake and penetration. 2015 , 03, 54-63	5

1215	Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach. 2015 , 23, 69-78	146
1214	Do drugs have access to the P-glycoprotein drug-binding pocket through gates?. 2015 , 11, 4525-9	18
1213	Utilizing the protein corona around silica nanoparticles for dual drug loading and release. 2015 , 7, 16251-65	24
1212	P-glycoprotein and membrane roles in multidrug resistance. 2015 , 7, 929-46	52
1211	Gene Essentiality Is a Quantitative Property Linked to Cellular Evolvability. 2015 , 163, 1388-99	95
1210	Molecular determinants of chemotherapy resistance in ovarian cancer. 2015 , 16, 1763-7	5
1209	Effect of siRNA pre-Exposure on Subsequent Response to siRNA Therapy. 2015 , 32, 3813-26	8
1208	Novel isatin derivatives of podophyllotoxin: synthesis and cytotoxic evaluation against human leukaemia cancer cells as potent anti-MDR agents. 2015 , 5, 97816-97823	22
1207	Quercetin inhibits proliferation and drug resistance in KB/VCR oral cancer cells and enhances its sensitivity to vincristine. 2015 , 67, 126-36	39
1206	Microparticles induce multifactorial resistance through oncogenic pathways independently of cancer cell type. 2015 , 106, 60-8	23
1205	Reversing cancer multidrug resistance: insights into the efflux by ABC transports from in silico studies. 2015 , 5, 27-55	25
1204	IND-2, a pyrimido[1,2-b:4,5-b']pyrazolo[3,4-b]quinoline derivative, circumvents multi-drug resistance and causes apoptosis in colon cancer cells. 2015 , 23, 602-11	34
1203	Lipid-based drug carriers for prodrugs to enhance drug delivery. 2015 , 17, 83-92	42
1202	Resistance to Photodynamic Therapy in Cancer. 2015 ,	4
1201	Ligand-directed stearic acid grafted chitosan micelles to increase therapeutic efficacy in hepatic cancer. 2015 , 12, 644-52	40
1200	Role of three-dimensional matrix stiffness in regulating the chemoresistance of hepatocellular carcinoma cells. 2015 , 62, 556-62	39
1199	A multichannel nanosensor for instantaneous readout of cancer drug mechanisms. 2015 , 10, 65-9	108
1198	FOX D1 promotes breast cancer proliferation and chemotherapeutic drug resistance by targeting p27. 2015 , 456, 232-7	45

1197	P-gp Inhibitory Activity from Marine Sponges, Tunicates and Algae. 2015 , 593-619	
1196	Coencapsulated doxorubicin and bromotetrandrine lipid nanoemulsions in reversing multidrug resistance in breast cancer in vitro and in vivo. 2015 , 12, 274-86	57
1195	Intratumoral morphological heterogeneity of breast cancer: neoadjuvant chemotherapy efficiency and multidrug resistance gene expression. 2014 , 4, 4709	29
1194	Simultaneously targeting tissue transglutaminase and kidney type glutaminase sensitizes cancer cells to acid toxicity and offers new opportunities for therapeutic intervention. 2015 , 12, 46-55	25
1193	Nanotechnology to Combat Multidrug Resistance in Cancer. 2015 , 245-272	5
1192	Biomedical Applications of Supramolecular Systems Based on Host-Guest Interactions. 2015 , 115, 7794-839	758
1191	Is reduction of tumor burden sufficient for the 21st century?. 2015 , 356, 149-55	1
1190	Modulation of imatinib cytotoxicity by selenite in HCT116 colorectal cancer cells. 2015 , 116, 37-46	16
1189	mPEG-b-PCL/TPGS mixed micelles for delivery of resveratrol in overcoming resistant breast cancer. 2015 , 12, 361-73	39
1188	Oncogenes associated with drug resistance in ovarian cancer. 2015 , 141, 381-95	32
1187	Gene Therapies for Cancer: Strategies, Challenges and Successes. 2015 , 230, 259-71	119
1186	Dual-drug delivery of curcumin and platinum drugs in polymeric micelles enhances the synergistic effects: a double act for the treatment of multidrug-resistant cancer. 2015 , 3, 163-74	110
1185	Effect of Molecular Structure, Substrate and Docking Scores on the Prediction of the Inhibition Constants of P-glycoprotein Inhibitors. 2016 , 07,	
1184	Green Tea Catechin-Based Complex Micelles Combined with Doxorubicin to Overcome Cardiotoxicity and Multidrug Resistance. 2016 , 6, 1277-92	69
1183	Targeting the chromatin remodeling enzyme BRG1 increases the efficacy of chemotherapy drugs in breast cancer cells. 2016 , 7, 27158-75	37
1182	Anti-inflammatory and Antitumor Activity of a Triple Therapy for a Colitis-Related Colorectal Cancer. 2016 , 7, 1632-1644	14
1181	Nanomicelles loaded with doxorubicin and curcumin for alleviating multidrug resistance in lung cancer. 2016 , 11, 5757-5770	38
1180	Antiproliferative activity of protein extracts from the black clam (<i>Chione flucitifraga</i>) on human cervical and breast cancer cell lines. 2016 , 15, 214-220	1

1179	Mathematical Modelling and Analysis of the Tumor Treatment Regimens with Pulsed Immunotherapy and Chemotherapy. 2016 , 2016, 6260474	19
1178	Biomolecular Network-Based Synergistic Drug Combination Discovery. 2016 , 2016, 8518945	18
1177	Systems Perturbation Analysis of a Large-Scale Signal Transduction Model Reveals Potentially Influential Candidates for Cancer Therapeutics. 2016 , 4, 10	18
1176	Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer. 2016 , 21,	345
1175	Antibody-Drug Conjugates for Cancer Therapy. 2016 , 4,	53
1174	Cancer Stem Cell Plasticity Drives Therapeutic Resistance. 2016 , 8,	106
1173	Focus on Extracellular Vesicles: New Frontiers of Cell-to-Cell Communication in Cancer. 2016 , 17, 175	190
1172	Poly (L-Glutamylglutamine) Polymer Enhances Doxorubicin Accumulation in Multidrug Resistant Breast Cancer Cells. 2016 , 21,	5
1171	DeBouganin Diabody Fusion Protein Overcomes Drug Resistance to ADCs Comprised of Anti-Microtubule Agents. 2016 , 21,	5
1170	The Anti-Cancer Effect of Polyphenols against Breast Cancer and Cancer Stem Cells: Molecular Mechanisms. 2016 , 8,	83
1169	Tumor Heterogeneity, Single-Cell Sequencing, and Drug Resistance. 2016 , 9,	70
1168	Activated Charge-Reversal Polymeric Nano-System: The Promising Strategy in Drug Delivery for Cancer Therapy. 2016 , 8,	26
1167	Role of the Drug Transporter ABCC3 in Breast Cancer Chemoresistance. 2016 , 11, e0155013	44
1166	The Reversal Effect and Its Mechanisms of Tetramethylpyrazine on Multidrug Resistance in Human Bladder Cancer. 2016 , 11, e0157759	17
1165	Reducing Both Pgp Overexpression and Drug Efflux with Anti-Cancer Gold-Paclitaxel Nanoconjugates. 2016 , 11, e0160042	12
1164	Nanostructured Lipid Carriers: A Novel Platform for Chemotherapeutics. 2016 , 13, 4-26	49
1163	Emergence of cytotoxic resistance in cancer cell populations: Single-cell mechanisms and population-level consequences. 2016 ,	
1162	Simotinib as a modulator of P-glycoprotein: substrate, inhibitor, or inducer?. 2016 , 27, 300-11	2

1161	Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance. 2016 , 39, 117-26	16
1160	How can nanomedicines overcome cellular-based anticancer drug resistance?. 2016 , 4, 5078-5100	29
1159	Dual cellular stimuli-responsive hydrogel nanocapsules for delivery of anticancer drugs. 2016 , 4, 4922-4933	14
1158	Natural Polyphenols in Cancer Chemoresistance. 2016 , 68, 879-91	35
1157	Self-Assembled DNA Nanostructures for Drug Delivery. 2016 , 34, 265-272	15
1156	A Potent and Selective P-gp Modulator for Altering Multidrug Resistance Due to Pump Overexpression. 2016 , 11, 374-6	11
1155	A paired comparison between glioblastoma "stem cells" and differentiated cells. 2016 , 138, 1709-18	34
1154	Anti-gastric cancer activity in three-dimensional tumor spheroids of bufadienolides. 2016 , 6, 24772	12
1153	Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models. 2016 , 17, 190	27
1152	Dioscin strengthens the efficiency of adriamycin in MCF-7 and MCF-7/ADR cells through autophagy induction: More than just down-regulation of MDR1. 2016 , 6, 28403	20
1151	Triptolide exerts pro-apoptotic and cell cycle arrest activity on drug-resistant human lung cancer A549/Taxol cells via modulation of MAPK and PI3K/Akt signaling pathways. 2016 , 12, 3586-3590	28
1150	Genomic and transcriptomic profiling of resistant CEM/ADR-5000 and sensitive CCRF-CEM leukaemia cells for unravelling the full complexity of multi-factorial multidrug resistance. 2016 , 6, 36754	33
1149	Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation. 2016 , 16, 578	57
1148	Predictive value of microparticle-associated tissue factor activity for permeability glycoprotein-mediated multidrug resistance in cancer. 2016 , 12, 3273-3277	2
1147	Correlation between the promoter methylation status of ATP-binding cassette sub-family G member 2 and drug sensitivity in colorectal cancer cell lines. 2016 , 35, 298-306	16
1146	The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2). 2016 , 117, 212-29	44
1145	Efficacy of tamoxifen in combination with docetaxel in patients with advanced non-small-cell lung cancer pretreated with platinum-based chemotherapy. 2016 , 27, 447-56	7
1144	Dysregulated FGF signalling in neoplastic disorders. 2016 , 53, 126-35	54

1143	Cytotoxicity of <i>Salvia miltiorrhiza</i> Against Multidrug-Resistant Cancer Cells. 2016 , 44, 871-94	9
1142	Reducible self-assembling cationic polypeptide-based micelles mediate co-delivery of doxorubicin and microRNA-34a for androgen-independent prostate cancer therapy. 2016 , 232, 203-14	67
1141	Drug membrane transporters and CYP3A4 are affected by hypericin, hyperforin or aristoforin in colon adenocarcinoma cells. 2016 , 81, 38-47	19
1140	Microfluidic Methods for Molecular Biology. 2016 ,	3
1139	Microfluidic Single-Cell Functional Proteomics. 2016 , 141-159	
1138	Multifunctional drug nanocarriers facilitate more specific entry of therapeutic payload into tumors and control multiple drug resistance in cancer. 2016 , 203-251	5
1137	Milk-derived multi-fluorescent graphene quantum dot-based cancer theranostic system. 2016 , 67, 468-477	95
1136	Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo, and Ex Vivo. 2016 , 15, 1845-58	34
1135	Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement. 2016 , 165, 79-92	44
1134	Recent insight into the biological activities of synthetic xanthone derivatives. 2016 , 116, 267-280	97
1133	Nanoscale Coordination Polymers Codeliver Chemotherapeutics and siRNAs to Eradicate Tumors of Cisplatin-Resistant Ovarian Cancer. 2016 , 138, 6010-9	89
1132	Cancer chemoresistance; biochemical and molecular aspects: a brief overview. 2016 , 89, 20-30	95
1131	miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance. 2016 , 94, 629-44	93
1130	Hyaluronic acid-coated poly(amino) ester nanoparticles as carrier of doxorubicin for overcoming drug resistance in breast cancer cells. 2016 , 6, 38624-38636	22
1129	MiR-106b~25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300. 2016 , 35, 1170-8	21
1128	Polysaccharide-based nanocomplexes for co-encapsulation and controlled release of 5-Fluorouracil and Temozolomide. 2016 , 92, 276-86	18
1127	Pristimerin overcomes adriamycin resistance in breast cancer cells through suppressing Akt signaling. 2016 , 11, 3111-3116	16
1126	H2S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance. 2016 , 59, 4881-9	35

1125	Reversing drug resistance of soft tumor-repopulating cells by tumor cell-derived chemotherapeutic microparticles. 2016 , 26, 713-27	107
1124	An in vitro model for the development of acquired tamoxifen resistance. 2016 , 32, 563-581	9
1123	Mitochondria-Targeted Chimeric Peptide for Trinitarian Overcoming of Drug Resistance. 2016 , 8, 25060-8	54
1122	Evaluation of nitric oxide donors impact on cisplatin resistance in various ovarian cancer cell lines. 2016 , 36, 26-37	6
1121	Acryloylphenylcarboxamides: A New Class of Breast Cancer Resistance Protein (ABCG2) Modulators. 2016 , 11, 2422-2435	11
1120	Adaptive Predictive Control Based Therapy of Bone Marrow Cancer**This work was supported by FEDER and Fundaçã para a Ciãcia e Tecnologia (Portugal) under contracts EXPL/EMSSIS/1954/2013 (CancerSys), PTDC/EMS-SIS/0642/2014 (PERSEIDS), and UIDB/05519/2013/2013-2014-13, 220-225	2
1119	Exploring the physicochemical profile and the binding patterns of selected novel anticancer Himalayan plant derived active compounds with macromolecular targets. 2016 , 5, 1-14	21
1118	miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27 pathway. 2016 , 37, 15315-15324	43
1117	Nanoscale Coordination Polymers Codeliver Carboplatin and Gemcitabine for Highly Effective Treatment of Platinum-Resistant Ovarian Cancer. 2016 , 13, 3665-3675	28
1116	Overcoming ABCG2-mediated multidrug resistance by a mineralized hyaluronan-drug nanocomplex. 2016 , 4, 6652-6661	1
1115	Involvement of CD147 on multidrug resistance through the regulation of P-glycoprotein expression in K562/ADR leukemic cell line. 2016 , 6, 33-8	3
1114	Aromatic heterocyclic esters of podophyllotoxin exert anti-MDR activity in human leukemia K562/ADR cells via ROS/MAPK signaling pathways. 2016 , 123, 226-235	30
1113	Multiple pH responsive zwitterionic micelles for stealth delivery of anticancer drugs. 2016 , 6, 64778-64790	16
1112	JAK-mediated autophagy regulates stemness and cell survival in cisplatin resistant bladder cancer cells. 2016 , 1860, 2484-2497	43
1111	A myrsinol diterpene isolated from a traditional herbal medicine, LANGDU reverses multidrug resistance in breast cancer cells. 2016 , 194, 1-5	12
1110	Solution Binding and Structural Analyses Reveal Potential Multidrug Resistance Functions for SAV2435 and CTR107 and Other GyrI-like Proteins. 2016 , 55, 4850-63	6
1109	Metabolic Features of Cancer Treatment Resistance. 2016 , 207, 135-56	27
1108	Discovery and Optimization of N-(4-(3-Aminophenyl)thiazol-2-yl)acetamide as a Novel Scaffold Active against Sensitive and Resistant Cancer Cells. 2016 , 59, 8276-92	16

1107	Decellularized matrices as in vitro models of extracellular matrix in tumor tissues at different malignant levels: Mechanism of 5-fluorouracil resistance in colorectal tumor cells. 2016 , 1863, 2749-2757	31
1106	Inhibiting autophagy increases epirubicin's cytotoxicity in breast cancer cells. 2016 , 107, 1610-1621	30
1105	Monitoring cancer prognosis, diagnosis and treatment efficacy using metabolomics and lipidomics. 2016 , 12, 146	62
1104	Genome-wide profiling of long non-coding RNA expression patterns in anthracycline-resistant breast cancer cells. 2016 , 49, 1695-1703	9
1103	Modulation of P-glycoprotein activity by novel synthetic curcumin derivatives in sensitive and multidrug-resistant T-cell acute lymphoblastic leukemia cell lines. 2016 , 305, 216-233	21
1102	Enabling Nanohybrid Drug Discovery through the Soft Chemistry Telescope. 2016 , 55, 11211-11224	17
1101	Integrating Enzymatic Self-Assembly and Mitochondria Targeting for Selectively Killing Cancer Cells without Acquired Drug Resistance. 2016 , 138, 16046-16055	198
1100	A network-based phenotype mapping approach to identify genes that modulate drug response phenotypes. 2016 , 6, 37003	9
1099	Nanomedicine strategies for sustained, controlled and targeted treatment of cancer stem cells. 2016 , 11, 3261-3282	33
1098	HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway. 2016 , 49, 2529-2537 ³³	33
1097	Standardized Extract from Caesalpinia spinosa is Cytotoxic Over Cancer Stem Cells and Enhance Anticancer Activity of Doxorubicin. 2016 , 44, 1693-1717	22
1096	Semisynthesis of some novel thiourea and carbamimidothioic acid derivatives using natural alkaloid L-norephedrine and their anticancer activity. 2016 , 42, 567-573	1
1095	Adaptive Resistance to an Inhibitor of Chromosomal Instability in Human Cancer Cells. 2016 , 17, 1755-1763	22
1094	Bufalin inhibits gefitinib resistant NCI-H460 human lung cancer cell migration and invasion in vitro. 2016 , 194, 1043-1050	19
1093	Xyloglucan as a mitomycin C carrier to reverse multidrug resistance. 2016 , 6, 107800-107809	2
1092	Abstracts accepted for American Conference on Pharmacometrics 2016 (ACoP7). 2016 , 43, 11-122	5
1091	Arsenic trioxide potentiates the effectiveness of etoposide in Ewing sarcomas. 2016 , 49, 2135-2146	7
1090	Apo ferritin Nanocage Delivers Combination of Microtubule and Nucleus Targeting Anticancer Drugs. 2016 , 8, 30824-30832	30

1089	Identifying EGFR mutation-induced drug resistance based on alpha shape model analysis of the dynamics. 2016 , 14, 12	9
1088	MicroRNA-320a promotes 5-FU resistance in human pancreatic cancer cells. 2016 , 6, 27641	50
1087	Optimization of Acryloylphenylcarboxamides as Inhibitors of ABCG2 and Comparison with Acryloylphenylcarboxylates. 2016 , 11, 2547-2558	11
1086	Biological characteristics of side population cells in a self-established human ovarian cancer cell line. 2016 , 12, 41-48	8
1085	A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001. 2016 , 10, 105-108	9
1084	miR-221 Mediates Chemoresistance of Esophageal Adenocarcinoma by Direct Targeting of DKK2 Expression. 2016 , 264, 804-814	55
1083	Nano-based strategies to overcome p-glycoprotein-mediated drug resistance. 2016 , 12, 1021-33	34
1082	Low potency toxins reveal dense interaction networks in metabolism. 2016 , 10, 19	2
1081	Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers. 2016 , 39, 411-433	29
1080	KLF8 Promotes Temozolomide Resistance in Glioma Cells via β -Catenin Activation. 2016 , 38, 1596-604	10
1079	Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisation. 2016 , 1860, 2627-45	45
1078	Etiology of phenotype switching strategy in time varying stochastic environment. 2016 , 462, 455-468	
1077	Emerging nanomedicine approaches fighting tumor metastasis: animal models, metastasis-targeted drug delivery, phototherapy, and immunotherapy. 2016 , 45, 6250-6269	286
1076	Up-regulation of HB-EGF by the COX-2/PGE2 signaling associates with the cisplatin resistance and tumor recurrence of advanced HNSCC. 2016 , 56, 54-61	10
1075	Mechanisms for Two-Step Proton Transfer Reactions in the Outward-Facing Form of MATE Transporter. 2016 , 110, 1346-54	15
1074	Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation. 2016 , 6,	33
1073	Nuclear Transcription Factor Kappa B Downregulation Reduces Chemoresistance in Bone Marrow-derived Cells Through P-glycoprotein Modulation. 2016 , 47, 78-88	6
1072	pH- and NIR Light-Responsive Polymeric Prodrug Micelles for Hyperthermia-Assisted Site-Specific Chemotherapy to Reverse Drug Resistance in Cancer Treatment. 2016 , 12, 2731-40	89

1071	Ambra1 in autophagy and apoptosis: Implications for cell survival and chemotherapy resistance. 2016 , 12, 367-374	21
1070	Synergistic antiproliferative effects of methotrexate-loaded smart silica nanocomposites in MDA-MB-231 breast cancer cells. 2016 , 44, 603-9	7
1069	Efficient cancer ablation by combined photothermal and enhanced chemo-therapy based on carbon nanoparticles/doxorubicin@SiO ₂ nanocomposites. 2016 , 97, 35-44	73
1068	Revisiting the role of nanoparticles as modulators of drug resistance and metabolism in cancer. 2016 , 12, 281-9	17
1067	Branched polyethyleneimine modified with hyaluronic acid via a PEG spacer for targeted anticancer drug delivery. 2016 , 6, 9232-9239	12
1066	Lysosomes as mediators of drug resistance in cancer. 2016 , 24, 23-33	255
1065	Tumor-Penetrating Peptide-Modified DNA Tetrahedron for Targeting Drug Delivery. 2016 , 55, 1326-31	90
1064	Overcoming multidrug resistance by targeting mitochondria with NO-donating doxorubicins. 2016 , 24, 967-75	21
1063	Antibody-mediated delivery of therapeutics for cancer therapy. 2016 , 13, 401-19	31
1062	Exosomes decrease sensitivity of breast cancer cells to adriamycin by delivering microRNAs. 2016 , 37, 5247-56	65
1061	2-Indolinone a versatile scaffold for treatment of cancer: a patent review (2008-2014). 2016 , 26, 149-73	29
1060	Novel in vitro transport method for screening the reversibility of P-glycoprotein inhibitors. 2016 , 100, 9-14	14
1059	Co-delivery of Se nanoparticles and pooled SiRNAs for overcoming drug resistance mediated by P-glycoprotein and class III β -tubulin in drug-resistant breast cancers. 2016 , 31, 197-210	59
1058	Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas. 2016 , 98, 235-41	30
1057	Cytokines in cancer drug resistance: Cues to new therapeutic strategies. 2016 , 1865, 255-65	91
1056	Pyrimido[1,2:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells. 2016 , 376, 118-26	18
1055	Combining intracellular antibodies to restore function of mutated p53 in cancer. 2016 , 138, 182-6	5
1054	Enhancing the efficacy of cytotoxic agents for cancer therapy using photochemical internalisation. 2016 , 138, 1049-57	31

1053	From fighting depression to conquering tumors: a novel tricyclic thiazepine compound as a tubulin polymerization inhibitor. 2016 , 7, e2143	3
1052	Cellulose conjugated FITC-labelled mesoporous silica nanoparticles: intracellular accumulation and stimuli responsive doxorubicin release. 2016 , 8, 5089-97	47
1051	Jacalin-capped silver nanoparticles minimize the dosage use of the anticancer drug, shikonin derivatives, against human chronic myeloid leukemia. 2016 , 6, 18980-18989	16
1050	Cancer Drug Resistance. 2016 ,	3
1049	Potent anti-angiogenic and cytotoxic effect of conferone on human colorectal adenocarcinoma HT-29 cells. 2016 , 23, 398-405	36
1048	Near Infrared-Guided Smart Nanocarriers for MicroRNA-Controlled Release of Doxorubicin/siRNA with Intracellular ATP as Fuel. 2016 , 10, 3637-47	121
1047	Chemically crosslinked nanogels of PEGylated poly ethyleneimine (l-histidine substituted) synthesized via metal ion coordinated self-assembly for delivery of methotrexate: Cytocompatibility, cellular delivery and antitumor activity in resistant cells. 2016 , 62, 897-907	32
1046	Tubulin inhibitors in non-small cell lung cancer: looking back and forward. 2016 , 17, 1113-29	18
1045	Cancer Drug Resistance: A Brief Overview from a Genetic Viewpoint. 2016 , 1395, 1-18	57
1044	Temozolomide reverses doxorubicin resistance by inhibiting P-glycoprotein in malignant glioma cells. 2016 , 126, 235-42	21
1043	Theranostic gas-generating nanoparticles for targeted ultrasound imaging and treatment of neuroblastoma. 2016 , 223, 197-206	58
1042	Catalytic Mechanism of the Maltose Transporter Hydrolyzing ATP. 2016 , 55, 224-31	11
1041	Mitochondrial ClpP activity is required for cisplatin resistance in human cells. 2016 , 1862, 252-64	15
1040	Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells. 2016 , 13, 428-37	47
1039	"Combo" nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. 2016 , 98, 3-18	317
1038	Binding and molecular dynamic studies of sesquiterpenes (2R-acetoxymethyl-1,3,3-trimethyl-4t-(3-methyl-2-buten-1-yl)-1t-cyclohexanol) derived from marine Streptomyces sp. VITJS8 as potential anticancer agent. 2016 , 100, 2869-82	24
1037	Design, synthesis and antitumor properties of glycosylated antitumor ether lipid (GAEL)-chlorambucil-hybrids. 2016 , 194, 139-48	13
1036	Dual delivery of biological therapeutics for multimodal and synergistic cancer therapies. 2016 , 98, 113-33	70

1035	Recent advances of cocktail chemotherapy by combination drug delivery systems. 2016 , 98, 19-34	384
1034	Anticancer activity of cryptotanshinone on acute lymphoblastic leukemia cells. 2016 , 90, 2275-2286	25
1033	Toward a Better Understanding of the Complexity of Cancer Drug Resistance. 2016 , 56, 85-102	200
1032	Chronic Oxidative Stress Increases Resistance to Doxorubicin-Induced Cytotoxicity in Renal Carcinoma Cells Potentially Through Epigenetic Mechanism. 2016 , 89, 27-41	17
1031	Sonoporation: Applications for Cancer Therapy. 2016 , 880, 263-91	35
1030	Monodistearoylphosphatidylethanolamine-hyaluronic acid functionalization of single-walled carbon nanotubes for targeting intracellular drug delivery to overcome multidrug resistance of cancer cells. 2016 , 96, 362-376	30
1029	Reversal of efflux of an anticancer drug in human drug-resistant breast cancer cells by inhibition of protein kinase C β (PKC β) activity. 2016 , 37, 1901-8	13
1028	Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect. 2016 , 31, 538-45	36
1027	Molecular mechanisms of drug resistance and its reversal in cancer. 2016 , 36, 716-26	184
1026	7-Ketocholesterol overcomes drug resistance in chronic myeloid leukemia cell lines beyond MDR1 mechanism. 2017 , 151, 12-23	16
1025	Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance. 2017 , 8, 361-365	35
1024	Dual-Responsive Bola-Type Supra-Amphiphile Constructed from Water-Soluble Pillar[5]arene and Naphthalimide-Containing Amphiphile for Intracellular Drug Delivery. 2017 , 9, 4843-4850	60
1023	Novel immune check point inhibiting antibodies in cancer therapy-Opportunities and challenges. 2017 , 30, 39-47	56
1022	Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. 2017 , 116, 509-514	14
1021	Glycan Alteration Imparts Cellular Resistance to a Membrane-Lytic Anticancer Peptide. 2017 , 24, 149-158	18
1020	Extracellular vesicles and blood diseases. 2017 , 105, 392-405	34
1019	siRNA-Encapsulated Hybrid Nanoparticles Target Mutant K-ras and Inhibit Metastatic Tumor Burden in a Mouse Model of Lung Cancer. 2017 , 6, 259-268	13
1018	Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization. 2017 , 29, 1606628	545

1017	How Cancer Cells Become Resistant to Cationic Lytic Peptides: It's the Sugar!. 2017 , 24, 121-122	1
1016	The role of exosomes and miRNAs in drug-resistance of cancer cells. 2017 , 141, 220-230	160
1015	Cellular Hierarchy as a Determinant of Tumor Sensitivity to Chemotherapy. 2017 , 77, 2231-2241	12
1014	2-Trifluoromethyl-2-Hydroxypropionamide Derivatives as Novel Reversal Agents of ABCG2 (BCRP)-Mediated Multidrug Resistance: Synthesis and Biological Evaluations. 2017 , 118, 2420-2429	5
1013	Polymers in the Co-delivery of siRNA and Anticancer Drugs for the Treatment of Drug-resistant Cancers. 2017 , 375, 24	17
1012	Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4. 2017 , 116, 620-625	29
1011	Two-dimensional transition metal dichalcogenide nanomaterials for combination cancer therapy. 2017 , 5, 1873-1895	87
1010	Annexin A1 is involved in resistance to 5-FU in colon cancer cells. 2017 , 37, 235-240	22
1009	Positively Charged Combinatory Drug Delivery Systems against Multi-Drug-Resistant Breast Cancer: Beyond the Drug Combination. 2017 , 9, 6804-6815	26
1008	Design, synthesis, biological evaluation, molecular docking and QSAR studies of 2,4-dimethylacridones as anticancer agents. 2017 , 130, 154-170	20
1007	Double-Network-Structured Graphene Oxide-Containing Nanogels as Photothermal Agents for the Treatment of Colorectal Cancer. 2017 , 18, 1010-1018	45
1006	Synthesis and in vitro anti-proliferative activity of some novel isatins conjugated with quinazoline/phthalazine hydrazines against triple-negative breast cancer MDA-MB-231 cells as apoptosis-inducing agents. 2017 , 32, 600-613	59
1005	Effect and mechanism of resveratrol on drug resistance in human bladder cancer cells. 2017 , 15, 1179-1187	25
1004	Multifunctional Telodendrimer Nanocarriers Restore Synergy of Bortezomib and Doxorubicin in Ovarian Cancer Treatment. 2017 , 77, 3293-3305	33
1003	Clear: Composition of Likelihoods for Evolve and Resequencing Experiments. 2017 , 206, 1011-1023	17
1002	Solid State NMR Characterization of Ibuprofen:Nicotinamide Cocrystals and New Idea for Controlling Release of Drugs Embedded into Mesoporous Silica Particles. 2017 , 14, 1800-1810	23
1001	Core-shell hierarchical mesostructured silica nanoparticles for gene/chemo-synergetic stepwise therapy of multidrug-resistant cancer. 2017 , 133, 219-228	91
1000	microRNA-200a-3p increases 5-fluorouracil resistance by regulating dual specificity phosphatase 6 expression. 2017 , 49, e327	29

999	Nanotechnology and nanocarrier-based approaches on treatment of degenerative diseases. 2017 , 7, 91-122	89
998	Chemosensitizing indomethacin-conjugated chitosan oligosaccharide nanoparticles for tumor-targeted drug delivery. 2017 , 57, 262-273	37
997	Anti-Angiogenic Cancer Therapy: Development of Resistance. 2017 , 1-11	
996	MicroRNA-146a induces immune suppression and drug-resistant colorectal cancer cells. 2017 , 39, 1010428317698365	37
995	Suppression of ABCG2 mediated MDR in vitro and in vivo by a novel inhibitor of ABCG2 drug transport. 2017 , 121, 184-193	12
994	New insights into antidiabetic drugs: Possible applications in cancer treatment. 2017 , 90, 1056-1066	29
993	Combination therapy with doxorubicin-loaded galactosylated poly(ethyleneglycol)-lithocholic acid to suppress the tumor growth in an orthotopic mouse model of liver cancer. 2017 , 116, 130-144	32
992	TRPC5-induced autophagy promotes drug resistance in breast carcinoma via CaMKK β /AMPK β /mTOR pathway. 2017 , 7, 3158	43
991	Hybrid Prodrug Nanoparticles with Tumor Penetration and Programmed Drug Activation for Enhanced Chemoresistant Cancer Therapy. 2017 , 9, 18450-18461	22
990	Nanoemulsion as Targeted Drug Delivery System for Cancer Therapeutics. 2017 , 3, 83-97	36
989	Lipid vesicles containing transferrin receptor binding peptide TfR-T and octa-arginine conjugate stearyl-R efficiently treat brain glioma along with glioma stem cells. 2017 , 7, 3487	15
988	Epigenetic targeting drugs potentiate chemotherapeutic effects in solid tumor therapy. 2017 , 7, 4035	43
987	Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug. 2017 , 436, 119-136	22
986	A novel diiminato manganese(III) complex as the promising anticancer agent induces G0/G1 cell cycle arrest and triggers apoptosis via mitochondrial-dependent pathways in MCF-7 and MDA-MB-231 human breast cancer cells. 2017 , 7, 24387-24398	17
985	Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors. 2017 , 19, 1669-1684	55
984	Multiple polysaccharide-drug complex-loaded liposomes: A unique strategy in drug loading and cancer targeting. 2017 , 173, 57-66	40
983	Revealing chemical processes and kinetics of drug action within single living cells via plasmonic Raman probes. 2017 , 7, 2296	8
982	Pharmacokinetics and Drug Interactions Determine Optimum Combination Strategies in Computational Models of Cancer Evolution. 2017 , 77, 3908-3921	36

981	Effective melanoma cancer suppression by iontophoretic co-delivery of STAT3 siRNA and imatinib using gold nanoparticles. 2017 , 525, 407-417	52
980	CoreShell Metal-Organic Frameworks as Fe ²⁺ Suppliers for Fe ²⁺ -Mediated Cancer Therapy under Multimodality Imaging. 2017 , 29, 3477-3489	77
979	FEN1 promotes tumor progression and confers cisplatin resistance in non-small-cell lung cancer. 2017 , 11, 640-654	53
978	Selective intracellular vaporisation of antibody-conjugated phase-change nano-droplets in vitro. 2017 , 7, 44077	15
977	5KTriphosphate siRNA targeting MDR1 reverses multi-drug resistance and activates RIG-I-induced immune-stimulatory and apoptotic effects against human myeloid leukaemia cells. 2017 , 58, 23-30	18
976	Evaluation of the use of therapeutic peptides for cancer treatment. 2017 , 24, 21	227
975	Molecular Mechanism of Drug Resistance. 2017 , 47-110	9
974	Synthesis, chemical nuclease activity, and in vitro cytotoxicity of benzimidazole-based Cu(II)/Co(II) complexes. 2017 , 28, 1539-1546	8
973	UCH-L1-containing exosomes mediate chemotherapeutic resistance transfer in breast cancer. 2017 , 115, 932-940	64
972	Perturbed Signaling and Role of Posttranslational Modifications in Cancer Drug Resistance. 2017 , 483-510	2
971	A microfluidic platform for drug screening in a 3D cancer microenvironment. 2017 , 94, 632-642	43
970	Genome-Wide Screen Reveals Mutants of Are Methotrexate-Resistant. 2017 , 7, 1251-1257	3
969	Drug Resistance in Cancer. 2017 , 449-473	1
968	Cholesterol-Containing Nuclease-Resistant siRNA Accumulates in Tumors in a Carrier-free Mode and Silences MDR1 Gene. 2017 , 6, 209-220	43
967	Design, Synthesis, and Pharmacological Characterization of N-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)yl)ethyl)phenyl)quinazolin-4-amine Derivatives: Novel Inhibitors Reversing P-Glycoprotein-Mediated Multidrug Resistance. 2017 , 60, 3289-3302	27
966	Salinomycin: A new paradigm in cancer therapy. 2017 , 39, 1010428317695035	65
965	Cancer-Cell-Specific Mitochondria-Targeted Drug Delivery by Dual-Ligand-Functionalized Nanodiamonds Circumvent Drug Resistance. 2017 , 9, 11780-11789	65
964	Chemosensitizing Effect of Saikosaponin B on B16F10 Melanoma Cells. 2017 , 69, 505-511	9

963	Exploration of 2-((Pyridin-4-ylmethyl)amino)nicotinamide Derivatives as Potent Reversal Agents against P-Glycoprotein-Mediated Multidrug Resistance. 2017 , 60, 2930-2943	28
962	GEAR: A database of Genomic Elements Associated with drug Resistance. 2017 , 7, 44085	15
961	Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo. 2017 , 49, e303	25
960	Mixed poly(vinyl pyrrolidone)-based drug-loaded nanomicelles shows enhanced efficacy against pancreatic cancer cell lines. 2017 , 102, 250-260	13
959	A green approach to dual-drug nanoformulations with targeting and synergistic effects for cancer therapy. 2017 , 24, 51-60	20
958	Drug Resistance in Bacteria, Fungi, Malaria, and Cancer. 2017 ,	9
957	The Key Role of Sulfation and Branching on Fucoidan Antitumor Activity. 2017 , 17, 1600340	58
956	Novel transferrin modified and doxorubicin loaded Pluronic 85/lipid-polymeric nanoparticles for the treatment of leukemia: In vitro and in vivo therapeutic effect evaluation. 2017 , 86, 547-554	28
955	Nanomaterial-Based Drug Delivery Carriers for Cancer Therapy. 2017 ,	1
954	Co-delivery of docetaxel and verapamil by reduction-sensitive PEG-PLGA-SS-DTX conjugate micelles to reverse the multi-drug resistance of breast cancer. 2017 , 151, 119-127	58
953	Lysosome-associated protein transmembrane4 is involved in multidrug resistance processes of colorectal cancer. 2017 , 14, 5229-5234	1
952	Fabrication of self-assembled folate-biotin-quaternized starch nanoparticles as co-carrier of doxorubicin and siRNA. 2017 , 32, 587-597	13
951	Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity. 2017 , 29, 1703969	260
950	SN38-PEG-PLGA-verapamil nanoparticles inhibit proliferation and downregulate drug transporter ABCG2 gene expression in colorectal cancer cells. 2017 , 6, 137-145	10
949	Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. 2017 , 32, 23-46	76
948	Modeling the Dynamics of Heterogeneity of Solid Tumors in Response to Chemotherapy. 2017 , 79, 2986-3012	11
947	Tumor-targeting templated silica nanoparticles as a dual-drug delivery system for anti-angiogenic ovarian cancer therapy. 2017 , 14, 2162-2170	10
946	Graphene Quantum Dots for Drug Delivery. 2017 , 115-125	2

945	Near infrared light mediated photochemotherapy for efficiently treating deep orthotopic tumors guided by ultrasound imaging. 2017 , 24, 1441-1452	4
944	CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy. 2017 , 114, 11751-11756	27
943	Amphiphilic Modulation of Glycosylated Antitumor Ether Lipids Results in a Potent Triamino Scaffold against Epithelial Cancer Cell Lines and BT474 Cancer Stem Cells. 2017 , 60, 9724-9738	15
942	Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers. 2017 , 25, 2607-2619	46
941	Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers. 2017 , 6, e373	125
940	Concurrently suppressing multidrug resistance and metastasis of breast cancer by co-delivery of paclitaxel and honokiol with pH-sensitive polymeric micelles. 2017 , 62, 144-156	39
939	Drug induced self-assembly of triblock copolymers into polymersomes for the synergistic dual-drug delivery of platinum drugs and paclitaxel. 2017 , 8, 6289-6299	11
938	Overcoming Multidrug Resistance through the Synergistic Effects of Hierarchical pH-Sensitive, ROS-Generating Nanoreactors. 2017 , 3, 2431-2442	93
937	Modeling Drug Resistance in PDX Models. 2017 , 115-126	
936	MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer. 2017 , 28, 852-860	30
935	Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer. 2017 , 141, 1600-1614	22
934	Recent advances in combretastatin based derivatives and prodrugs as antimetabolic agents. 2017 , 8, 1592-1603	44
933	Molecular approaches to potentiate cisplatin responsiveness in carcinoma therapeutics. 2017 , 17, 815-825	11
932	Evaluation of the Antiproliferative Activity of <i>Maerua edulis</i> (Capparaceae) on Jurkat-T cells. 2017 , 7, 214-227	1
931	Covalent, Non-Covalent, Encapsulated Nanodrug Regulate the Fate of Intra- and Extracellular Trafficking: Impact on Cancer and Normal Cells. 2017 , 7, 6454	14
930	Anticancer effect of <i>Saussurea lappa</i> extract via dual control of apoptosis and autophagy in prostate cancer cells. 2017 , 96, e7606	16
929	Activation of ALDH1A1 in MDA-MB-468 breast cancer cells that over-express CYP2J2 protects against paclitaxel-dependent cell death mediated by reactive oxygen species. 2017 , 143, 79-89	18
928	Development of resistance to photodynamic therapy (PDT) in human breast cancer cells is photosensitizer-dependent: Possible mechanisms and approaches for overcoming PDT-resistance. 2017 , 144, 63-77	32

927	Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. 2017 , 23, 1063-1071	169
926	Cepharanthine hydrochloride reverses P-glycoprotein-mediated multidrug resistance in human ovarian carcinoma A2780/Taxol cells by inhibiting the PI3K/Akt signaling pathway. 2017 , 38, 2558-2564	14
925	Role of MicroRNA Regulation in Obesity-Associated Breast Cancer: Nutritional Perspectives. 2017 , 8, 868-888	21
924	Red Blood Cells for Drug Delivery. 2017 , 1, 1700270	45
923	Alpha-Mangostin Reverses Multidrug Resistance by Attenuating the Function of the Multidrug Resistance-Linked ABCG2 Transporter. 2017 , 14, 2805-2814	12
922	Exploring Selection Bias by Causal Frailty Models: The Magnitude Matters. 2017 , 28, 379-386	17
921	p62/SQSTM1 as an oncotarget mediates cisplatin resistance through activating RIP1-NF- κ B pathway in human ovarian cancer cells. 2017 , 108, 1405-1413	40
920	A chemo/photo- co-therapeutic system for enhanced multidrug resistant cancer treatment using multifunctional mesoporous carbon nanoparticles coated with poly (curcumin-dithiodipropionic acid). 2017 , 122, 524-537	16
919	Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer. 2017 , 261, 287-296	48
918	Lessons Learned from Two Decades of Anticancer Drugs. 2017 , 38, 852-872	53
917	Horizontal transfer of miR-106a/b from cisplatin resistant hepatocarcinoma cells can alter the sensitivity of cervical cancer cells to cisplatin. 2017 , 38, 146-158	29
916	Overcoming multidrug resistance using folate receptor-targeted and pH-responsive polymeric nanogels containing covalently entrapped doxorubicin. 2017 , 9, 10404-10419	47
915	An Ursolic Acid Derived Small Molecule Triggers Cancer Cell Death through Hyperstimulation of Macropinocytosis. 2017 , 60, 6638-6648	28
914	Patient-Derived Xenograft Models of Human Cancer. 2017 ,	5
913	Modeling multi-mutation and drug resistance: analysis of some case studies. 2017 , 14, 6	17
912	Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer. 2017 , 138, 273-292	94
911	Branched Gold Nanoparticle Coating of Clostridium novyi-NT Spores for CT-Guided Intratumoral Injection. 2017 , 13, 1602722	26
910	Co-delivery of multiple drug resistance inhibitors by polymer/inorganic hybrid nanoparticles to effectively reverse cancer drug resistance. 2017 , 149, 250-259	21

909	Natural Selection in Cancer Biology: From Molecular Snowflakes to Trait Hallmarks. 2017 , 7,	28
908	PRPS1 silencing reverses cisplatin resistance in human breast cancer cells. 2017 , 95, 385-393	14
907	Prolonged exposure of colon cancer cells to 5-fluorouracil nanoparticles improves its anticancer activity. 2017 , 25, 206-213	25
906	Clonal cooperativity in heterogenous cancers. 2017 , 64, 79-89	32
905	Design of a doxorubicin-peptidomimetic conjugate that targets HER2-positive cancer cells. 2017 , 125, 914-924	12
904	Phototheranostic nanoplatform based on a single cyanine dye for image-guided combinatorial phototherapy. 2017 , 13, 955-963	28
903	Cancer: A disease at the crossroads of trade-offs. 2017 , 10, 215-225	34
902	Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial. 2017 , 79, 9-16	9
901	Resensitization of Akt Induced Docetaxel Resistance in Breast Cancer by Kturin AKa Lipopeptide Molecule from Marine Bacteria Bacillus megaterium. 2017 , 7, 17324	19
900	Salvia Biotechnology. 2017 ,	1
899	Withanolide D Exhibits Similar Cytostatic Effect in Drug-Resistant and Drug-Sensitive Multiple Myeloma Cells. 2017 , 8, 610	10
898	Biodegradable Core-shell Dual-Metal-Organic-Frameworks Nanotheranostic Agent for Multiple Imaging Guided Combination Cancer Therapy. 2017 , 7, 4605-4617	57
897	Evaluation of anticancer drug in a polymer 3D cell chip. 2017 , 7, 2752	5
896	Platinum covalent shell cross-linked micelles designed to deliver doxorubicin for synergistic combination cancer therapy. 2017 , 12, 3697-3710	16
895	An Optimal Control Approach for the Treatment of Solid Tumors with Angiogenesis Inhibitors. 2017 , 5, 49	13
894	Adenoviral Vectors Armed with Cell Fusion-Inducing Proteins as Anti-Cancer Agents. 2017 , 9,	8
893	Expression of multidrug resistance protein P-glycoprotein in correlation with markers of hypoxia (HIF-1 β , EPO, EPO-R) in invasive breast cancer with metastasis to lymph nodes. 2017 , 13, 1303-1314	20
892	ROS mediated pro-apoptotic effects of on breast cancer cells. 2017 , 9, 89-100	11

891	The Impact of Melatonin on Colon Cancer Cells Resistance to Doxorubicin in an in Vitro Study. 2017 , 18,	19
890	Nanoparticles: A Novel Approach to Target Tumors. 2017 , 113-129	3
889	HMGB1-mediated autophagy attenuates gemcitabine-induced apoptosis in bladder cancer cells involving JNK and ERK activation. 2017 , 8, 71642-71656	42
888	The use of functional epirubicin liposomes to induce programmed death in refractory breast cancer. 2017 , 12, 4163-4176	18
887	Cytosolic Cl ⁻ Affects the Anticancer Activity of Paclitaxel in the Gastric Cancer Cell Line, MKN28 Cell. 2017 , 42, 68-80	14
886	Nanoparticle System for Anticancer Drug Delivery: Targeting to Overcome Multidrug Resistance. 2017 , 159-169	5
885	Dual-drug loaded nanoneedles with targeting property for efficient cancer therapy. 2017 , 15, 91	13
884	Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance. 2017 , 15, 189	11
883	Anti-tumor effects of the American cockroach,. 2017 , 12, 26	28
882	GMZ-1 is a podophyllotoxin derivative that suppresses growth and induces apoptosis in adriamycin-resistant K562/A02 cells through modulation of MDR1 expression. 2018 , 17, 474-478	3
881	Nanoparticle-based drug delivery systems: What can they really do ?. 2017 , 6, 681	38
880	The Association Between Cancer and ABC Transporters. 2017 , 10,	
879	genetic variants in leukemias: current insights into treatment outcomes. 2017 , 10, 169-181	12
878	Suppression of microRNA-629 enhances sensitivity of cervical cancer cells to 1S-1Kacetoxychavicol acetate via regulating RSU1. 2017 , 10, 1695-1705	23
877	A New Series of Pyrrole-Based Chalcones: Synthesis and Evaluation of Antimicrobial Activity, Cytotoxicity, and Genotoxicity. 2017 , 22,	14
876	Current diagnostics and treatment of fibrosarcoma -perspectives for future therapeutic targets and strategies. 2017 , 8, 104638-104653	45
875	Simultaneous Determination of Twenty-Five Compounds in Rat Plasma Using Ultra-High Performance Liquid Chromatography-Polarity Switching Tandem Mass Spectrometry and Its Application to a Pharmacokinetic Study. 2017 , 22,	6
874	Proteins regulating the intercellular transfer and function of P-glycoprotein in multidrug-resistant cancer. 2017 , 11, 768	17

873	SYNTHESIS OF 4-HYDROXY-3-(1-HYDROXY-2-(SUBSTITUTEDAMINO)ETHYL)-1-PHENYL/ METHYL QUINOLIN-2(1H)-ONE AS ANTICANCER AGENTS. 2017 , 10, 225	3
872	Microarray-based detection and expression analysis of new genes associated with drug resistance in ovarian cancer cell lines. 2017 , 8, 49944-49958	49
871	Nanocarriers in Improving Chemotherapy of Multidrug Resistant Tumors: Key Developments and Perspectives. 2017 , 23, 3301-3308	7
870	The dual-hit metabolic modulator LDCA synergistically potentiates doxorubicin to selectively combat cancer-associated hallmarks. 2017 , 7, 53322-53333	1
869	Genetic determinants for chemo- and radiotherapy resistance in bladder cancer. 2017 , 6, 1081-1089	20
868	H6, a novel hederagenin derivative, reverses multidrug resistance in vitro and in vivo. 2018 , 341, 98-105	62
867	Studying new antibiotics for multidrug resistant infections: are today's patients paying for unproved future benefits?. 2018 , 360, k587	19
866	New tools for old drugs: Functional genetic screens to optimize current chemotherapy. 2018 , 36, 30-46	27
865	Biomaterial scaffolds for non-invasive focal hyperthermia as a potential tool to ablate metastatic cancer cells. 2018 , 166, 27-37	19
864	RETRACTED: Arsenic Trioxide Inhibits Proliferation and Induced apoptosis of Leukemia Stem Cells with Drug Resistance. 2018 , 69, 66-71	
863	Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro. 2018 , 154, 10-17	29
862	MDR1 not CYP3A4 gene expression is the predominant mechanism of innate drug resistance in pediatric soft tissue sarcoma patients. 2018 , 22, 317-324	6
861	Enantiomeric pairs of copper(II) polypyridyl-alanine complex salts: anticancer studies. 2018 , 43, 479-496	6
860	Strategy to targeting the immune resistance and novel therapy in colorectal cancer. 2018 , 7, 1578-1603	17
859	The multifaceted role of exosomes in cancer progression: diagnostic and therapeutic implications [corrected]. 2018 , 41, 223-252	40
858	Overcoming Ovarian Cancer Drug Resistance with a Cold Responsive Nanomaterial. 2018 , 4, 567-581	36
857	2-(4-dihydroxy-6-methoxy-3,5-dimethylchalcone, a potent Nrf2/ARE pathway inhibitor, reverses drug resistance by decreasing glutathione synthesis and drug efflux in BEL-7402/5-FU cells. 2018 , 119, 252-259	11
856	Chitosan-based hydrogels: Preparation, properties and applications. 2018 , 115, 194-220	150

855	The dual-inhibitory effect of miR-338-5p on the multidrug resistance and cell growth of hepatocellular carcinoma. 2018 , 3, 3	19
854	Time-lapse live cell imaging to monitor doxorubicin release from DNA origami nanostructures. 2018 , 6, 1605-1612	33
853	Does the use of melatonin overcome drug resistance in cancer chemotherapy?. 2018 , 196, 143-155	37
852	miR-1266 Contributes to Pancreatic Cancer Progression and Chemoresistance by the STAT3 and NF-B Signaling Pathways. 2018 , 11, 142-158	40
851	Elimination of stem-like cancer cell side-population by auranofin through modulation of ROS and glycolysis. 2018 , 9, 89	61
850	Synergistic effect of a novel autophagy inhibitor and Quizartinib enhances cancer cell death. 2018 , 9, 138	15
849	Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC. 2018 , 63, 934-944	17
848	Multidrug Resistance in Cancer Circumvented Using a Cytosolic Drug Reservoir. 2018 , 5, 1700289	11
847	Jatrophane diterpenoids from Euphorbia sororia as potent modulators against P-glycoprotein-based multidrug resistance. 2018 , 146, 157-170	21
846	Tumor stressors induce two mechanisms of intracellular P-glycoprotein-mediated resistance that are overcome by lysosomal-targeted thiosemicarbazones. 2018 , 293, 3562-3587	27
845	Exosome-mediated breast cancer chemoresistance via miR-155 transfer. 2018 , 8, 829	152
844	Targeted production of reactive oxygen species in mitochondria to overcome cancer drug resistance. 2018 , 9, 562	190
843	Emerging nanomaterials with advanced drug delivery functions; focused on methotrexate delivery. 2018 , 359, 32-51	54
842	Synthesis of N-(1-(6-acetamido-5-phenylpyrimidin-4-yl) piperidin-3-yl) amide derivatives as potential inhibitors for mitotic kinesin spindle protein. 2018 , 148, 106-115	2
841	Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells. 2018 , 8, 967	133
840	The Static Magnetic Field Remotely Boosts the Efficiency of Doxorubicin through Modulating ROS Behaviors. 2018 , 8, 990	17
839	Switching off the interactions between graphene oxide and doxorubicin using vitamin C: combining simplicity and efficiency in drug delivery. 2018 , 6, 1251-1259	18
838	Multifunctional Shell-Core Nanoparticles for Treatment of Multidrug Resistance Hepatocellular Carcinoma. 2018 , 28, 1706124	42

837	Bcl-2 Antiapoptotic Family Proteins and Chemoresistance in Cancer. 2018 , 137, 37-75	88
836	Integrative analysis of rewired central metabolism in temozolomide resistant cells. 2018 , 495, 2010-2016	5
835	Docetaxel-carboxymethylcellulose nanoparticles ameliorate CCl-induced hepatic fibrosis in mice. 2018 , 26, 516-524	8
834	Reduction Responsive Nanovesicles Derived from Novel α -Tocopheryl-Lipoic Acid Conjugates for Efficacious Drug Delivery to Sensitive and Drug Resistant Cancer Cells. 2018 , 29, 255-266	18
833	Synthesis, structural characterization and cytotoxicity studies of T-shaped silver(I) complexes derived from 1-benzyl-3H-benzimidazolium p-toluenesulfonates. 2018 , 142, 63-70	9
832	PRMT5 as a druggable target for glioblastoma therapy. 2018 , 20, 753-763	44
831	Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo. 2018 , 37, 31	17
830	KRDS: a web server for evaluating drug resistance mutations in kinases by molecular docking. 2018 , 10, 20	1
829	Pharmacological Characterization of the RPMI 2650 Model as a Relevant Tool for Assessing the Permeability of Intranasal Drugs. 2018 , 15, 2246-2256	7
828	Unlike Butylcycloheptylprodigiosin, Isolated Undecylprodigiosin from <i>Streptomyces parvulus</i> Is Not a MDR1 and BCRP Substrate in Multidrug-Resistant Cancers. 2018 , 37, 535-542	3
827	Resistance to Ibrutinib in B Cell Malignancies: One Size Does Not Fit All. 2018 , 4, 197-206	6
826	Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? An update. 2018 , 19, 475-393	5
825	Downregulation of miR-374b-5p promotes chemotherapeutic resistance in pancreatic cancer by upregulating multiple anti-apoptotic proteins. 2018 , 52, 1491-1503	23
824	Anti-tumour effects of beta-sitosterol are mediated by AMPK/PTEN/HSP90 axis in AGS human gastric adenocarcinoma cells and xenograft mouse models. 2018 , 152, 60-70	24
823	Natural product toosendanin reverses the resistance of human breast cancer cells to adriamycin as a novel PI3K inhibitor. 2018 , 152, 153-164	25
822	Caveolin-1, cancer and therapy resistance. 2018 , 143, 2092-2104	59
821	Predictive approaches for drug combination discovery in cancer. 2018 , 19, 263-276	41
820	Possible Role of microRNA-122 in Modulating Multidrug Resistance of Hepatocellular Carcinoma. 2018 , 33, 21-30	24

819	MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy. 2017 , 8, e2540	139
818	Toward Hydrogen Sulfide Based Therapeutics: Critical Drug Delivery and Developability Issues. 2018 , 38, 57-100	90
817	Genetic background influences susceptibility to chemotherapy-induced hematotoxicity. 2018 , 18, 319-330	17
816	Is RPMI 2650 a Suitable In Vitro Nasal Model for Drug Transport Studies?. 2018 , 43, 13-24	14
815	Exploration of 1,2,3-triazole-pyrimidine hybrids as potent reversal agents against ABCB1-mediated multidrug resistance. 2018 , 143, 1535-1542	30
814	Modeling the chemotherapy-induced selection of drug-resistant traits during tumor growth. 2018 , 436, 120-134	17
813	Naturally modified nonionic alginate functionalized upconversion nanoparticles for the highly efficient targeted pH-responsive drug delivery and enhancement of NIR-imaging. 2018 , 57, 424-435	26
812	Biological evaluation of p-toluene sulphonylhydrazone as carbonic anhydrase IX inhibitors: An approach to fight hypoxia-induced tumors. 2018 , 106, 840-850	45
811	Smart pH-sensitive micelles based on redox degradable polymers as DOX/GNPs carriers for controlled drug release and CT imaging. 2018 , 163, 29-40	42
810	The Impact of Di(2-ethylhexyl)phthalate on Cancer Progression. 2018 , 66, 183-197	10
809	Heat shock proteins and cancer: intracellular chaperones or extracellular signalling ligands?. 2018 , 373,	61
808	Modulating secreted components of tumor microenvironment: A masterstroke in tumor therapeutics. 2018 , 19, 3-12	30
807	A modified 384-well-device for versatile use in 3D cancer cell (co-)cultivation and screening for investigations of tumor biology in vitro. 2018 , 18, 132-139	6
806	MicroRNA-195 desensitizes HCT116 human colon cancer cells to 5-fluorouracil. 2018 , 412, 264-271	32
805	Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo. 2018 , 155, 112-123	43
804	Comparative in vitro study on cytotoxicity of recombinant hairpin peptides. 2018 , 91, 294-303	16
803	Chemo-photothermal effects of doxorubicin/silica-carbon hollow spheres on liver cancer.. 2018 , 8, 36775-36784	
802	Applications of Aptamers in Cancer Therapy. 2018 ,	1

801	The Roles of microRNAs in Regulating Chemotherapy Resistance of Non-Small Cell Lung Cancer. 2018 , 23, 5983-5988	11
800	Abductive Network Action Inference for Targeted Therapy Discovery. 2018 , 335, 3-25	4
799	Network spectra for drug-target identification in complex diseases: new guns against old foes. 2018 , 3, 51	5
798	. 2018 ,	
797	Cancer Stem Cells: Emergent Nature of Tumor Emergency. 2018 , 9, 544	7
796	Experimental Studies of the Effects of Progesterone on the Functional Activity of P-Glycoprotein. 2018 , 52, 587-592	0
795	Down-regulation of ABCE1 inhibits temozolomide resistance in glioma through the PI3K/Akt/NF- κ B signaling pathway. 2018 , 38,	14
794	Dendrimer-like mesoporous silica nanospheres with suitable surface functionality to combat the multidrug resistance. 2018 , 553, 349-362	5
793	Chemoresistance of Cancer Cells: Requirements of Tumor Microenvironment-mimicking Models in Anti-Cancer Drug Development. 2018 , 8, 5259-5275	89
792	Overview of DNA Self-Assembling: Progresses in Biomedical Applications. 2018 , 10,	11
791	Targeted Graphene Oxide Networks: Cytotoxicity and Synergy with Anticancer Agents. 2018 , 10, 43523-43532	14
790	Precise nanomedicine for intelligent therapy of cancer. 2018 , 61, 1503-1552	256
789	Transcriptional profiling of NCI/ADR-RES cells unveils a complex network of signaling pathways and molecular mechanisms of drug resistance. 2018 , 11, 221-237	6
788	Building Block Based Construction of Membrane-Organelle Double Targeted Nanosystem for Two-Drug Delivery. 2018 , 29, 3677-3685	10
787	Nanocarrier-Based Combination Chemotherapy for Resistant Tumor: Development, Characterization, and Ex Vivo Cytotoxicity Assessment. 2018 , 19, 3839-3849	8
786	Gold Nanorod-Based Nanohybrids for Combinatorial Therapeutics. 2018 , 3, 12633-12647	14
785	Casein micelles for oral delivery of SN-38 and elacridar to overcome BCRP-mediated multidrug resistance in gastric cancer. 2018 , 133, 240-249	18
784	MicroRNA-424 serves an anti-oncogenic role by targeting cyclin-dependent kinase 1 in breast cancer cells. 2018 , 40, 3416-3426	26

783	Flavonoids and Cancer Stem Cells Maintenance and Growth. 2018 , 587-622	5
782	Overcoming multiple drug resistance in cancer using polymeric micelles. 2018 , 15, 1127-1142	24
781	Real-Time Determination of the Cell-Cycle Position of Individual Cells within Live Tumors Using FUCCI Cell-Cycle Imaging. 2018 , 7,	11
780	Selenium Nanoparticles: Biomedical Applications. 2018 , 393-412	15
779	Isorhamnetin suppresses PANC-1 pancreatic cancer cell proliferation through S phase arrest. 2018 , 108, 925-933	19
778	TdIF1: a putative oncogene in NSCLC tumor progression. 2018 , 3, 28	7
777	Thiol redox-sensitive cationic polymers for dual delivery of drug and gene. 2018 , 9, 751-773	3
776	Overcoming Drug Resistance by Targeting Cancer Bioenergetics with an Activatable Prodrug. 2018 , 4, 2370-2383	52
775	Single cell transcriptome analysis of MCF-7 reveals consistently and inconsistently expressed gene groups each associated with distinct cellular localization and functions. 2018 , 13, e0199471	6
774	Analysis of miRNA signature differentially expressed in exosomes from adriamycin-resistant and parental human breast cancer cells. 2018 , 38,	13
773	Nitric oxide reverses drug resistance by inhibiting ATPase activity of p-glycoprotein in human multi-drug resistant cancer cells. 2018 , 1862, 2806-2814	14
772	FoxG1 facilitates proliferation and inhibits differentiation by downregulating FoxO/Smad signaling in glioblastoma. 2018 , 504, 46-53	15
771	Overcoming P-Glycoprotein-Mediated Multidrug Resistance in Colorectal Cancer: Potential Reversal Agents among Herbal Medicines. 2018 , 2018, 3412074	17
770	A multi-state model of chemoresistance to characterize phenotypic dynamics in breast cancer. 2018 , 8, 12058	13
769	lH-Pyrazolo[3,4-b]quinolin-3-amine derivatives inhibit growth of colon cancer cells via apoptosis and sub G1 cell cycle arrest. 2018 , 28, 2244-2249	13
768	The challenge of drug resistance in cancer treatment: a current overview. 2018 , 35, 309-318	206
767	Anticancer activity study of A adenosine receptor agonists. 2018 , 205, 155-163	6
766	Olmudinib (HM61713) reversed multidrug resistance by inhibiting the activity of ATP-binding cassette subfamily G member 2 and. 2018 , 8, 563-574	18

765	Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety as Orally Bioavailable Reversal Agents against P-Glycoprotein-Mediated Multidrug Resistance. 2018 , 61, 5988-6001	38
764	Promising Applications in Medicine. 2018 , 79-135	
763	In situ fluorescence monitoring of diagnosis and treatment: a versatile nanoprobe combining tumor targeting based on MUC1 and controllable DOX release by telomerase. 2018 , 54, 8277-8280	22
762	Novel Potent ABCB1 Modulator, Phenethylisoquinoline Alkaloid, Reverses Multidrug Resistance in Cancer Cell. 2018 , 15, 4021-4030	5
761	Modeling continuous levels of resistance to multidrug therapy in cancer. 2018 , 64, 733-751	9
760	Intracellular self-disassemble polysaccharide nanoassembly for multi-factors tumor drug resistance modulation of doxorubicin. 2018 , 6, 2527-2540	30
759	Inhibitor of DNA binding 3 reverses cisplatin resistance in human lung adenocarcinoma cells by regulating the PI3K/Akt pathway. 2018 , 16, 1634-1640	6
758	Magnetically responsive release of 5-FU from superparamagnetic egg albumin coated iron oxide core-shell nanoparticles. 2018 , 47, 240-253	9
757	The novel strategies for next-generation cancer treatment: miRNA combined with chemotherapeutic agents for the treatment of cancer. 2018 , 9, 10164-10174	53
756	FGF2 Dual Warhead Conjugate with Monomethyl Auristatin E and β -Amanitin Displays a Cytotoxic Effect towards Cancer Cells Overproducing FGF Receptor 1. 2018 , 19,	15
755	HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response. 2018 , 48, 1505-1518	21
754	Functional Characterization of ABCC Proteins from and Their Involvement with Thiol Transport. 2018 , 9, 205	12
753	The Ever-Evolving Concept of the Cancer Stem Cell in Pancreatic Cancer. 2018 , 10,	62
752	Microfluidic Devices for Drug Delivery Systems and Drug Screening. 2018 , 9,	155
751	Dynamic microRNA activity identifies therapeutic targets in trastuzumab-resistant HER2 breast cancer. 2018 , 115, 2613-2623	9
750	Enantiomeric Effect of d-Amino Acid Substitution on the Mechanism of Action of β -Helical Membrane-Active Peptides. 2017 , 19,	8
749	Anticancer Profiling for Coumarins and Related β -Naphthoquinones from against Solid Tumor Cells In Vitro. 2018 , 23,	15
748	Anticancer drug discovery from Chinese medicinal herbs. 2018 , 13, 35	40

747	SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines. 2018 , 433, 259-272	12
746	Synthesis, characterization, solution equilibria, DFT study, DNA binding affinity and cytotoxic properties of a cobalt(II) complex with a 5-pyrazolone ligand. 2018 , 482, 738-748	8
745	Mutual concessions and compromises between stromal cells and cancer cells: driving tumor development and drug resistance. 2018 , 41, 353-367	48
744	Recent Advances in the Studies of Molecular Mechanisms Regulating Multidrug Resistance in Cancer Cells. 2018 , 83, 779-786	11
743	An extracellular matrix (ECM) model at high malignant colorectal tumor increases chondroitin sulfate chains to promote epithelial-mesenchymal transition and chemoresistance acquisition. 2018 , 370, 571-578	19
742	Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer. 2018 , 38, 2058-2109	69
741	A proteomic analysis of chemoresistance development via sequential treatment with doxorubicin reveals novel players in MCF-7 breast cancer cells. 2018 , 42, 1987-1997	5
740	Intrinsic Xenobiotic Resistance of the Intestinal Stem Cell Niche. 2018 , 46, 681-695.e5	14
739	Antibody-drug conjugates (ADCs): Potent biopharmaceuticals to target solid and hematological cancers- an overview. 2018 , 48, 106-117	9
738	Rapid identification of antimicrometastases drugs using integrated model systems with two dimensional monolayer, three dimensional spheroids, and zebrafish xenotransplantation tumors. 2018 , 115, 2828-2843	12
737	The role of HIF-1 β in chemo-/radioresistant tumors. 2018 , 11, 3003-3011	43
736	Novel thermoresponsive star-like nanomicelles for targeting of anticancer agent. 2018 , 107, 143-154	20
735	PD-1 Blockade for Improving the Antitumor Efficiency of Polymer-Doxorubicin Nanoprodrug. 2018 , 14, e1802403	42
734	Knockdown of serine/threonine protein phosphatase 5 enhances gemcitabine sensitivity by promoting apoptosis in pancreatic cancer cells. 2018 , 15, 8761-8769	4
733	Upregulation of let-7f-5p promotes chemotherapeutic resistance in colorectal cancer by directly repressing several pro-apoptotic proteins. 2018 , 15, 8695-8702	15
732	Liver Cancer Stem Cells. 2018 , 289-315	1
731	Tuning Spatial Profiles of Selection Pressure to Modulate the Evolution of Drug Resistance. 2018 , 120, 238102	18
730	Multitalented Ginger and Its Clinical Development for Cancer Treatment. 2018 , 351-370	0

729	The Onus of Sphingolipid Enzymes in Cancer Drug Resistance. 2018 , 140, 235-263	8
728	In-vitro cytotoxicity of Trigona itama honey against human lung adenocarcinoma epithelial cell line (A549). 2019 , 30, 100955	4
727	Danazol mediates collateral sensitivity via STAT3/Myc related pathway in multidrug-resistant cancer cells. 2019 , 9, 11628	3
726	Application of Nanotechnology in Targeting of Cancer Stem Cells: A Review. 2019 , 12, 227-239	22
725	Role of nucleic acid amplification assays in monitoring treatment response in chagas disease: Usefulness in clinical trials. 2019 , 199, 105120	13
724	Stochastic modeling of phenotypic switching and chemoresistance in cancer cell populations. 2019 , 9, 10845	10
723	Adapting and Surviving: Intra and Extra-Cellular Remodeling in Drug-Resistant Gastric Cancer Cells. 2019 , 20,	28
722	Bioactive Natural Products for the Management of Cancer: from Bench to Bedside. 2019 ,	2
721	Chemotherapy Resistance in Advanced Ovarian Cancer Patients. 2019 , 11, 1179299X19860815	101
720	Enhancement of chemosensitivity by WEE1 inhibition in EGFR-TKIs resistant non-small cell lung cancer. 2019 , 117, 109185	4
719	Bioinformatics analysis of dysregulated microRNAs in exosomes from docetaxel-resistant and parental human breast cancer cells. 2019 , 11, 5425-5435	7
718	Novel tetrahydroacridine derivatives with iodobenzoic moieties induce G0/G1 cell cycle arrest and apoptosis in A549 non-small lung cancer and HT-29 colorectal cancer cells. 2019 , 460, 123-150	5
717	MicroRNA-222 promotes drug resistance to doxorubicin in breast cancer via regulation of miR-222/bim pathway. 2019 , 39,	14
716	Drug Resistance in Cancer and Role of Nanomedicine-Based Natural Products. 2019 , 177-218	
715	Recent Advancements in aptamer-bioconjugates: Sharpening Stones for breast and prostate cancers targeting. 2019 , 53, 101146	18
714	Extracellular Vesicles: Subcellular Organelles With the Potential to Spread Cancer Resistance. 2019 , 39, 3395-3404	12
713	Evolution of cancer cell populations under cytotoxic therapy and treatment optimisation: insight from a phenotype-structured model. 2019 , 53, 1157-1190	19
712	Rational Design of Stimuli-Responsive Polymers Modified Nanopores for Selective and Sensitive Determination of Salivary Glucose. 2019 , 91, 14029-14035	10

711	Lignan enriched fraction (LRF) of <i>Phyllanthus amarus</i> promotes apoptotic cell death in human cervical cancer cells in vitro. 2019 , 9, 14950	3
710	Angiotensin II-induced micro RNA-21 culprit for non-small-cell lung adenocarcinoma. 2019 , 80, 1031-1039	5
709	Extracellular vesicles as a novel source of biomarkers in liquid biopsies for monitoring cancer progression and drug resistance. 2019 , 47, 100647	61
708	Reversal of drug resistance by JS-K and nitric oxide in ABCB1- and ABCG2-expressing multi-drug resistant human tumor cells. 2019 , 120, 109468	11
707	Doxorubicin combined with betulinic acid or lonidamine in RGD ligand-targeted pH-sensitive micellar system for ovarian cancer treatment. 2019 , 571, 118751	12
706	Chlorophyll and Chlorophyll Derivatives Interfere with Multi-Drug Resistant Cancer Cells and Bacteria. 2019 , 24,	8
705	Cancer Nanomedicine: A New Era of Successful Targeted Therapy. 2019 , 2019, 1-13	31
704	Role of hypoxia in cancer therapy by regulating the tumor microenvironment. 2019 , 18, 157	447
703	A Novel Class of N-Sulfonyl and N-Sulfamoyl Noscapine Derivatives that Promote Mitotic Arrest in Cancer Cells. 2019 , 14, 1968-1981	4
702	Tissue Architectural Cues Drive Organ Targeting of Tumor Cells in Zebrafish. 2019 , 9, 187-206.e16	19
701	miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer. 2019 , 23, 8114-8127	21
700	SPP1 inhibition improves the cisplatin chemo-sensitivity of cervical cancer cell lines. 2019 , 83, 603-613	19
699	Modulation of RAB7A Protein Expression Determines Resistance to Cisplatin through Late Endocytic Pathway Impairment and Extracellular Vesicular Secretion. 2019 , 11,	24
698	Towards early monitoring of chemotherapy-induced drug resistance based on single cell metabolomics: Combining single-probe mass spectrometry with machine learning. 2019 , 1092, 42-48	13
697	Cooperative adaptation to therapy (CAT) confers resistance in heterogeneous non-small cell lung cancer. 2019 , 15, e1007278	14
696	Carrier-Free Supramolecular Hydrogel Composed of Dual Drugs for Conquering Drug Resistance. 2019 , 11, 33706-33715	28
695	PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC. 2019 , 9, 12437	11
694	Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors. 2019 , 14, 395-404	21

693	3D Quantitative and Ultrastructural Analysis of Mitochondria in a Model of Doxorubicin Sensitive and Resistant Human Colon Carcinoma Cells. 2019 , 11,	8
692	Mask-free generation of multicellular 3D heterospheroids array for high-throughput combinatorial anti-cancer drug screening. 2019 , 183, 108182	17
691	Recent nanotechnological interventions targeting PI3K/Akt/mTOR pathway: A focus on breast cancer. 2019 , 59, 133-146	26
690	Elimination of Osteosarcoma by Necroptosis with Graphene Oxide-Associated Anti-HER2 Antibodies. 2019 , 20,	11
689	Principles of Cancer Treatment and Anticancer Drug Development. 2019 ,	3
688	Resistance to Targeted Therapies in Lymphomas. 2019 ,	
687	The multi-factorial nature of clinical multidrug resistance in cancer. 2019 , 46, 100645	155
686	RBCK1 contributes to chemoresistance and stemness in colorectal cancer (CRC). 2019 , 118, 109250	18
685	Minimal intervening control of biomolecular networks leading to a desired cellular state. 2019 , 9, 13124	3
684	Novel virosecurinine bivalent mimetics as potent reversal agents against P-glycoprotein-mediated multidrug resistance. 2019 , 183, 111726	8
683	Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway. 2019 , 14, 2215-2223	46
682	The CK2 inhibitor CX4945 reverses cisplatin resistance in the A549/DDP human lung adenocarcinoma cell line. 2019 , 18, 3845-3856	11
681	Design, synthesis and biological evaluation of N-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-4-oxo-3,4-dihydrophthalazine-1-carboxamide derivatives as novel P-glycoprotein inhibitors reversing multidrug resistance. 2019 , 86, 166-175	8
680	Towards rapid prediction of drug-resistant cancer cell phenotypes: single cell mass spectrometry combined with machine learning. 2019 , 55, 616-619	36
679	Salinomycin decreases feline sarcoma and carcinoma cell viability when combined with doxorubicin. 2019 , 15, 36	2
678	Drug-loaded exosomal preparations from different cell types exhibit distinctive loading capability, yield, and antitumor efficacies: a comparative analysis. 2019 , 14, 531-541	56
677	Glutathione S-transferases P1 protects breast cancer cell from adriamycin-induced cell death through promoting autophagy. 2019 , 26, 2086-2099	19
676	CDK Inhibitors as Sensitizing Agents for Cancer Chemotherapy. 2019 , 125-149	5

675	MoS ₂ -based biomaterials for cancer therapy. 2019 , 141-161	1
674	Molecular Engineering-Based Aptamer-Drug Conjugates with Accurate Tunability of Drug Ratios for Drug Combination Targeted Cancer Therapy. 2019 , 58, 11661-11665	34
673	Molecular Engineering-Based Aptamer-Drug Conjugates with Accurate Tunability of Drug Ratios for Drug Combination Targeted Cancer Therapy. 2019 , 131, 11787-11791	8
672	Multifunctional DNA Origami Nanoplatfoms for Drug Delivery. 2019 , 14, 2193-2202	26
671	Targeting multidrug resistance in cancer by natural chemosensitizers. 2019 , 43,	34
670	The biochemical and molecular mechanisms involved in the role of tumor micro-environment stress in development of drug resistance. 2019 , 1863, 1390-1397	17
669	Effective MDR reversers through phytochemical study of Euphorbia boetica. 2019 , 30, 498-511	4
668	Novel Method for Preparation of Site-Specific, Stoichiometric-Controlled Dual Warhead Conjugate of FGF2 via Dimerization Employing Sortase A-Mediated Ligation. 2019 , 16, 3588-3599	11
667	Molecular Targets, Anti-cancer Properties and Potency of Synthetic Indole-3-carbinol Derivatives. 2019 , 19, 540-554	12
666	Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance. 2019 , 179, 849-862	20
665	Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma. 2019 , 16, 453-467	7
664	The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?. 2019 , 31, 824-833	26
663	Current Applications of Nanoemulsions in Cancer Therapeutics. 2019 , 9,	72
662	Monoterpene indole alkaloids as leads for targeting multidrug resistant cancer cells from the African medicinal plant <i>Tabernaemontana elegans</i> . 2019 , 18, 971-987	4
661	Androgen receptor plasticity and its implications for prostate cancer therapy. 2019 , 81, 101871	23
660	A self-assembled, modular nucleic acid-based nanoscaffold for multivalent theranostic medicine. 2019 , 9, 2662-2677	7
659	The cell-penetrating FOXM1 N-terminus (M1-138) demonstrates potent inhibitory effects on cancer cells by targeting FOXM1 and FOXM1-interacting factor SMAD3. 2019 , 9, 2882-2896	5
658	Autophagy and its regulation by ginseng components. 2019 , 43, 349-353	12

657	Avapritinib: A Selective Inhibitor of KIT and PDGFR β that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines. 2019 , 16, 3040-3052	28
656	Synergistic effect of paclitaxel and verapamil to overcome multi-drug resistance in breast cancer cells. 2019 , 516, 183-188	5
655	Inorganic Nanoparticles as Drug Delivery Systems and Their Potential Role in the Treatment of Chronic Myelogenous Leukaemia. 2019 , 18, 1533033819853241	15
654	Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential. 2019 , 9,	82
653	MicroRNAs and response to therapy in leukemia. 2019 , 120, 14233-14246	3
652	Synthesis and In Vitro Antitumor Activity of Novel Chromenones Bearing Benzothiazole Moiety. 2019 , 45, 42-53	16
651	Multifunctionalized Micelles Facilitate Intracellular Doxorubicin Delivery for Reversing Multidrug Resistance of Breast Cancer. 2019 , 16, 2502-2510	16
650	Two/three-dimensional interfacial properties of the novel peptide as a selective destroyer of biomembrane. 2019 , 574, 62-68	1
649	Cytotoxicity of cucurbitacin E from Citrullus colocynthis against multidrug-resistant cancer cells. 2019 , 62, 152945	25
648	Multi-targeted anti-leukemic drug design with the incorporation of silicon into Nelarabine: How silicon increases bioactivity. 2019 , 134, 266-273	2
647	EGFR and HER2 Inhibitors as Sensitizing Agents for Cancer Chemotherapy. 2019 , 1-11	3
646	Confirmation of Selected Synergistic Cancer Drug Combinations Identified in an HTS Campaign and Exploration of Drug Efflux Transporter Contributions to the Mode of Synergy. 2019 , 24, 653-668	4
645	Cancer Stem Cells: Acquisition, Characteristics, Therapeutic Implications, Targeting Strategies and Future Prospects. 2019 , 15, 331-355	46
644	Dysoxylactam A: A Macrocyclolipopeptide Reverses P-Glycoprotein-Mediated Multidrug Resistance in Cancer Cells. 2019 , 141, 6812-6816	22
643	WYE-354 restores Adriamycin sensitivity in multidrug-resistant acute myeloid leukemia cell lines. 2019 , 41, 3179-3188	5
642	Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis. 2019 , 2019, 8727935	2
641	Microfluidic device for the analysis of MDR cancerous cell-derived exosomesKresponse to nanotherapy. 2019 , 21, 35	12
640	Single-Cell Omics Analyses Enabled by Microchip Technologies. 2019 , 21, 365-393	30

639	Peptoid drug discovery and optimization via surface X-ray scattering. 2019 , 110, e23274	6
638	Down-regulation of miR-543 expression increases the sensitivity of colorectal cancer cells to 5-Fluorouracil through the PTEN/PI3K/AKT pathway. 2019 , 39,	27
637	Immune-adjuvant loaded Bi ₂ Se ₃ nanocage for photothermal-improved PD-L1 checkpoint blockade immune-tumor metastasis therapy. 2019 , 12, 1770-1780	14
636	C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas. 2019 , 8,	14
635	Recent advances of stimuli-responsive systems based on transition metal dichalcogenides for smart cancer therapy. 2019 , 7, 2588-2607	21
634	Enhanced radiosensitization of ternary CuBiSe nanoparticles by photo-induced hyperthermia in the second near-infrared biological window. 2019 , 11, 7157-7165	13
633	On-chip anticancer drug screening - Recent progress in microfluidic platforms to address challenges in chemotherapy. 2019 , 137, 236-254	43
632	Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents. 2019 , 852, 231-243	20
631	Mathematical Approach to Differentiate Spontaneous and Induced Evolution to Drug Resistance During Cancer Treatment. 2019 , 3, 1-20	21
630	Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives. 2019 , 79, 633-645	22
629	Computational algorithms for in silico profiling of activating mutations in cancer. 2019 , 76, 2663-2679	7
628	Nucleic Acid-Based Functional Nanomaterials as Advanced Cancer Therapeutics. 2019 , 15, e1900172	43
627	Nanomaterials-Based siRNA Delivery: Routes of Administration, Hurdles and Role of Nanocarriers. 2019 , 67-114	7
626	Human recombinant FSH induces chemoresistance in human breast cancer cells via HIF-1 β activation 2019 , 100, 1521-1535	5
625	Nanocomposites as biomolecules delivery agents in nanomedicine. 2019 , 17, 48	44
624	Extracellular and intracellular microRNAs in pancreatic cancer: from early diagnosis to reducing chemoresistance. 2019 , 1,	2
623	Nanotechnology in Modern Animal Biotechnology. 2019 ,	2
622	Clinical application of ceramide in cancer treatment. 2019 , 26, 407-415	19

621	MiR-873/PD-L1 axis regulates the stemness of breast cancer cells. 2019 , 41, 395-407	76
620	Nitric Oxide-Releasing Functional Nanomaterials for Anticancer Therapy. 2019 , 191-218	2
619	Cisplatin, glutathione and the third wheel: a copper-(1,10-phenanthroline) complex modulates cisplatin-GSH interactions from antagonism to synergism in cancer cells resistant to cisplatin.. 2019 , 9, 5362-5376	7
618	The role and mechanisms of action of microRNAs in cancer drug resistance. 2019 , 11, 25	252
617	Application of Computational Biology and Artificial Intelligence Technologies in Cancer Precision Drug Discovery. 2019 , 2019, 8427042	25
616	Impact of Induced Syncytia Formation on the Oncolytic Potential of Myxoma Virus. 2019 , 8, 57-69	
615	Shwachman-Bodian-Diamond syndrome protein desensitizes breast cancer cells to apoptosis in stiff matrices by repressing the caspase 8-mediated pathway. 2019 , 23, 414-421	
614	The Emerging Role of the SLCO1B3 Protein in Cancer Resistance. 2020 , 27, 17-29	6
613	Cold Atmospheric Plasma Restores Paclitaxel Sensitivity to Paclitaxel-Resistant Breast Cancer Cells by Reversing Expression of Resistance-Related Genes. 2019 , 11,	15
612	Organic Nanoparticles as Drug Delivery Systems and Their Potential Role in the Treatment of Chronic Myeloid Leukemia. 2019 , 18, 1533033819879902	8
611	Ablation Can Confer Drug Resistance to Cancer Cells via a Malate-Aspartate Shuttle-Mediated Mechanism. 2019 , 11,	7
610	Quantitative Chemotherapeutic Profiling of Gynecologic Cancer Cell Lines Using Approved Drugs and Bioactive Compounds. 2019 , 12, 441-452	9
609	Multidrug resistance phenotype: Relation between phenotype induction and its characteristics in erythroleukemia cells. 2019 , 43, 214-219	3
608	Linc00161 regulated the drug resistance of ovarian cancer by sponging microRNA-128 and modulating MAPK1. 2019 , 58, 577-587	30
607	Regulation of Ca Signaling for Drug-Resistant Breast Cancer Therapy with Mesoporous Silica Nanocapsule Encapsulated Doxorubicin/siRNA Cocktail. 2019 , 13, 274-283	81
606	Paris saponin VII reverses chemoresistance in breast MCF-7/ADR cells. 2019 , 232, 47-54	6
605	The Multitarget Activity of Natural Extracts on Cancer: Synergy and Xenohormesis. 2018 , 6,	16
604	Curcumin in combination with anti-cancer drugs: A nanomedicine review. 2019 , 139, 91-105	72

603	Acyl-CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression. 2019 , 159, 52-63	23
602	Enzyme-Instructed Supramolecular Self-Assembly with Anticancer Activity. 2019 , 31, e1804814	45
601	Nanocarriers for drug delivery applications. 2019 , 17, 849-865	85
600	Versatile applications of three-dimensional objects fabricated by two-photon-initiated polymerization. 2019 , 9, 53-66	8
599	Effect of amide linkage of PEG-lipid conjugates on the stability and cytotoxic activity of goniodiol loaded in PEGylated liposomes. 2019 , 50, 1-8	8
598	The epigallocatechin gallate derivative Y reverses drug resistance mediated by the ABCB1 transporter both and. 2019 , 9, 316-323	11
597	Synthesis and antiproliferative activities of doxorubicin thiol conjugates and doxorubicin-SS-cyclic peptide. 2019 , 161, 594-606	19
596	Smart pH-Sensitive Nanogels for Controlled Release in an Acidic Environment. 2019 , 20, 130-140	31
595	Identification of Smac mimetics as novel substrates for p-glycoprotein. 2019 , 440-441, 126-134	7
594	A phase 2 randomised study of veliparib plus FOLFIRI+bevacizumab versus placebo plus FOLFIRI+bevacizumab in metastatic colorectal cancer. 2019 , 120, 183-189	20
593	Glioblastoma Therapy in the Age of Molecular Medicine. 2019 , 5, 46-65	44
592	Design, synthesis, and biological evaluation of indole carboxylic acid esters of podophyllotoxin as antiproliferative agents. 2019 , 28, 81-94	4
591	Prevention of oral carcinogenesis in rats by <i>Dracaena cinnabari</i> resin extracts. 2019 , 23, 2287-2301	8
590	High NEK2 confers to poor prognosis and contributes to cisplatin-based chemotherapy resistance in nasopharyngeal carcinoma. 2019 , 120, 3547-3558	19
589	Delivery of MTH1 inhibitor (TH287) and MDR1 siRNA via hyaluronic acid-based mesoporous silica nanoparticles for oral cancers treatment. 2019 , 173, 599-606	31
588	Redox-responsive hyaluronic acid nanogels for hyperthermia- assisted chemotherapy to overcome multidrug resistance. 2019 , 203, 378-385	25
587	Co-delivery of resveratrol and docetaxel via polymeric micelles to improve the treatment of drug-resistant tumors. 2019 , 14, 78-85	35
586	Role of Structural Bioinformatics in Drug Discovery by Computational SNP Analysis: Analyzing Variation at the Protein Level. 2017 , 12, 151-161	24

585	In Silico implementation of evolutionary paradigm in therapy design: Towards anti-cancer therapy as Darwinian process. 2020 , 485, 110038	0
584	Influence of phenothiazine molecules on the interactions between positively charged poly-L-lysine and negatively charged DPPC/DPPG membranes. 2020 , 227, 117563	1
583	The NEDD4-1 E3 ubiquitin ligase: A potential molecular target for bortezomib sensitivity in multiple myeloma. 2020 , 146, 1963-1978	10
582	Metabolic and non-metabolic pathways that control cancer resistance to anthracyclines. 2020 , 98, 181-191	28
581	Epigenetic reprogramming and potential application of epigenetic-modifying drugs in acquired chemotherapeutic resistance. 2020 , 94, 219-259	13
580	Efflux transporters in cancer resistance: Molecular and functional characterization of P-glycoprotein. 2020 , 1-30	0
579	Isatin-azole hybrids and their anticancer activities. 2020 , 353, e1900272	31
578	Self-Propelled Micro/Nanomotors for On-Demand Biomedical Cargo Transportation. 2020 , 16, e1902464	45
577	Investigation of solid tumor progression with account of proliferation/migration dichotomy via Darwinian mathematical model. 2020 , 80, 601-626	7
576	Novel fluorescent probes for L-cysteine based on the xanthone skeleton. 2020 , 387, 112153	4
575	The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs. 2019 , 21,	6
574	Folate-Gold-Bilirubin Nanoconjugate Induces Apoptotic Death in Multidrug-Resistant Oral Carcinoma Cells. 2020 , 45, 285-296	8
573	Magnetic Hybrid Wax Nanocomposites as Externally Controlled Theranostic Vehicles: High MRI Enhancement and Synergistic Magnetically Assisted Thermo/Chemo Therapy. 2020 , 26, 4531-4538	8
572	Reverting chemoresistance of targeted agents by a ultrasoluble dendritic nanocapsule. 2020 , 317, 67-77	4
571	MiR-142-3p enhances chemosensitivity of breast cancer cells and inhibits autophagy by targeting HMGB1. 2020 , 10, 1036-1046	21
570	Parameritannin A-2 from <i>Urceola huaitingii</i> enhances doxorubicin-induced mitochondria-dependent apoptosis by inhibiting the PI3K/Akt, ERK1/2 and p38 pathways in gastric cancer cells. 2020 , 316, 108924	7
569	Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy. 2020 , 104, 575-587	129
568	Enhanced anticancer effect of doxorubicin by TPGS-coated liposomes with Bcl-2 siRNA-corona for dual suppression of drug resistance. 2020 , 15, 646-660	15

567	C-Myc inhibition sensitizes pre-B ALL cells to the anti-tumor effect of vincristine by altering apoptosis and autophagy: Proposing a probable mechanism of action for 10058-F4. 2020 , 870, 172821	10
566	Regulatory Variant as Predictor of Epirubicin-Based Neoadjuvant Chemotherapy in Luminal A Breast Cancer. 2020 , 10, 571517	2
565	Genomics and Transcriptomics: The Powerful Technologies in Precision Medicine. 2020 , 13, 627-640	7
564	Molecular and cellular paradigms of multidrug resistance in cancer. 2020 , e1291	8
563	Molecular profiling of afatinib-resistant non-small cell lung cancer cells in vivo derived from mice. 2020 , 161, 105183	4
562	Numerical optimisation of chemotherapy dosage under antiangiogenic treatment in the presence of drug resistance. 2020 , 43, 10671-10689	1
561	Molecular mechanisms of breast cancer chemoresistance by immune checkpoints. 2020 , 263, 118604	3
560	Combining Inorganic Chemistry and Biology: The Underestimated Potential of Metal Complexes in Medicine. 2020 , 21, 3044-3046	14
559	Nitrogen-containing naringenin derivatives for reversing multidrug resistance in cancer. 2020 , 28, 115798	8
558	GRP78 targeting: Hitting two birds with a stone. 2020 , 260, 118317	33
557	Drug resistance in cancer: mechanisms and tackling strategies. 2020 , 72, 1125-1151	33
556	Mechanisms of Taxane Resistance. 2020 , 12,	32
555	Mesenchymal Stem Cell-Secreted Exosome Promotes Chemoresistance in Breast Cancer via Enhancing miR-21-5p-Mediated Expression. 2020 , 19, 283-293	14
554	Structure-Based Design, Synthesis, and Biological Evaluation of New Triazolo[1,5-]Pyrimidine Derivatives as Highly Potent and Orally Active ABCB1 Modulators. 2020 , 63, 15979-15996	12
553	Thrombospondin-1 Receptor CD47 Overexpression Contributes to P-Glycoprotein-Mediated Multidrug Resistance Against Doxorubicin in Thyroid Carcinoma FTC-133 Cells. 2020 , 10, 551228	2
552	Molecular and Functional Roles of MicroRNAs in the Progression of Hepatocellular Carcinoma-A Review. 2020 , 21,	22
551	Past, Present, and Future of Anticancer Nanomedicine. 2020 , 15, 5719-5743	13
550	The Spectrum of Design Solutions for Improving the Activity-Selectivity Product of Peptide Antibiotics against Multidrug-Resistant Bacteria and Prostate Cancer PC-3 Cells. 2020 , 25,	3

549	pH/redox sequentially responsive nanoparticles with size shrinkage properties achieve deep tumor penetration and reversal of multidrug resistance. 2020 , 8, 4767-4778	14
548	Labeled-protein corona-coated BiS nanorods targeted to lysosomes for bioimaging and efficient photothermal cancer therapy. 2020 , 196, 111291	3
547	Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors. 2020 , 50, 100682	72
546	Application of DNA nanostructures in cancer therapy. 2020 , 21, 100861	3
545	Autophagy-mediating microRNAs in cancer chemoresistance. 2020 , 36, 517-536	14
544	Bibenzyls and bisbybenzyls of bryophytic origin as promising source of novel therapeutics: pharmacology, synthesis and structure-activity. 2020 , 28, 701-734	13
543	Counteracting Chemoresistance with Metformin in Breast Cancers: Targeting Cancer Stem Cells. 2020 , 12,	10
542	Human spermbots for patient-representative 3D ovarian cancer cell treatment. 2020 , 12, 20467-20481	8
541	FUCCI Real-Time Cell-Cycle Imaging as a Guide for Designing Improved Cancer Therapy: A Review of Innovative Strategies to Target Quiescent Chemo-Resistant Cancer Cells. 2020 , 12,	7
540	A Sequentially Responsive Nanosystem Breaches Cascaded Bio-barriers and Suppresses P-Glycoprotein Function for Reversing Cancer Drug Resistance. 2020 , 12, 54343-54355	7
539	Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M). 2020 , 105, 104274	3
538	Deciphering the chemical instability of sphaeropsidin A under physiological conditions - degradation studies and structural elucidation of the major metabolite. 2020 , 18, 8147-8160	
537	Branched β -helical peptides enhanced antitumor efficacy and selectivity. 2020 , 8, 6387-6394	0
536	Photosensitizer With Illumination Enhances Antitumor Effect of Anti-ROBO1 Immunotoxin on Maxillary Sinus Squamous Cell Carcinoma. 2020 , 40, 3793-3799	1
535	Exploring Specific miRNA-mRNA Axes With Relationship to Taxanes-Resistance in Breast Cancer. 2020 , 10, 1397	5
534	Mechanisms of Resistance to Chemotherapy in Breast Cancer and Possible Targets in Drug Delivery Systems. 2020 , 12,	11
533	Harmine and Piperlongumine Revert TRIB2-Mediated Drug Resistance. 2020 , 12,	7
532	Study on reversal of ABCB1 mediated multidrug resistance in Colon cancer by acetogenins: An - approach. 2020 , 1-12	7

531	Aberrant DNA Methylation of ABC Transporters in Cancer. 2020 , 9,	7
530	Applications of Minimally Invasive Nanomedicine-Based Therapies in 3D in vitro Cancer Platforms. 2020 , 1, 1-109	
529	Synthesis, characterization and bioactivity studies of new dithiocarbazate complexes. 2020 , 44, 8878-8889	6
528	The functional role of surface molecules on extracellular vesicles in cancer, autoimmune diseases, and coagulopathy. 2020 , 108, 1565-1573	6
527	Rab27B enhances drug resistance in hepatocellular carcinoma by promoting exosome-mediated drug efflux. 2020 , 41, 1583-1591	5
526	Synthetic macromolecules as therapeutics that overcome resistance in cancer and microbial infection. 2020 , 252, 120078	42
525	The Role of a Proprotein Convertase Inhibitor in Reactivation of Tumor-Associated Macrophages and Inhibition of Glioma Growth. 2020 , 17, 31-46	7
524	Acquired resistance to DZNep-mediated apoptosis is associated with copy number gains of AHCY in a B-cell lymphoma model. 2020 , 20, 427	1
523	P-glycoprotein and multidrug resistance-associated protein-1 expression in acute myeloid leukemia: Biological and prognosis implications. 2020 , 42, 594-603	9
522	Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model. 2020 , 19, 1320-1327	3
521	MDR1 Gene Polymorphisms and Its Association With Expression as a Clinical Relevance in Terms of Response to Chemotherapy and Prognosis in Ovarian Cancer. 2020 , 11, 516	3
520	Inhibition of Patched Drug Efflux Increases Vemurafenib Effectiveness against Resistant Braf Melanoma. 2020 , 12,	7
519	Effect of melatonin supplementation in combination with neoadjuvant chemotherapy to miR-210 and CD44 expression and clinical response improvement in locally advanced oral squamous cell carcinoma: a randomized controlled trial. 2020 , 32, 12	9
518	Mathematical Details on a Cancer Resistance Model. 2020 , 8, 501	6
517	Discovering and validating cancer genetic dependencies: approaches and pitfalls. 2020 , 21, 671-682	19
516	Molecular insights and novel approaches for targeting tumor metastasis. 2020 , 585, 119556	33
515	A milbemycin compound isolated from Streptomyces Sp. FJS31-2 with cytotoxicity and reversal of cisplatin resistance activity in A549/DDP cells. 2020 , 128, 110322	4
514	Pharmacological Activity, Pharmacokinetics, and Toxicity of Timosaponin AIII, a Natural Product Isolated From Bunge: A Review. 2020 , 11, 764	12

513	Ultrasound-responsive alkaline nanorobots for the treatment of lactic acidosis-mediated doxorubicin resistance. 2020 , 12, 13801-13810	9
512	Hsa_Circ_0007841 Enhances Multiple Myeloma Chemotherapy Resistance Through Upregulating ABCG2. 2020 , 19, 1533033820928371	6
511	Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors. 2020 , 12,	5
510	The Pyrazolo[3,4-d]pyrimidine Derivative, SCO-201, Reverses Multidrug Resistance Mediated by ABCG2/BCRP. 2020 , 9,	8
509	Sulforaphane as an anticancer molecule: mechanisms of action, synergistic effects, enhancement of drug safety, and delivery systems. 2020 , 43, 371-384	29
508	The role of long non-coding RNAs in mediating chemoresistance by modulating autophagy in cancer. 2020 , 17, 1727-1740	13
507	Increased HDAC Activity and c-MYC Expression Mediate Acquired Resistance to WEE1 Inhibition in Acute Leukemia. 2020 , 10, 296	7
506	LncRNA SDHAP1 confers paclitaxel resistance of ovarian cancer by regulating EIF4G2 expression via miR-4465. 2020 , 168, 171-181	16
505	Anticancer Effects of Herbal Medicine Compounds and Novel Formulations: a Literature Review. 2020 , 51, 765-773	11
504	Nanotechnology-based targeted drug delivery systems and drug resistance in colorectal cancer. 2020 , 173-198	
503	The Roles of Long Noncoding RNAs HNF1B-AS1 and HNF4B-AS1 in Drug Metabolism and Human Diseases. 2020 , 6,	4
502	Intratumoral Administration of a Novel Cytotoxic Formulation with Strong Tissue Dispersive Properties Regresses Tumor Growth and Elicits Systemic Adaptive Immunity in In Vivo Models. 2020 , 21,	4
501	Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines. 2020 , 180, 114137	10
500	Chronic exposure of human glioblastoma tumors to low concentrations of a pesticide mixture induced multidrug resistance against chemotherapy agents. 2020 , 202, 110940	6
499	Cancer therapy: Attempt cure or manage drug resistance?. 2020 , 13, 1660-1672	17
498	Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance. 2020 , 52, 100712	36
497	Nanoemulsions for intravenous drug delivery. 2020 , 581-601	4
496	Targeting Functional Activity of AKT Has Efficacy against Aggressive Neuroblastoma. 2020 , 3, 148-160	1

495	Overcoming the diverse mechanisms of multidrug resistance in lung cancer cells by photodynamic therapy using pTHPP-loaded PLGA-lipid hybrid nanoparticles. 2020 , 149, 218-228	12
494	Mathematical modelling of multi-mutation and drug resistance model with fractional derivative. 2020 , 59, 2291-2304	9
493	Interpenetrating Polymer Network: Biomedical Applications. 2020 ,	2
492	regulates paclitaxel resistance in lung adenocarcinoma A549 cells. 2020 , 48, 639-647	12
491	Rociletinib (CO-1686) enhanced the efficacy of chemotherapeutic agents in ABCG2-overexpressing cancer cells and o. 2020 , 10, 799-811	9
490	Multiple Myeloma: Available Therapies and Causes of Drug Resistance. 2020 , 12,	62
489	Total Synthesis of Dysoxylactam A. 2020 , 22, 1776-1779	7
488	ROS in cancer therapy: the bright side of the moon. 2020 , 52, 192-203	517
487	Rosmarinic acid reverses non-small cell lung cancer cisplatin resistance by activating the MAPK signaling pathway. 2020 , 34, 1142-1153	21
486	Revolutionizing technologies of nanomicelles for combinatorial anticancer drug delivery. 2020 , 43, 100-109	9
485	SERCA and P-glycoprotein inhibition and ATP depletion are necessary for celastrol-induced autophagic cell death and collateral sensitivity in multidrug-resistant tumor cells. 2020 , 153, 104660	12
484	The need for rapid therapeutic efficacy testing for cancer therapy. 2020 , 113, 104382	
483	Magnetic Driven Nanocarriers for pH-Responsive Doxorubicin Release in Cancer Therapy. 2020 , 25,	16
482	Fabrication of core/shell/shell structure nanoparticle with anticancer drug and dual-photosensitizer co-loading for synergistic chemotherapy and photodynamic therapy. 2020 , 297, 110049	10
481	Emerging Insights into Anticancer Chemopreventive Activities of Nutraceutical Moringa oleifera: Molecular Mechanisms, Signal Transduction and In Vivo Efficacy. 2020 , 6, 38-51	9
480	Clinical implications of cancer stem cells in digestive cancers: acquisition of stemness and prognostic impact. 2020 , 50, 1560-1577	14
479	MicroRNA-153-3p enhances the sensitivity of chronic myeloid leukemia cells to imatinib by inhibiting B-cell lymphoma-2-mediated autophagy. 2020 , 33, 610-618	8
478	Ethnobotanical Study of Medicinal Plants Used by Traditional Healers to Treat Cancer-Like Symptoms in Eleven Districts, Ethiopia. 2020 , 2020, 7683450	8

477	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs. 2020 , 83, 1461-1472	15
476	Advances in phytochemical and modern pharmacological research of. 2020 , 58, 265-275	22
475	Smart gold nanocages for mild heat-triggered drug release and breaking chemoresistance. 2020 , 323, 387-397	18
474	Cytotoxicity of 4-substituted quinoline derivatives: Anticancer and antileishmanial potential. 2020 , 28, 115511	12
473	Tumor microenvironment-induced structure changing drug/gene delivery system for overcoming delivery-associated challenges. 2020 , 323, 203-224	33
472	The selective c-Met inhibitor capmatinib offsets cisplatin-nephrotoxicity and doxorubicin-cardiotoxicity and improves their anticancer efficacies. 2020 , 398, 115018	11
471	Clinical Opportunities for Continuous Biosensing and Closed-Loop Therapies. 2020 , 2, 319-340	25
470	The Significance of MicroRNAs Expression in Regulation of Extracellular Matrix and Other Drug Resistant Genes in Drug Resistant Ovarian Cancer Cell Lines. 2020 , 21,	13
469	The in Vitro Antiplasmodial and Antiproliferative Activity of New Ferrocene-Based β -Aminocresols Targeting Hemozoin Inhibition and DNA Interaction. 2020 , 21, 2643-2658	4
468	Overcoming Doxorubicin Resistance with Lipid-Polymer Hybrid Nanoparticles Photoreleasing Nitric Oxide. 2020 , 17, 2135-2144	13
467	Molecular avenues in targeted doxorubicin cancer therapy. 2020 , 16, 687-700	13
466	Organosilicon Compounds, SILA-409 and SILA-421, as Doxorubicin Resistance-Reversing Agents in Human Colon Cancer Cells. 2020 , 25,	2
465	Targeted Engineering of Medicinal Chemistry for Cancer Therapy: Recent Advances and Perspectives. 2021 , 60, 5626-5643	13
464	Zielgerichtete Wirkstoffe für die Krebstherapie: Aktuelle Entwicklungen und Perspektiven. 2021 , 133, 5686-5705	1
463	Codelivery of survivin inhibitor and chemotherapeutics by tumor-derived microparticles to reverse multidrug resistance in osteosarcoma. 2021 , 45, 382-393	2
462	Intracellular RNA and nuclear DNA-dual-targeted tumor therapy via upconversion nanoplatforms with UCL/MR dual-mode bioimaging. 2021 , 405, 126606	5
461	Melatonin increases the chemosensitivity of diffuse large B-cell lymphoma cells to epirubicin by inhibiting P-glycoprotein expression via the NF- κ B pathway. 2021 , 14, 100876	3
460	A Structure-Activity Relationship Study of Novel Hydroxamic Acid Inhibitors around the S1 Subsite of Human Aminopeptidase N. 2021 , 16, 234-249	

459	DNA addition polymerization with logic operation for controllable self-assembly of three-dimensional nanovehicles and combinatorial cancer therapy. 2021 , 408, 127258	8
458	Proteasomal dysfunction and ER stress triggers 2Khydroxy-retrochalcone-induced paraptosis in cancer cells. 2021 , 45, 164-176	1
457	Recent progress in layered double hydroxides as a cancer theranostic nanoplatform. 2021 , 13, e1679	6
456	Mitochondria-Specific Agents for Photodynamic Cancer Therapy: A Key Determinant to Boost the Efficacy. 2021 , 10, e2001240	14
455	Alkylated monoterpene indole alkaloid derivatives as potent P-glycoprotein inhibitors in resistant cancer cells. 2021 , 210, 112985	4
454	Non-coding RNAs and potential therapeutic targeting in cancer. 2021 , 1875, 188491	36
453	Multivalent rubber-like RNA nanoparticles for targeted co-delivery of paclitaxel and MiRNA to silence the drug efflux transporter and liver cancer drug resistance. 2021 , 330, 173-184	16
452	Nanobody-displaying porous silicon nanoparticles for the co-delivery of siRNA and doxorubicin. 2021 , 9, 133-147	12
451	Cytotoxic and chemotaxonomic study of isolated metabolites from <i>Centaurea aegyptiaca</i> . 2021 , 68, 159-168	5
450	Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I. 2021 , 18, 73-102	6
449	Mangiferin induces immune responses and evaluates the survival rate in WEHI-3 cell generated mouse leukemia in vivo. 2020 ,	2
448	Ginger extract activates caspase independent paraptosis in cancer cells via ER stress, mitochondrial dysfunction, AIF translocation and DNA damage. 2021 , 73, 147-159	12
447	Glaucarubinone sensitizes KB cells to paclitaxel by inhibiting ABC transporters via ROS-dependent and p53-mediated activation of apoptotic signaling pathways. 2016 , 7, 42353-42373	13
446	Mechanisms of chemoresistance and approaches to overcome its impact in gynecologic cancers. 2021 , 77-126	
445	Current treatment modalities in major gynecologic cancers: Emphasis on response rates. 2021 , 127-154	
444	Nanomedicine-mediated ubiquitination inhibition boosts antitumor immune response via activation of dendritic cells. 2021 , 14, 3900	1
443	FOXA1 is a determinant of drug resistance in breast cancer cells. 2021 , 186, 317-326	4
442	Real-Time Fluorescence Image-Guided Oncolytic Virotherapy for Precise Cancer Treatment. 2021 , 22,	1

441	Extracellular Vesicles in Chemoresistance. 2021 , 97, 211-245	0
440	Emerging need of advanced drug delivery systems in cancer. 2021 , 27-36	2
439	In Vitro and In Vivo Tumor Models for the Evaluation of Anticancer Nanoparticles. 2021 , 1295, 271-299	2
438	Landscape of natural product diversity in land-plants as source for anticancer molecules. 2021 , 233-254	0
437	Drugs Resistance Management. 2021 , 539-558	
436	Drug Resistance in Cancer. 2021 , 367-386	0
435	A generator of peroxyxynitrite activatable with red light. 2021 , 12, 4740-4746	1
434	Suppression Of Aberrant Activation Of NF- κ B Pathway In Drug-resistant Leukemia Stem Cells Contributes To Parthenolide-potentiated Reversal Of Drug Resistance In Leukemia. 2021 , 12, 5519-5529	3
433	Elucidating the anticancer activities of guanidinium-functionalized amphiphilic random copolymers by varying the structure and composition in the hydrophobic monomer. 2021 , 11, 8977-8992	1
432	Mechanistic basis of breast cancer resistance protein inhibition by new indeno[1,2-b]indoles. 2021 , 11, 1788	6
431	Predicting chemosensitivity using drug perturbed gene dynamics. 2021 , 22, 15	1
430	Role of ABCB1 in mediating chemoresistance of triple-negative breast cancers. 2021 , 41,	4
429	Hypoxia-Induced Autophagy Enhances Cisplatin Resistance in Human Bladder Cancer Cells by Targeting Hypoxia-Inducible Factor-1. 2021 , 2021, 8887437	4
428	Smart Nanocarriers for Targeted Cancer Therapy. 2021 , 21, 546-557	1
427	Roles of microRNAs in Gastrointestinal Cancer Stem Cell Resistance and Therapeutic Development. 2021 , 22,	3
426	ABIN-1 is a key regulator in RIPK1-dependent apoptosis (RDA) and necroptosis, and ABIN-1 deficiency potentiates necroptosis-based cancer therapy in colorectal cancer. 2021 , 12, 140	1
425	Disruption of pH Dynamics Suppresses Proliferation and Potentiates Doxorubicin Cytotoxicity in Breast Cancer Cells. 2021 , 13,	4
424	U.S. FDA Approved Drugs from 2015-June 2020: A Perspective. 2021 , 64, 2339-2381	75

423	Methiothepin Increases Chemotherapy Efficacy against Resistant Melanoma Cells. 2021 , 26,	5
422	The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications. 2021 , 13,	4
421	ROS-Mediated Necrosis by Glycolipid Biosurfactants on Lung, Breast, and Skin Melanoma Cells. 2021 , 11, 622470	6
420	Molecular and biological functions of gingerol as a natural effective therapeutic drug for cervical cancer. 2021 , 14, 43	6
419	Host-guest inclusion for enhancing anticancer activity of pemetrexed against lung carcinoma and decreasing cytotoxicity to normal cells. 2021 , 32, 3034-3034	5
418	Controlling Cancer Cell Behavior by Improving the Stiffness of Gastric Tissue-Decellularized ECM Bioink With Cellulose Nanoparticles. 2021 , 9, 605819	9
417	Exosomal miR-222 from adriamycin-resistant MCF-7 breast cancer cells promote macrophages M2 polarization via PTEN/Akt to induce tumor progression. 2021 , 13, 10415-10430	11
416	Mitoxantrone-Loaded PLGA Nanoparticles for Increased Sensitivity of Glioblastoma Cancer Cell to TRAIL-Induced Apoptosis. 1	0
415	Genomic Alterations and Possible Druggable Mutations in Carcinoma of Unknown Primary (CUP).	
414	Steroids-has the time come to extend their use to AML?. 2021 , 33, 7	1
413	Frontiers in the treatment of glioblastoma: Past, present and emerging. 2021 , 171, 108-138	29
412	NCX-4040, a Unique Nitric Oxide Donor, Induces Reversal of Drug-Resistance in Both ABCB1- and ABCG2-Expressing Multidrug Human Cancer Cells. 2021 , 13,	2
411	Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells. 2021 , 549, 171-178	3
410	Prospects of Delivering Natural Compounds by Polymer-Drug Conjugates in Cancer Therapeutics. 2021 ,	1
409	DNA repair and cholesterol-mediated drug efflux induce dose-dependent chemoresistance in nutrient-deprived neuroblastoma cells. 2021 , 24, 102325	
408	Multidrug Resistance in Mammals and Fungi-From MDR to PDR: A Rocky Road from Atomic Structures to Transport Mechanisms. 2021 , 22,	11
407	Autophagy signals orchestrate chemoresistance of gynecological cancers. 2021 , 1875, 188525	3
406	DUSP16 promotes cancer chemoresistance through regulation of mitochondria-mediated cell death. 2021 , 12, 2284	6

405	Implicating extracellular vesicles in Plasmodium falciparum artemisinin resistance development. 2021 , 22, 194-200	0
404	Nanomedicine in cancer therapy: promises and hurdles of polymeric nanoparticles.	3
403	A Dual pH-Responsive DOX-Encapsulated Liposome Combined with Glucose Administration Enhanced Therapeutic Efficacy of Chemotherapy for Cancer. 2021 , 16, 3185-3199	3
402	Horizontal Transfer of miR-643 from Cisplatin-Resistant Cells Confers Chemoresistance to Recipient Drug-Sensitive Cells by Targeting APOE. 2021 , 10,	2
401	Cancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target. 2021 , 22,	17
400	Prospective Drug Candidates as Human Multidrug Transporter ABCG2 Inhibitors: an In Silico Drug Discovery Study. 2021 , 79, 189-200	11
399	Acquired drug resistance enhances imidazoquinoline efflux by P-glycoprotein.	
398	Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance. 2021 , 40, 174	7
397	Quantification of long-term doxorubicin response dynamics in breast cancer cell lines to direct treatment schedules.	1
396	Transporter associated with antigen processing 1 (TAP1) expression and prognostic analysis in breast, lung, liver, and ovarian cancer. 2021 , 99, 1293-1309	7
395	Paclitaxel-Based Chemotherapy Targeting Cancer Stem Cells from Mono- to Combination Therapy. 2021 , 9,	5
394	Essential Oils, and , Chemosensitize Resistant Human Uterine Sarcoma MES-SA/Dx5 Cells to Doxorubicin by Inducing Apoptosis and Targeting P-Glycoprotein. 2021 , 13,	1
393	Fabricating nanoparticles co-loaded with survivin siRNA and Pt(IV) prodrug for the treatment of platinum-resistant lung cancer. 2021 , 601, 120577	3
392	In-Silico Evaluation of Genetic Alterations in Ovarian Carcinoma and Therapeutic Efficacy of NSC777201, as a Novel Multi-Target Agent for TTK, NEK2, and CDK1. 2021 , 22,	2
391	Angiogenesis and chemotherapy resistance: optimizing chemotherapy scheduling using mathematical modeling. 2021 , 147, 2281-2299	4
390	A Synergistic Combination of Niclosamide and Doxorubicin as an Efficacious Therapy for All Clinical Subtypes of Breast Cancer. 2021 , 13,	3
389	MiR-375 reduces the stemness of gastric cancer cells through triggering ferroptosis. 2021 , 12, 325	16
388	The role of endolysosomal trafficking in anticancer drug resistance. 2021 , 57, 100769	7

- 387 The Long-Term DEHP Exposure Confers Multidrug Resistance of Triple-Negative Breast Cancer Cells through ABC Transporters and Intracellular ROS. **2021**, 10, 1
- 386 Anti-carcinogenic Effect of Cathepsin K Inhibitor, Odanacatib with a Low Dose of Cisplatin Against Human Breast Carcinoma MCF-7 and MDA-MB231 Cells. **2021**, 17, 159-169
- 385 Crosstalk between miRNAs and signaling pathways involved in pancreatic cancer and pancreatic ductal adenocarcinoma. **2021**, 901, 174006 3
- 384 MiR-181c sensitizes ovarian cancer cells to paclitaxel by targeting GRP78 through the PI3K/Akt pathway. **2021**, 2
- 383 Effects and Mechanisms of Saikosaponin D Improving the Sensitivity of Human Gastric Cancer Cells to Cisplatin. **2021**, 6, 18745-18755 2
- 382 Co-administration of a branched arginine-rich polymer enhances the anti-cancer efficacy of doxorubicin. **2021**, 203, 111752 2
- 381 Molecular Modelling a Key Method for Potential Therapeutic Drug Discovery.. **2021**, 37, 29427-29431
- 380 Phytochemicals reverse P-glycoprotein mediated multidrug resistance via signal transduction pathways. **2021**, 139, 111632 7
- 379 Isobavachalcone as an Active Membrane Perturbing Agent and Inhibitor of ABCB1 Multidrug Transporter. **2021**, 26, 3
- 378 The mutational profile of immune surveillance genes in diagnostic and refractory/relapsed DLBCLs. **2021**, 21, 829
- 377 Flavonoid display ability to target microRNAs in cancer pathogenesis. **2021**, 189, 114409 4
- 376 Combined State and Parameter Identifiability for a Model of Drug-Resistant Cancer Dynamics. **2021**, 143,
- 375 Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP). **2021**, 11, 15112 1
- 374 The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer. **2021**, 13, 16
- 373 Discovery of dual targeting PEGylated BG-P-TAT to norepinephrine transporter (NET) and thyrointegrin $\beta v \beta$ in the treatment of neuroblastoma. **2021**, 43, 116278 0
- 372 LightSpot-FL-1 Fluorescent Probe: An Innovative Tool for Cancer Drug Resistance Analysis by Direct Detection and Quantification of the P-glycoprotein (P-gp) on Monolayer Culture and Spheroid Triple Negative Breast Cancer Models. **2021**, 13, 0
- 371 ABCB1 Does Not Require the Side-Chain Hydrogen-Bond Donors Gln, Gln, Gln to Confer Cellular Resistance to the Anticancer Drug Taxol. **2021**, 22, 1
- 370 Abnormal saccharides affecting cancer multi-drug resistance (MDR) and the reversal strategies. **2021**, 220, 113487 4

369	Targeted Delivery of Drugs and Genes Using Polymer Nanocarriers for Cancer Therapy. 2021 , 22,	6
368	Relation between ABCB1 overexpression and COX2 and ALOX5 genes in human erythroleukemia cell lines. 2021 , 155, 106553	
367	Hyaluronic acid-functionalized halloysite nanotubes for targeted drug delivery to CD44-overexpressing cancer cells. 2021 , 28, 102682	4
366	Viability of Nanostructured Lipid Carrier System in Overcoming the Barriers Associated with Chemotherapeutic Delivery. 2021 , 17,	0
365	Breaking the Silence of Tumor Response: Future Prospects of Targeted Radionuclide Therapy. 2021 , ,	0
364	Amplification of tumor oxidative stresses by Poly(disulfide acetal) for multidrug resistance reversal. 2021 , 276, 121005	7
363	CircATL2 enhances paclitaxel resistance of ovarian cancer via impacting miR-506-3p/NFIB axis. 2021 , ,	1
362	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs. 2021 , 84, 2544-2553	2
361	Cancer Therapy Challenge: It Is Time to Look in the "St. Patrick's Well" of the Nature. 2021 , 22,	1
360	Evaluation of the cytotoxic anticancer effect of polysaccharide of <i>Nepeta septemcrenata</i> . 2021 , 10,	1
359	Mechanistic investigation of synergistic interaction of tocopherol succinate with a quinoline-based inhibitor of mammalian target of rapamycin. 2021 ,	0
358	Development and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor. 2021 , 28, 1258-1270.e13	10
357	Current Advances and Outlook in Gastric Cancer Chemoresistance: A Review. 2021 ,	3
356	Anticancer Activity of Some Ruthenium(III) Complexes with Quinolone Antibiotics: In Vitro Cytotoxicity, Cell Cycle Modulation, and Apoptosis-Inducing Properties in LoVo Colon Cancer Cell Line. 2021 , 11, 8594	3
355	Targeting Drug Chemo-Resistance in Cancer Using Natural Products. 2021 , 9,	9
354	Chemoreversal Agents from Taiwanofungus Genus and Their More Potent Methyl Derivatives Targeting Signal Transducer and Activator of Transcription 3 (STAT3) Phosphorylation. 2021 , 14,	
353	Piperine for treating breast cancer: A review of molecular mechanisms, combination with anticancer drugs, and nanosystems. 2021 ,	2
352	An insight into aptamer engineered dendrimer for cancer therapy. 2021 , 159, 110746	23

351	Design and application of hybrid cyclic-linear peptide-doxorubicin conjugates as a strategy to overcome doxorubicin resistance and toxicity. 2021 , 226, 113836	3
350	Cationic polymer synergizing with chemotherapeutics and re-purposing antibiotics against cancer cells. 2021 , 9, 2174-2182	1
349	Recent advances in covalent organic frameworks for cancer diagnosis and therapy. 2021 , 9, 5745-5761	10
348	Therapeutic Applications of Noble Metal (Au, Ag, Pt)-Based Nanomedicines for Melanoma. 2021 , 161-202	0
347	Preparation of Nanoemulsions of Mentha piperita Essential Oil and Investigation of Their Cytotoxic Effect on Human Breast Cancer Lines. 2021 , 11, 428-436	13
346	Dual-targeting SERS-encoded graphene oxide nanocarrier for intracellular co-delivery of doxorubicin and 9-aminoacridine with enhanced combination therapy. 2021 , 146, 6893-6901	3
345	Membrane Transport Proteins and Drug Transport. 2003 , 249-293	3
344	Multidrug Resistance in Solid Tumor and Its Reversal. 2009 , 121-148	6
343	A20 expressing tumors and anticancer drug resistance. 2014 , 809, 65-81	10
342	Molecular Determinants of Intrinsic Multidrug Resistance in Cancer Cells and Tumors. 2006 , 241-260	2
341	Studying drug resistance using genetically engineered mouse models for breast cancer. 2010 , 596, 33-45	9
340	Resistance to Histone Deacetylase Inhibitors in the Treatment of Lymphoma. 2019 , 87-110	1
339	Exploiting Cancer Cells Metabolic Adaptability to Enhance Therapy Response in Cancer. 2020 , 1219, 297-310	1
338	The Role of MicroRNA in Lung Cancer Drug Resistance and Targeted Therapy. 2014 , 51-82	2
337	Resistance to chemotherapy in ovarian carcinoma. 2007 , 176, 51-60	21
336	Clinical Anticancer Drugs for Cancer Treatment. 2017 , 7-13	1
335	Natural and Acquired Resistance to Cancer Therapies. 2015 , 651-660.e4	1
334	Natural and Acquired Resistance to Cancer Therapies. 2008 , 583-592	1

333	Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles. 2017 , 83, 35-43	44
332	Overcoming Resistance to Drugs Targeting Mutation. 2020 , 1,	24
331	Chapter 3:Rational Design of Translational Nanocarriers. 2013 , 32-62	2
330	Effect of different agents onto multidrug resistant cells revealed by fluorescence correlation spectroscopy. 2007 , 32, 139-141	1
329	The impact of competition between cancer cells and healthy cells on optimal drug delivery. 2020 , 15, 42	2
328	Validation of a Mathematical Model of Cancer Incorporating Spontaneous and Induced Evolution to Drug Resistance.	2
327	Mathematical Details on a Cancer Resistance Model.	5
326	Evolutionary stability of collateral sensitivity to antibiotics in the model pathogen <i>Pseudomonas aeruginosa</i> .	2
325	Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance. 2018 , 128, 4098-4114	17
324	Solid Lipid Nanoparticles for Anti-Tumor Drug Delivery. 2006 , 741-776	3
323	IMPLICATIONS FOR THERAPY Personalized Therapy of Cancer. 2013 , 101-105	2
322	A novel synthetic analog of 5, 8-disubstituted quinazolines blocks mitosis and induces apoptosis of tumor cells by inhibiting microtubule polymerization. 2010 , 5, e10499	6
321	Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/Dox. 2011 , 6, e24684	36
320	In vitro studies on erythrosine-based photodynamic therapy of malignant and pre-malignant oral epithelial cells. 2012 , 7, e34475	41
319	Antitumor and angiostatic activities of the antimicrobial peptide dermaseptin B2. 2012 , 7, e44351	43
318	Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. 2012 , 7, e45268	21
317	Praziquantel synergistically enhances paclitaxel efficacy to inhibit cancer cell growth. 2012 , 7, e51721	13
316	Functionalized graphene oxide mediated adriamycin delivery and miR-21 gene silencing to overcome tumor multidrug resistance in vitro. 2013 , 8, e60034	116

315	Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance. 2013 , 8, e82062	71
314	Genetic variations in radiation and chemotherapy drug action pathways and survival in locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy. 2013 , 8, e82750	7
313	Antitumor Activity of a 5-Hydroxy-1H-Pyrrol-2-(5H)-One-Based Synthetic Small Molecule In Vitro and In Vivo. 2015 , 10, e0128928	10
312	High-Copy Overexpression Screening Reveals PDR5 as the Main Doxorubicin Resistance Gene in Yeast. 2015 , 10, e0145108	7
311	Down-Regulation of MicroRNA-210 Confers Sensitivity towards 1 S -1KAcetoxychavicol Acetate (ACA) in Cervical Cancer Cells by Targeting SMAD4. 2017 , 40, 291-298	16
310	The MicroRNA-551a/MEF2C Axis Regulates the Survival and Sphere Formation of Cancer Cells in Response to 5-Fluorouracil. 2019 , 42, 175-182	3
309	Mode of photoexcited C fullerene involvement in potentiating cisplatin toxicity against drug-resistant L1210 cells. 2019 , 9, 211-217	2
308	The potential role of miRNAs and exosomes in chemotherapy in ovarian cancer. 2018 , 25, R663-R685	38
307	The natural adaptive evolution of cancer: The metastatic ability of cancer cells. 2020 , 20, 303-309	2
306	Vegetative polysaccharides: new target and direction of clinical use. 2018 , 16, 5-9	1
305	Long noncoding RNA Inc-LOC645166 promotes adriamycin resistance via NF- B /GATA3 axis in breast cancer. 2020 , 12, 8893-8912	5
304	microRNAs targeting cellular cholesterol: implications for combating anticancer drug resistance. 2020 , 11, 20-42	3
303	Selective amino acid restriction therapy (SAART): a non-pharmacological strategy against all types of cancer cells. 2015 , 2, 857-66	6
302	Microenvironment drug resistance in multiple myeloma: emerging new players. 2016 , 7, 60698-60711	101
301	Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer. 2014 , 5, 944-58	101
300	Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. 2013 , 4, 2186-207	119
299	Antitumor activity of the c-Myc inhibitor KSI-3716 in gemcitabine-resistant bladder cancer. 2014 , 5, 326-37	27
298	A recombinant fungal compound induces anti-proliferative and pro-apoptotic effects on colon cancer cells. 2017 , 8, 28854-28864	11

297	RNA sequencing-based cell proliferation analysis across 19 cancers identifies a subset of proliferation-informative cancers with a common survival signature. 2017 , 8, 38668-38681	15
296	Metformin increases chemo-sensitivity via gene downregulation encoding DNA replication proteins in 5-Fu resistant colorectal cancer cells. 2017 , 8, 56546-56557	18
295	mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition. 2017 , 8, 69204-69218	15
294	Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin. 2014 , 5, 2778-91	35
293	Chronic treatment with cisplatin induces replication-dependent sister chromatid recombination to confer cisplatin-resistant phenotype in nasopharyngeal carcinoma. 2014 , 5, 6323-37	10
292	APC loss in breast cancer leads to doxorubicin resistance via STAT3 activation. 2017 , 8, 102868-102879	14
291	Acquired resistance to PI3K/mTOR inhibition is associated with mitochondrial DNA mutation and glycolysis. 2017 , 8, 110133-110144	15
290	Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma. 2014 , 5, 7805-19	20
289	AP-1 confers resistance to anti-cancer therapy by activating XIAP. 2018 , 9, 14124-14137	7
288	Leptin-Notch axis impairs 5-fluorouracil effects on pancreatic cancer. 2018 , 9, 18239-18253	24
287	Imbalanced sphingolipid signaling is maintained as a core proponent of a cancerous phenotype in spite of metabolic pressure and epigenetic drift. 2019 , 10, 449-479	3
286	Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in -mutant mammary tumours. 2019 , 10, 2586-2606	11
285	PAK6 increase chemoresistance and is a prognostic marker for stage II and III colon cancer patients undergoing 5-FU based chemotherapy. 2015 , 6, 355-67	32
284	MicroRNAs in B-cells: from normal differentiation to treatment of malignancies. 2015 , 6, 7-25	19
283	Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108]. 2012 , 3, 686-99	29
282	Enhanced therapeutic effect of Adriamycin on multidrug resistant breast cancer by the ABCG2-siRNA loaded polymeric nanoparticles assisted with ultrasound. 2015 , 6, 43779-90	29
281	Tea nanoparticle, a safe and biocompatible nanocarrier, greatly potentiates the anticancer activity of doxorubicin. 2016 , 7, 5877-91	21
280	Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer. 2016 , 7, 29187-98	3

279	Emerging targets in cancer drug resistance.. 2019 , 2, 161-177	15
278	Resistance to anti-tubulin agents: From vinca alkaloids to epothilones.. 2019 , 2, 82-106	6
277	Regulation of ABCB1 activity by microRNA-200c and microRNA-203a in breast cancer cells: the quest for microRNAs involvement in cancer drug resistance.. 2019 , 2, 897-911	3
276	Imaging probes for non-invasive tumoral detection and functional monitoring of cancer multidrug resistance.. 2020 , 3, 209-224	1
275	Knockdown of Circular RNA Hsa_circ_0000714 Can Regulate RAB17 by Sponging miR-370-3p to Reduce Paclitaxel Resistance of Ovarian Cancer Through CDK6/RB Pathway. 2020 , 13, 13211-13224	13
274	Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective. 2016 , 22, 4360-4373	39
273	10-Phenyltriazoyl Artemisinin is a Novel P-glycoprotein Inhibitor that Suppresses the Overexpression and Function of P-glycoprotein. 2018 , 24, 5590-5597	7
272	Role of ATP-Binding Cassette Transporter Proteins in CNS Tumors: Resistance- Based Perspectives and Clinical Updates. 2020 , 26, 4747-4763	2
271	Fanconi Anemia DNA Repair Pathway as a New Mechanism to Exploit Cancer Drug Resistance. 2020 , 20, 779-787	2
270	Elucidation of the molecular mechanisms of a salicylhydrazide class of compounds by proteomic analysis. 2009 , 9, 189-201	7
269	Macrophage Flipping from Foe to Friend: A Matter of Interest in Breast Carcinoma Heterogeneity Driving Drug Resistance. 2019 , 19, 189-198	7
268	Recent Development of 1,2,4-triazole-containing Compounds as Anticancer Agents. 2020 , 20, 1441-1460	13
267	Moxifloxacin-isatin Hybrids Tethered by 1,2,3-triazole and their Anticancer Activities. 2020 , 20, 1461-1467	8
266	Phage Display Technology and its Applications in Cancer Immunotherapy. 2019 , 19, 229-235	6
265	Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. 2008 , 1, 93-105	202
264	Reversal of Multidrug Resistance in an Epirubicin-Resistant Gastric Cancer Cell Subline. 2018 , 19, 1237-1242	2
263	Modulation of the interplay between p53, ICAM-1 and VEGF in drug-treated LoVo colon cancer cells. 2019 , 24, 261-270	2
262	Optimization Of Cancer Treatment Through Overcoming Drug Resistance. 2018 , 1,	11

261	Expression of LRP Gene in Breast Cancer Patients Correlated with MRP1 as Two Independent Predictive Biomarkers in Breast Cancer. 2018 , 19, 3111-3115	1
260	Reversal Effect of Dihydromyricetin on Multiple Drug Resistance in SGC7901/5-FU Cells. 2020 , 21, 1269-1274	4
259	Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity. 2020 , 21,	159
258	Lipid Drug Carriers for Cancer Therapeutics: An Insight into Lymphatic Targeting, P-gp, CYP3A4 Modulation and Bioavailability Enhancement. 2020 , 10, 524-541	4
257	Recent Advances in Microbubble-Augmented Cancer Therapy. 2020 , 4, 155	2
256	miR-30a Enriched Colostrum-Fraction Can Inhibit The DDP-induced Autophagy of HeLa Cells and Promote The Tumor Shrink*. 2012 , 39, 1099-1108	1
255	Curcumin cytotoxicity is enhanced by PTEN disruption in colorectal cancer cells. 2013 , 19, 6814-24	15
254	Role of non-coding RNAs in pancreatic cancer: the bane of the microworld. 2014 , 20, 9405-17	16
253	Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402). 2002 , 8, 1029-34	36
252	[PPAR-βsilencing inhibits the apoptosis of A549 cells by upregulating Bcl-2]. 2013 , 16, 125-30	3
251	[Advances in hypoxia microenvironment and chemotherapy-resistant of lung cancer]. 2014 , 17, 265-8	3
250	Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models. 2016 ,	14
249	Novel insights into the role of Clostridium novyi-NT related combination bacteriolytic therapy in solid tumors. 2021 , 21, 110	9
248	Targeting Multidrug Resistance with Small Molecules for Cancer Therapy. 2010 , 18, 375-385	6
247	Decreased Interaction of Raf-1 with Its Negative Regulator Spry2 as a Mechanism for Acquired Drug Resistance. 2011 , 19, 174-180	7
246	Autophagy-Dependent Survival of Mutant B-Raf Melanoma Cells Selected for Resistance to Apoptosis Induced by Inhibitors against Oncogenic B-Raf. 2013 , 21, 114-20	18
245	Harnessing of Programmed Necrosis for Fighting against Cancers. 2014 , 22, 167-75	19
244	A Novel Submicron Emulsion System Loaded with Doxorubicin Overcome Multi-Drug Resistance in MCF-7/ADR Cells. 2015 , 77, 499-504	2

243	Marine-derived Fungi Extracts Enhance the Cytotoxic Activity of Doxorubicin in Nonsmall Cell Lung Cancer Cells A459. 2017 , 9, S92-S98	11
242	Expression of HER2 in Breast Cancer Promotes a Massive Reorganization of Gene Activity and Suggests a Role for Epigenetic Regulation. 2012 , 3,	2
241	Nanomedicine strategies for sustained, controlled, and targeted treatment of cancer stem cells of the digestive system. 2016 , 8, 735-744	19
240	Butein Disrupts Hsp90's Molecular Chaperoning Function and Exhibits Anti-proliferative Effects Against Drug-resistant Cancer Cells. 2013 , 34, 3345-3349	4
239	Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma. 2013 , 2, 265-282	41
238	Sildenafil Enhances the Anticancer Activity of Paclitaxel in an ABCB1-Mediated Multidrug Resistance Xenograft Mouse Model. 2014 , 3, 169-173	1
237	Molecular modeling and docking of small molecule inhibitors against NEK2. 2016 , 12, 62-68	16
236	Establishment and partial characterization of an epirubicin-resistant gastric cancer cell line with upregulated ABCB1. 2014 , 15, 6849-53	5
235	Association between ABCB1 immunohistochemical expression and overall survival in gastric cancer patients. 2014 , 15, 6935-8	12
234	Arsenic Trioxide Promotes Paclitaxel Cytotoxicity in Resistant Breast Cancer Cells. 2015 , 16, 5191-7	27
233	Reversal of Multidrug Resistance and Computational Studies of Pistagremic Acid Isolated from <i>Pistacia integerrima</i> . 2016 , 17, 2311-4	3
232	Evolutionary stability of collateral sensitivity to antibiotics in the model pathogen. 2019 , 8,	25
231	Bioactivities by a crude extract from the Greenlandic <i>Pseudomonas</i> sp. In5 involves the nonribosomal peptides, nunamycin and nunapeptin. 2015 , 3, e1476	8
230	A novel defined hypoxia-related gene signature to predict the prognosis of oral squamous cell carcinoma. 2021 , 9, 1565	4
229	Theoretical modeling of collaterally sensitive drug cycles: shaping heterogeneity to allow adaptive therapy. 2021 , 83, 47	3
228	Plant-Based Drugs as an Adjuvant to Cancer Chemotherapy.	2
227	CRISPR screens guide the way for PARP and ATR inhibitor biomarker discovery. 2021 ,	3
226	Identification of Novel Anthracycline Resistance Genes and Their Inhibitors. 2021 , 14,	0

- 225 Cytotoxic and apoptotic effects of 1,2-diborolanes with strong donor substitutes on human cancer cells. **2021**, 117, 105443 0
- 224 Tumor Endothelial Markers. **2008**, 333-342
- 223 Failure modes in anticancer drug discovery and development. **2008**, 424-435 0
- 222 Functional Imaging of Multidrug Resistance and Its Applications. **2009**, 601-643
- 221 Abstract B60: Overcoming drug resistant cancer by hyaluronic acid based nanogel formulated with anticancer drugs. **2012**, 18, B60-B60
- 220 Evolutionary Dynamics of Drug Resistant Mutants in Targeted Treatment of CML. **2014**, 59-72 1
- 219 Ligand-Appended Liposomes: Targeted Breast Cancer Therapy. 4316-4327 1
- 218 RNA sequencing-based cell proliferation analysis across 19 cancers identifies a subset of proliferation-informative cancers with a common survival signature.
- 217 Targeted Drug Delivery in Solid Tumors. **2016**, 233-252
- 216 Clear: Composition of Likelihoods for Evolve And Resequencing Experiments.
- 215 Small Molecule Inhibitors. **2017**, 771-795
- 214 Anticancer Activity of Salvia miltiorrhiza and Its Secondary Metabolites. **2017**, 179-207 0
- 213 miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer.
- 212 Mitochondrial expression and activity of P-glycoprotein under oxidative stress in outer blood-retinal barrier. **2017**, 10, 1055-1063 5
- 211 A multi-state model of chemoresistance to characterize phenotypic dynamics in breast cancer.
- 210 A mathematical approach to differentiate spontaneous and induced evolution to drug resistance during cancer treatment. 1
- 209 Tuning Spatial Profiles of Selection Pressure to Modulate the Evolution of Resistance.
- 208 Effect of estradiol on P-glycoprotein functional activity in experiment. **2018**, 80-86

- 207 Anti-angiogenic Cancer Therapy: Development of Resistance. **2019**, 313-323 1
- 206 Cancer Drug Resistance. **2019**, 77-85
- 205 Yin and Yang of Pluripotency: Results of Analysis of Genes Overexpressed In Tumor-Initiating Cells of Krebs-2 Ascites Carcinoma. **2019**, 14, 160-187 1
- 204 Inhibition of Colon Cancer Cell Viability and Tumor Growth by Benzoximemethyl Amine Through Apoptosis. **2019**, 15, 716-723
- 203 The significance of microRNA genes expression in ovarian cancer cell lines resistant to cytotoxic drugs.
- 202 A QSAR Study on the 4-Substituted Coumarins as Potent Tubulin Polymerization Inhibitors. **2020**, 10, 271-277
- 201 The Emerging Role of Exosomes in Cancer Chemoresistance. **2021**, 9, 737962 5
- 200 Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers. **2021**, 13, 1 1
- 199 Discovery of the Triazolo[1,5-]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance. **2021**, 64, 16187-16204 5
- 198 Modeling of drug resistance: Comparison of two hypotheses for slowly proliferating tumors on the example of low-grade gliomas.
- 197 Antibody-Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers. **2021**, 21, 162-186 0
- 196 Bioactive Compounds of Seaweeds and Their Effects on Certain Types of Cancer. **2020**, 8, 112-119
- 195 The efficacy of the anticancer 3-bromopyruvate is potentiated by antimycin and menadione by unbalancing mitochondrial ROS production and disposal in U118 glioblastoma cells. **2020**, 6, e05741 2
- 194 Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer.. **2021**, 4, 264-297
- 193 Key genes and drug delivery systems to improve the efficiency of chemotherapy. **2021**, 4, 163-191 1
- 192 IPN Systems for Cancer Therapy. **2020**, 237-262
- 191 m6A Modification in Non-Coding RNA: The Role in Cancer Drug Resistance. **2021**, 11, 746789 4
- 190 Role of taurine, its haloamines and its lncRNA TUG1 in both inflammation and cancer progression. On the road to therapeutics? (Review). **2020**, 57, 631-664 9

- 189 Modeling collaterally sensitive drug cycles: shaping heterogeneity to allow adaptive therapy. 2
- 188 *Pseudomonas aeruginosa* exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines. **2015**, 64, 164-73 13
- 187 Chemotherapie. **2006**, 560-577
- 186 The Microenvironment and Drug Resistance. **2006**, 201-210
- 185 Non-invasive imaging of PI3K/Akt/mTOR signalling in cancer. **2012**, 2, 418-31 13
- 184 Simultaneous analysis of multidrug resistance 1(MDR1) C3435T, G2677T/A, and C1236T genotypes in Hamadan City population, West of Iran. **2015**, 19, 57-62 5
- 183 Synthesis and in vitro evaluation of amphiphilic peptides and their nanostructured conjugates. **2015**, 5, 41-9 8
- 182 MiR-218 inhibits HMGB1-mediated autophagy in endometrial carcinoma cells during chemotherapy. **2015**, 8, 6617-26 28
- 181 Polyphyllin I (PPI) increased the sensitivity of hepatocellular carcinoma HepG2 cells to chemotherapy. **2015**, 8, 20664-9 13
- 180 Transient resistance to DNA damaging agents is associated with expression of microRNAs-135b and -196b in human leukemia cell lines. **2016**, 7, 27-47 6
- 179 Inhibition of autophagy results in a reversal of taxol resistance in nasopharyngeal carcinoma by enhancing taxol-induced caspase-dependent apoptosis. **2017**, 9, 1934-1942 11
- 178 Exogenous glutathione contributes to cisplatin resistance in lung cancer A549 cells. **2018**, 10, 1295-1309 16
- 177 [Advances in tumor chemo-resistance regulated by MicroRNA]. **2014**, 17, 741-9 1
- 176 Triggers Apoptosis, Combats Oxidative Stress and Inhibits Growth of Ehrlich Ascites Carcinoma Mouse Model. **2018**, 17, 1328-1338 2
- 175 Triptolide reduces proliferation and enhances apoptosis in drug-resistant human oral cancer cells. **2019**, 12, 1204-1213 2
- 174 MY-5445, a phosphodiesterase type 5 inhibitor, resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs. **2020**, 10, 164-178 4
- 173 Licochalcone B Ameliorates Liver Cancer via Targeting of Apoptotic Genes, DNA Repair Systems, and Cell Cycle Control. **2020**, 19, 372-386
- 172 Homologous recombination repair creates mutations in non-coding genome that alter Topoisomerase-1 cleavage sites & orchestrates irinotecan resistance. 0

171	A Phenylfurocoumarin Derivative Reverses ABCG2-Mediated Multidrug Resistance In Vitro and In Vivo. 2021 , 22,	0
170	Peptide dendrimers as potentiators of conventional chemotherapy in the treatment of pancreatic cancer in a mouse model. 2021 , 170, 121-121	3
169	Glycyrrhizin as a Nitric Oxide Regulator in Cancer Chemotherapy. 2021 , 13,	0
168	Quaternary Ammonium Salts Anchored on Cross-Linked (-)-Lipoic Acid Nanoparticles for Drug-Resistant Tumor Therapy. 2021 , 13, 56850-56857	0
167	Modulating undruggable targets to overcome cancer therapy resistance.. 2021 , 60, 100788	2
166	Mathematical characterization of population dynamics in breast cancer cells treated with doxorubicin.	
165	Insights Into the Prognostic Value and Immunological Role of NAAA in Pan-Cancer.. 2021 , 12, 812713	0
164	The Microstructure, Antibacterial and Antitumor Activities of Chitosan Oligosaccharides and Derivatives.. 2022 , 20,	13
163	Advanced applications of cerium oxide based nanozymes in cancer.. 2022 , 12, 1486-1493	6
162	The Effect of Fatty Acids on Ciprofloxacin Cytotoxic Activity in Prostate Cancer Cell Lines-Does Lipid Component Enhance Anticancer Ciprofloxacin Potential?. 2022 , 14,	3
161	[(WR)WKA]-Doxorubicin Conjugate: A Delivery System to Overcome Multi-Drug Resistance against Doxorubicin.. 2022 , 11,	1
160	A pH-sensitive liposome formulation of a peptidomimetic-Dox conjugate for targeting HER2 ⁺ cancer.. 2021 , 612, 121364	2
159	Optimal chemotherapy counteracts cancer adaptive resistance in a cell-based, spatially-extended, evolutionary model.. 2022 ,	1
158	The role of polyphenols in overcoming cancer drug resistance: a comprehensive review.. 2022 , 27, 1	17
157	Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer.. 2022 , 60, 100811	3
156	Acquisition of taxane resistance by p53 inactivation in ovarian cancer cells.. 2022 ,	1
155	Extracellular Vesicles as Biomarkers and Therapeutic Targets in Cancers.	0
154	Pyrraline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis.. 2022 , 41, 45	1

153	The MicroRNA-Based Strategies to Combat Cancer Chemoresistance Regulating Autophagy.. 2022 , 12, 841625	1
152	Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition.. 2021 , 100795	6
151	Anticancer drug resistance: An update and perspective.. 2021 , 100796	17
150	Tumor Microenvironment Features and Chemoresistance in Pancreatic Ductal Adenocarcinoma: Insights into Targeting Physicochemical Barriers and Metabolism as Therapeutic Approaches. 2021 , 13,	5
149	Role of Plant Secondary Metabolites as Modulators of Multidrug Resistance in Cancer Therapy. 2022 , 415-435	
148	Laboratory Techniques in Cellular and Molecular Medicine.	
147	Opportunities in combinational chemo-immunotherapy for breast cancer using nanotechnology: an emerging landscape.. 2022 ,	1
146	Cell membrane coated-nanoparticles for cancer immunotherapy. 2022 ,	6
145	Swelling triggered release of cisplatin from gelatin coated gold nanoparticles. 1-13	0
144	Development and molecular characterization of doxorubicin-resistant canine mammary gland tumour cells. 2022 , 50, 125-145	
143	Yeast β -glucan increases etoposide sensitivity in lung cancer cell line A549 by suppressing Nrf2 via the non-canonical NF- κ B pathway.. 2022 ,	0
142	A review of machine learning approaches for drug synergy prediction in cancer.. 2022 ,	1
141	Ribosomal protein L5 (RPL5)/ E2F transcription factor 1 (E2F1) signaling suppresses breast cancer progression via regulating endoplasmic reticulum stress and autophagy.. 2022 , 13, 8076-8086	1
140	Quantification of long-term doxorubicin response dynamics in breast cancer cell lines to direct treatment schedules.. 2022 , 18, e1009104	0
139	Implication of metabolomics and transporter modulation based strategies to minimize multidrug resistance and enhance site-specific bioavailability: a needful consideration toward modern anticancer drug discovery.. 2022 , 1-19	0
138	Quinazoline Based HDAC Dual Inhibitors as Potential Anti-Cancer Agents.. 2022 , 27,	0
137	Hypoxia-induced PVT1 promotes lung cancer chemoresistance to cisplatin by autophagy via PVT1/miR-140-3p/ATG5 axis.. 2022 , 8, 104	0
136	Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells.. 2022 , 10,	2

- 135 Circular RNA as a Novel Biomarker for Diagnosis and Prognosis and Potential Therapeutic Targets in Multiple Myeloma.. **2022**, 14, 2
- 134 Small-molecule MDM2 inhibitors in clinical trials for cancer therapy.. **2022**, 236, 114334 0
- 133 Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor. **2022**, 1
- 132 In Silico and In Vitro Screening of 50 Curcumin Compounds as EGFR and NF- κ B Inhibitors.. **2022**, 23, 0
- 131 Colorectal Cancer: The Contribution of CXCL12 and Its Receptors CXCR4 and CXCR7.. **2022**, 14, 2
- 130 Pheophorbide A and SN38 conjugated hyaluronan nanoparticles for photodynamic- and cascadic chemotherapy of cancer stem-like ovarian cancer.. **2022**, 289, 119455 0
- 129 Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia.. **2022**, 100950 0
- 128 Swietephragmin D, a limonoid from Swietenia mahagoni, reverses multidrug resistance by inhibiting P-glycoprotein dependent efflux. **2022**, 2, 100266
- 127 Single cell mass spectrometry studies reveal metabolomic features and potential mechanisms of drug-resistant cancer cell lines.. **2022**, 1206, 339761 0
- 126 Acquired Drug Resistance Enhances Imidazoquinoline Efflux by P-Glycoprotein.. **2021**, 14, 0
- 125 Delineating the Role of PI3K Signaling Pathway in the Stem Cell Therapeutics of ROS-Induced Carcinomas. **2022**, 1-26
- 124 Evaluation of Anti-Cancer Effects of Caspian Cobra (Naja naja oxiana) Snake Venom in Comparison with Doxorubicin in HeLa Cancer Cell Line and Normal HFF Fibroblast. **2021**, 29, 20-27
- 123 Ultrasounds in cancer therapy: A summary of their use and unexplored potential.. **2022**, 16, 531 0
- 122 CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer.. **2022**, 13, 862125 0
- 121 Mechanisms of cancer stem cells drug resistance and the pivotal role of HMGA2.. **2022**, 234, 153906
- 120 Table_1.XLS. **2018**,
- 119 Data_Sheet_1.doc. **2020**,
- 118 Data_Sheet_2.docx. **2020**,

117 Image_1.TIF. 2020,

116 Image_2.TIF. 2020,

115 Image_3.TIF. 2020,

114 Table_1.docx. 2020,

113 Table_2.docx. 2020,

112 Table_3.docx. 2020,

111 Table_4.docx. 2020,

110 Table_5.docx. 2020,

109 Table_6.xlsx. 2020,

108 Presentation1.pptx. 2018,

107 Data_Sheet_1.docx. 2020,

106 Table_1.DOCX. 2020,

105 DHMEQ enhances the cytotoxic effect of cisplatin and carboplatin in ovarian cancer cell lines.. 2021 , 11, 6024-6041

104 The role of miR-153 and related upstream/downstream pathways in cancers: from a potential biomarker to treatment of tumor resistance and a therapeutic target.. 2022, 39, 62

103 Proteomic quantification of perturbation to pharmacokinetic target proteins in liver disease.. 2022, 104601 ○

102 Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer. 2022, 13,

101 Curcuma aeruginosa Roxb. exhibits cytotoxicity in A-549 and HeLa cells by inducing apoptosis through caspase-dependent pathways. 2022, 150, 113039 ○

100 Drug Delivery to Primary and Metastatic Brain Tumors: Challenges and Opportunities. 2022, 723-762 ○

- 99 The Research Landscape of Ferroptosis in Cancer: A Bibliometric Analysis. **2022**, 10, 0
- 98 Nanostructured Lipid Carriers: New Insight for Cancer Therapy. **2022**, 12, 0
- 97 Detachment of Hexokinase II From Mitochondria Promotes Collateral Sensitivity in Multidrug Resistant Chronic Myeloid Leukemia Cells. 12, 0
- 96 Interactions between EGFR and EphA2 promote tumorigenesis through the action of Ephexin1. **2022**, 13, 0
- 95 Exosome-Mediated Response to Cancer Therapy: Modulation of Epigenetic Machinery. **2022**, 23, 6222 1
- 94 Epigenetic modifications control loss of adhesion and aggressiveness of cancer stem cells derived from head and neck squamous cell carcinoma with intrinsic resistance to cisplatin. **2022**, 105468 0
- 93 Sensitization of FOLFOX-resistant colorectal cancer cells via the modulation of a novel pathway involving protein phosphatase 2A. **2022**, 104518 0
- 92 Photodynamic Therapy and Photochemical Internalization. **2021**, 7-22 0
- 91 High drug loading polymer micelle@ZIF-8 hybrid core-shell nanoparticles through donor-acceptor coordination interaction for pH/H₂O₂-responsive drug release. **2022**, 16, 0
- 90 Optical Modulation of Blood-Brain-Tumor Barrier Permeability Enhances Drug Delivery in Diverse Preclinical Glioblastoma Models. 0
- 89 Intelligent design of polymersomes for antibacterial and anticancer applications. 0
- 88 Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches. 12, 5
- 87 Discovery of Novel Quinazoline Derivatives as Potent Antitumor Agents. **2022**, 27, 3906 0
- 86 Nano-Based Drug Delivery of Anticancer Chemotherapeutic Drugs Targeting Breast Cancer. **2022**, 17, 0
- 85 Clinical potential of nanotechnology as smart therapeutics: A step toward targeted drug delivery. **2022**, 133-154 0
- 84 Scales of Cancer Evolution: Selfish Genome or Cooperating Cells?. **2022**, 14, 3253 0
- 83 Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management. **2022**, 15, 4
- 82 Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment. **2022**, 188, 114445 5

81	Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. 2004 , 3, 633-640	31
80	Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in β -tubulin. 2004 , 3, 1319-1327	8
79	ROS-generating, pH-responsive and highly tunable reduced graphene oxide-embedded microbeads showing intrinsic anticancer properties and multi-drug co-delivery capacity for combination cancer therapy. 2022 , 29, 2481-2490	2
78	Optimal control of two cytotoxic drug maximum tolerated dose steers and exploits cancer adaptive resistance in a cell-based framework. 2022 ,	
77	A Novel Drug Modulator Diarylheptanoid (trans-1,7-Diphenyl-5-hydroxy-1-heptene) from Curcuma comosa Rhizomes for P-glycoprotein Function and Apoptosis Induction in K652/ADR Leukemic Cells. 2022 , 23, 8989	
76	Nanoemulsion and nanogel containing Artemisia dracunculus essential oil; larvicidal effect and antibacterial activity. 2022 , 15,	3
75	Ambra1 in cancer: implications for clinical oncology.	0
74	Nanomedicines for Overcoming Cancer Drug Resistance. 2022 , 14, 1606	
73	Next-Generation Personalized Medicine: Implementation of Variability Patterns for Overcoming Drug Resistance in Chronic Diseases. 2022 , 12, 1303	1
72	Nrf2/p-Fyn/ABCB1 axis accompanied by p-Fyn nuclear accumulation plays pivotal roles in vinorelbine resistance in non-small cell lung cancer. 2022 , 48,	
71	Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk. 2022 , 22,	1
70	NASMDR: a framework for miRNA-drug resistance prediction using efficient neural architecture search and graph isomorphism networks.	0
69	Advancement in use of silicon phthalocyanine derivatives for cancer treatment. 2022 , 206, 110608	1
68	Development of fullerene nanospherical miRNA and application in overcoming resistant breast cancer. 2022 , 26, 101019	
67	The WD repeat-containing protein 5 (WDR5) antagonist WDR5-0103 restores the efficacy of cytotoxic drugs in multidrug-resistant cancer cells overexpressing ABCB1 or ABCG2. 2022 , 154, 113663	1
66	Simultaneous crosslinking of CD20 and CD38 receptors by drug-free macromolecular therapeutics enhances B cell apoptosis in vitro and in vivo. 2022 , 350, 584-599	0
65	Synthesis and Characterization of Nano-Selenium Using Plant Biomolecules and Their Potential Applications. 2022 , 25-40	0
64	Magnetoelectric core-shell CoFe ₂ O ₄ @BaTiO ₃ nanorods: their role in drug delivery and effect on multidrug resistance pump activity in vitro. 2022 , 12, 24958-24979	0

63	Animal Models in Cancer Research: Breast Cancer. 2022 , 1-20	0
62	Tuning the anticancer properties of Pt(II) complexes via structurally flexible N-(2-picoly)salicylimine ligands. 2022 , 12, 27582-27595	1
61	Delineating the Role of PI3K Signaling Pathway in the Stem Cell Therapeutics of ROS-Induced Carcinomas. 2022 , 2153-2177	0
60	Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma. 2022 , 11,	1
59	Mathematical characterization of population dynamics in breast cancer cells treated with doxorubicin. 9,	0
58	HCV and tumor-initiating stem-like cells. 13,	0
57	The role of lncRNA H19 in tumorigenesis and drug resistance of human Cancers. 13,	2
56	Antioxidative, anticancer, and antibacterial activities of a nanogel containing Mentha spicata L. essential oil and electrospun nanofibers of polycaprolactone-hydroxypropyl methylcellulose. 2022 , 22,	0
55	Smart systems in bio-encapsulation for cancer therapy. 2022 , 223-236	0
54	Cancer-Associated Membrane Protein as Targeted Therapy for Bladder Cancer. 2022 , 14, 2218	0
53	Insights of ethyl acetate fraction from Vassobia breviflora in multidrug-resistant bacteria and cancer cells: from biological to therapeutic. 2022 , 85, 972-987	0
52	Trends in metabolic signaling pathways of tumor drug resistance: A scientometric analysis. 12,	0
51	Small interfering RNA (siRNA): discovery, pharmacology and clinical development An introductory review.	2
50	Metformin Improves Ovarian Cancer Sensitivity to Paclitaxel and Platinum-Based Drugs: A Review of In Vitro Findings. 2022 , 23, 12893	3
49	Paclitaxel Resistance Related to Nuclear Envelope Structural SturdinessRunning Title: Lamin A/C Expression and Paclitaxel Resistance. 2022 , 100881	0
48	Planispine A Sensitized Cancer Cells to Cisplatin by Inhibiting the Fanconi Anemia Pathway. 2022 , 27, 7288	0
47	Combination of niclosamide and current therapies to overcome resistance for cancer: New frontiers for an old drug. 2022 , 155, 113789	1
46	Pathways of Angiogenic and Inflammatory Cytokines in Multiple Myeloma: Role in Plasma Cell Clonal Expansion and Drug Resistance. 2022 , 11, 6491	1

45	Current understanding of biological interactions and processing of DNA origami nanostructures: Role of machine learning and implications in drug delivery. 2022 , 61, 108052	1
44	Competition between populations: preventing domination of resistant population using optimal control. 2023 , 114, 671-693	0
43	Terfenadine resensitizes doxorubicin activity in drug-resistant ovarian cancer cells via an inhibition of CaMKII/CREB1 mediated ABCB1 expression. 12,	0
42	Multifunctional hybrid nanoparticles in diagnosis and therapy of breast cancer. 2022 , 352, 1024-1047	0
41	Pre-clinical and clinical importance of miR-21 in human cancers: Tumorigenesis, therapy response, delivery approaches and targeting agents. 2023 , 187, 106568	1
40	Extrinsic cell death pathway plasticity: a driver of clonal evolution in cancer?. 2022 , 8,	0
39	Therapeutic Importance of Kaempferol in the Treatment of Cancer through the Modulation of Cell Signalling Pathways. 2022 , 27, 8864	0
38	Identification of a signature based on non-apoptotic regulatory cell death to improve prognosis prediction in acute myeloid leukaemia.	0
37	Biological and pharmacological roles of m6A modifications in cancer drug resistance. 2022 , 21,	1
36	Drug Resistance: The Role of Exosomal miRNA in the Microenvironment of Hematopoietic Tumors. 2023 , 28, 116	0
35	Evaluating Fate of Emerging Resistance Hitting the Brakes on Conventional Treatment Approach. 2023 , 99-122	0
34	Aptamers in Cancer Therapy: Problems and New Breakthroughs.	0
33	Green Tea Catechin Potentiating Doxorubicine Effects against BE(2)C Neuroblastoma Cells In Vitro. 2023 , In Press,	0
32	Overcoming cancer chemotherapy resistance by the induction of ferroptosis. 2023 , 66, 100916	1
31	Disruption of ovarian cancer STAT3 and p38 signaling with a small molecule inhibitor of PTP4A3 phosphatase. JPET-AR-2022-001401	0
30	Ultrasound boosts doxorubicin efficacy against sensitive and resistant ovarian cancer cells. 2023 , 183, 119-131	0
29	RPN2 in cancer: An overview. 2023 , 857, 147168	1
28	Secosteroidquinoline hybrids as new anticancer agents. 2023 , 228, 106245	0

- 27 KBEKLERDE MEME TUMÖRLERİNİN GÜNCEL KEMOTERAPİ YAKLAIMI: MİKROBALONCUKLAR. ○
- 26 Nanoenabled Tumor Energy Metabolism Disorder via Sonodynamic Therapy for Multidrug Resistance Reversal and Metastasis Inhibition. **2023**, 15, 309-326 ○
- 25 Carbon nanotubes as nanovectors for targeted delivery of platinum based anticancer drugs. **2023**, 205-227 ○
- 24 Mechanisms of multidrug resistance in cancer. **2023**, 51-83 ○
- 23 The Role of Solute Carrier Transporters in Efficient Anticancer Drug Delivery and Therapy. **2023**, 15, 364 ○
- 22 Animal Models in Cancer Research: Breast Cancer. **2023**, 247-266 ○
- 21 Mechanisms of photodynamic therapy for cancer treatment. **2023**, 55-79 ○
- 20 ATP-binding cassette efflux transporters and MDR in cancer. **2023**, 28, 103537 1
- 19 Semi-Synthetic Dihydrotestosterone Derivatives Modulate Inherent Multidrug Resistance and Sensitize Colon Cancer Cells to Chemotherapy. **2023**, 15, 584 ○
- 18 Genetic Characterization of *Trypanosoma cruzi* I Populations from an Oral Chagas Disease Outbreak in Venezuela: Natural Resistance to Nitroheterocyclic Drugs. **2023**, 9, 582-592 ○
- 17 Imidazo[1,2-a]Pyridine Derivatives as Novel Dual-Target Inhibitors of ABCB1 and ABCG2 for Reversing Multidrug Resistance. **2023**, 66, 2804-2831 ○
- 16 Discovery of novel VEGFR2-TK inhibitors by phthalimide pharmacophore based virtual screening, molecular docking, MD simulation and DFT. 1-22 ○
- 15 Cytotoxicity of the methanol extracts and compounds of *Brucea antidysenterica* (Simaroubaceae) towards multifactorial drug-resistant human cancer cell lines. **2023**, 23, ○
- 14 Carbon Dots-Based Nanozyme for Drug-Resistant Lung Cancer Therapy by Encapsulated Doxorubicin/siRNA Cocktail. Volume 18, 933-948 ○
- 13 Design, synthesis and biological evaluation of seco-DSP/DCK derivatives reversing P-glycoprotein-mediated paclitaxel resistance in A2780/T cells. **2023**, 250, 115218 ○
- 12 Induction of Drug-Resistance and Production of a Culture Medium Able to Induce Drug-Resistance in Vinblastine Untreated Murine Myeloma Cells. **2023**, 23, 2051 ○
- 11 Role of IL-6/STAT3 Axis in Resistance to Cisplatin in Gastric Cancers. **2023**, 11, 694 ○
- 10 Codelivery of Phytochemicals with Conventional Anticancer Drugs in Form of Nanocarriers. **2023**, 15, 889 ○

- 9 Significance of FUT8 in Pancreatic Cancer and Others. **2023**, 105-124 ○
- 8 Tuning anticancer properties and DNA-binding of Pt(II) complexes via alteration of nitrogen softness/basicity of tridentate ligands. **2023**, 13, 9333-9346 ○
- 7 The importance of personalized medicine in chronic myeloid leukemia management: a narrative review. **2023**, 24, ○
- 6 Nanoparticle-Based Combination Therapy for Ovarian Cancer. Volume 18, 1965-1987 ○
- 5 Transcriptomic identification of differentially expressed genes in Levonorgestrel resistant endometrial cancer cell lines. ○
- 4 Characterization of Potent ABCG2 Inhibitor Derived from Chromone: From the Mechanism of Inhibition to Human Extracellular Vesicles for Drug Delivery. **2023**, 15, 1259 ○
- 3 In situ supramolecular self-assembly for alleviating multidrug resistance in cancer. **2023**, 2, 100033 ○
- 2 Therapeutic vulnerabilities of cancer stem cells and effects of natural products. ○
- 1 Pterostilbene isothiocyanate reduces miR-21 level by impeding Dicer-mediated processing of pre-miR-21 in 5-fluorouracil and tamoxifen-resistant human breast cancer cell lines. **2023**, 13, ○